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Abstract 
Estimates of the marginal productivity of the health sector are required for a wide range of resource 
allocation decisions. Founding these estimates on robust empirical analysis can inform these 
decisions and improve allocative efficiency as a result. This paper estimates the marginal 
productivity of the English NHS for a ten year period between 2003/04 and 2012/13. Data on 
expenditure and mortality by programme budget categories from this period are used in conjunction 
with socio-economic and demographic variables from the censuses from 2001 and 2011, as part of 
an econometric strategy that employs an established instrumental variable approach that is 
subjected to a number of sensitivity analyses. The results of the econometric analysis, along with 
additional data on burden of disease, are used to generate an estimate of marginal productivity. This 
paper finds that the point estimates of the amount of resources, in nominal terms, to produce an 
additional unit of health benefit has ranged from £5,000 to £15,000 per quality-adjusted life year 
between 2003/04 and 2012/13. These results are discussed in the context of the existing literature, 
and the potential policy implications for decisions about resource allocation are explored. 
 
Keywords: productivity; econometric modelling; programme budgeting; health opportunity costs; 
allocative efficiency  
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1. Introduction 
The UK’s National Health Service (NHS) is one of the largest employers in the world, ranked 5th in 
2015 according to Forbes magazine (McCarthy 2015). In 2003, public expenditure on healthcare for 
the UK was £92.6 billion (in 2015 prices, roughly 5.6% of GDP) compared to £125.7 billion in 2012 (in 
2015 prices, roughly 7% of GDP)(Nuffield Trust 2015). Given the scale of the NHS, there is 
considerable interest in assessing the productivity of NHS expenditures and its evolution over time 
(Bojke et al. 2017). 
 
Studies considering the productivity of healthcare tend to focus on estimating productivity with 
respect to a measure of output (an instrumental goal (Murray & Frenk 2000)), while only 9% of 
studies reviewed by Hollingsworth (2008) considered outcomes (intrinsic goals) such as ‘health 
status, mortality or quality of care’. However, decisions around resource allocation within and 
between competing sectors, including health, are more appropriately guided by the productivity of 
sectors measured in terms of outcomes, since trading-off the value of outputs among all possible 
health system activities would seem not appropriate and trading-off outputs from different sectors 
would seem impractical. In this way estimates of productivity in terms of outcomes can be seen as 
relevant to notions of allocative efficiency, while output-based productivity estimates are more 
relevant to concerns about productive efficiency. For the purposes of informing allocative efficiency, 
productivity at the margin is most commonly the estimand of interest, since this reflects the 
additional beneficial outcome that could be gained with additional resource. Conversely, it also 
reflects the benefit foregone if resources are taken away from the sector. For allocation decisions 
within the health sector it reflects the benefit foregone if resources are committed to a specific type 
of expenditure and removed from the overall discretionary budget, and can be used to estimate 
health opportunity costs of new health technologies (Claxton, Martin, et al. 2015; Culyer 2018). 
 
The relative abundance of studies estimating productivity in terms of outputs as opposed to 
outcomes stems from two main reasons. First, studies considering the performance of healthcare 
delivery generally do so to make comparisons between the productivity of institutions or to track the 
productivity of an institution or set of institutions over time (Smith & Street 2012). Having some way 
of keeping track of these measures, either publicly or privately, is important owing to the many 
inter-locking agency relationships that characterise healthcare systems of all designs (Propper 1995; 
Propper & Wilson 2012). For comparing productivity in this context, it is not necessarily essential to 
consider outcomes. Second, attributing outcomes to inputs, such as expenditures, can prove more 
challenging than attributing outputs to inputs. This is because the process determining outcomes is 
complicated with unknown causal mechanisms relating to environmental factors, in addition to the 
unknown relationship with the input of interest. Nevertheless, resource allocation decisions are 
made whether or not there exists empirical evidence regarding the marginal productivity of public 
sectors. In the absence of explicit estimates, decisions are made with implicit assumptions about 
what the marginal productivities might be. This means that it is vital that empirical analysis is 
conducted where possible using an appropriate and robust, although inevitably not perfect, 
methodology so that resource allocation decision making is evidence-based and accountable. 
 
Estimating the causal link between healthcare expenditure and health outcomes is fraught with 
empirical challenges. Healthcare expenditure is usually linked by some mechanism to healthcare 
need that will usually be related to health outcomes. In addition, health outcomes are also 
determined in large part by environmental factors where the causal pathway may not be known 
(Hauck et al. 2016). In particular, when seeking to draw inferences from international comparisons, 
researchers might have failed to adjust for all the potential external influences on health outcomes. 
For example, Gravelle & Backhouse (1987) examine some of the methodological difficulties 
associated with empirical investigation of the determinants of mortality rates. These include 
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heterogeneity between observational units, simultaneous equation bias and the associated 
endogeneity problem (that the level of healthcare input might reflect unobservable factors that 
influence the level of health outcome achieved), and that a lag may occur between expenditure and 
outcomes (studies typically assume that expenditure has an contemporaneous effect on mortality). 
Because of these reasons, the failure to identify strong and consistent relationships between 
healthcare expenditure and health outcomes (after controlling for other factors) has become a 
recurring theme in the literature (Gallet & Doucouliagos 2017). 
 
In a bid to overcome the econometric challenges associated with this kind of study, and to provide 
policy-relevant estimates of marginal productivity for national decision making, recent studies have 
increasingly started to employ instrumental variable-based (IV) regression approaches using sub-
national data (Martin et al. 2008; Martin et al. 2012; Claxton, Martin, et al. 2015; Andrews et al. 
2017; L C Edney et al. 2018a; L C Edney et al. 2018b). This presents considerable advantages over the 
use of aggregate country level data. The first is that the estimated effect has an intrinsic link to the 
parameter of interest, since the estimated coefficient reflects the average implications for health of 
variations in expenditure at the margin. Second, the use of sub-national data can reduce the likely 
aggregation bias suffered by estimates compared to international data. Third, analysis of sub-
national data generally allows for the inclusion of a broader range of variables since numerous 
sources of data can be linked and available data is not constrained by the need for international 
comparability of data. Further, in an analysis using sub-national data from a single country, there is 
likely to be a much better understanding of the underlying data generating processes that can 
inform an identification strategy for the consistent estimation of causal effects. 
 
Studies using sub-national data typically use local-level information on expenditure and outcomes, 
as well as healthcare need, environmental factors affecting health and potential IVs (Martin et al. 
2008; Martin et al. 2012; Claxton, Martin, et al. 2015; Andrews et al. 2017; L C Edney et al. 2018a). 
For analysis of English data the local level in published papers has been the primary care trust (PCT), 
a health authority responsible for organising healthcare and meeting the healthcare needs of the 
local population. Two main approaches have been used to estimate the effect of healthcare 
expenditures in England, which differ in terms of how equations to be estimated are structured and 
also how the effect of expenditure on outcomes is identified using IVs.1 One approach, Andrews et 
al. (2017), directly estimates the elasticity of all-cause mortality with respect to health expenditure. 
IVs are chosen on the basis that the per capita budget assigned to each health authority is the 
product of the national per capita budget and four adjustments reflecting local circumstances, 
where three of these might plausibly be unrelated to mortality. Using these three adjustments as IVs 
for total healthcare expenditure, Andrews et al. (2017) report an elasticity of all-cause mortality with 
respect to expenditure of -0.71 for 2005/06. The other approach, Martin et al. (2008 and 2012) and 
Claxton et al. (2015), uses national data on expenditure and outcomes in different disease areas 
(programme budget categories, PBCs) reported at a local level (primary care trusts, PCTs). An 
expenditure equation is estimated to quantify how the overall budget is allocated across PBCs, in 
addition an outcome equation is estimated to quantify the elasticity of PBC-specific mortality with 
respect to PBC-specific healthcare expenditure. The IVs used in this approach reflect factors, such as 
socio-economic deprivation and the availability of informal care in the community, which directly 
influence healthcare expenditures, but plausibly only indirectly impact on mortality rates through 
healthcare expenditure levels. This second strategy for finding IVs has generalisability beyond the 
English NHS and has been employed in the analysis of Australian data where an elasticity of all-cause 
mortality with respect to health expenditure of -2.2 is reported (L C Edney et al. 2018a; L C Edney et 
al. 2018b).  
                                                          
1 A third approach has recently been explored, Claxton et al. (2018), which essentially employs an approach that is a hybrid 
of these two approaches employing the Andrews et al. (2017) approach to IVs for all expenditure in order to estimate 
elasticities for certain PBC-specific mortalities instead of all-cause mortality. 
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The elasticities of mortality with respect to expenditure are interesting results in themselves, but 
they do not fully express the marginal productivity of the NHS in the most useful way. This is because 
the NHS is not only concerned with life-saving care, but the improvement of health overall. 
Therefore, a measure of marginal productivity should ideally reflect the effect of NHS expenditures 
on extending survival (resulting from reduced mortality) as well as improving health-related quality 
of life. Combining estimated elasticities of disease-specific mortality with respect to disease-specific 
expenditures with additional information about age, gender and life expectancy of the patient 
population, Claxton et al. (2015) are able to express the mortality effects in terms of cost per life-
year (£25 214 per life year for 2008/09 healthcare expenditures). Further, by using the effect of 
expenditure on the mortality and life-year burden of disease as a surrogate for the effects on a more 
complete measure of health burden (one that also includes morbidity burden), they express the 
result in terms of cost per QALY, which reflects the likely impact of expenditure at the margin on 
both mortality and morbidity (£12 936 per QALY for 2008/09 healthcare expenditures) (Claxton, 
Martin, et al. 2015). 
 
This paper estimates the marginal productivity of the English NHS for a ten year period between 
2003/04 and 2012/13 applying the methodology used in  Martin et al. (2008 and 2012) and Claxton 
et al. (2015) to new data and conducting additional forms of sensitivity analysis. In so doing, a 
number of empirical challenges are overcome regarding the consistency of collection of data. The 
datasets used are described in section 2, along with an overview of the empirical approach and 
methods used. Discussions of specific methodological challenges are detailed in section 3. In section 
4, marginal productivity results for the ten year period, point estimates and key percentiles of the 
distribution, are expressed in terms of the amount of resource used to produce a unit of health 
benefit (cost per QALY) and the amount of health benefits produced using a unit of resource (QALY 
per cost). Finally these results are discussed in section 5, before a conclusion is presented in section 
6. Additional information on the detail of the methods outlined in the paper and results sensitivity 
analyses which were undertaken are presented as part of the Appendix. 
  




This paper uses two recently established data sets to examine the relationship between NHS 
expenditure and mortality rates for various disease categories. One data set contains mortality rates 
(standardised years of life lost rates, SYLLR) for various disease categories at the level of Local 
Authorities, LAs, in three year periods from 2003/04/05 to 2012/13/14. The other data set presents 
NHS expenditure (adjusted for unavoidable cost-factors) by geographically defined local health 
authorities, PCTs, on 23 broad programmes of care (PBCs). This data set embraces most items of 
publicly funded expenditure, including inpatient, outpatient and community care, and 
pharmaceutical prescriptions. A third source is used in this paper, namely UK censuses from 2001 
and 2011. These census datasets contain a vast amount of information, including demographic and 
socio-economic variables, recorded at a number of geographic levels, including LAs for both years. 
Finally, additional information on the age, gender, life expectancy and health-related quality of life 
of the patient population is taken from ONS (2011) and WHO (2008). 
 
A key challenge to empirical research with these data is establishing consistency in the definition of 
geographical areas across the different data sources. In order to understand this, it is worth 
exploring the policy context of the UK NHS from which most of these data derive. NHS revenue is 
generated almost entirely from national taxation, and access to the system is generally free to the 
patient. The system is organised geographically, with responsibility for the local administration of 
the NHS devolved to health bodies. These health bodies are allocated fixed annual budgets by the 
Department of Health and Social Care, within which they are expected to manage the healthcare in 
the locality. The precise nature of the health bodies to which responsibility is devolved has varied 
over recent years due to various policy reforms from successive governments. In 2003/04 
responsibility was devolved to PCTs, of which there were initially 303, reducing to 152 in October 
2006, until more recently in April 2013 when responsibility was transferred to 211 clinical 
commissioning groups (CCGs). In addition, responsibilities for expenditures on public health have 
been taken away from PCTs and instead devolved to local authorities (LAs) from 2012. 
 
We obtain mortality data for LAs as opposed to PCTs. This is because mortality data (specifically the 
standardised years of life lost rate by PBC) is only available at PCT-level up until 2008/09/10 but is 
available for all ten years at LA-level. Census variables are available at LA-level from both 2001 and 
2011. The remaining variables (PBC expenditure data, healthcare need derived from the UK 
Department of Health and Social Care resource allocation model based on the Combining Age-
Related and Additional Needs formula (hereafter CARAN need), raw population, unified weighted 
population, market forces factor, and PBC-specific indices of need) are only available at PCT-level for 
all waves of data and so have to be mapped to LA-level using a UK Department of Health and Social 
Care tool.2 
 
Taken together, a single dataset is produced that contains information on mortality and expenditure 
by PBC and measures of healthcare need, observed for all LAs over the ten year period. Socio-
economic and demographic variables are only observed in 2001 and 2011 so values for all LAs 
2003/04 – 2010/11 are calculated by linearly interpolating between these two observed values and 
2011 values are used for 2011/12 – 2013/14.3 
                                                          
2 Some PBC-specific measures of need are used in a select few disease areas, e.g. mental health, infectious diseases, and these are 
available only at CCG-level for 2012/13. In the 2012/13 analysis these measures of need were taken from 2011/12 values available at PCT-
level. For the majority of PCTs there is no mapping issue because there is a one-to-one mapping of PCT to LA. The sensitivity of results to 
the mapping tool was investigated as part of preliminary work, using data from 2008/09 where both PCT-level and LA-level are available, 
and the results were largely robust to inaccuracies resulting from the mapping process (see Claxton et al., 2017). 
3 Index of Multiple Deprivation (IMD) is observed for each LA once according to the 2007 definition and once according to the 2010 
definition. The former definition is used for 2003/04 – 2008/09 and the latter used for 2009/10 – 2012/13. 
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2.2 Descriptive statistics 
In this section, descriptive statistics of the key variables are presented, averaging across the ten years as well as providing information on the extent of 
variation that exists between LAs and within LAs over time. 
 
Table 1 - Descriptive statistics 
Variable name N Mean Min Max CV SD 
SD 
(between) SD (within) 




NHS expenditure - all cause 1520 1520.64 820.54 2456.31 0.22 331.11 198.19 265.68 91.14 
NHS expenditure - cancer 1520 91.66 28.78 195.75 0.26 23.89 14.10 19.32 13.52 
NHS expenditure - circulatory 1520 127.88 64.43 328.13 0.21 26.23 21.02 15.78 14.66 
NHS expenditure - respiratory 1520 75.45 31.61 153.97 0.27 20.34 15.14 13.63 8.80 
NHS expenditure - gastro-intestinal 1520 80.63 24.14 141.45 0.23 18.43 14.30 11.68 9.31 
SYLLR - all cause 1504 457.55 198.66 790.42 0.19 85.17 81.98 26.86 22.26 
SYLLR - cancer 1504 155.86 22.48 224.60 0.14 21.32 20.95 9.95 9.88 
SYLLR - circulatory 1504 96.33 30.86 189.60 0.25 24.55 22.21 11.29 8.00 
SYLLR - respiratory 1501 23.55 1.16 68.74 0.37 8.62 8.08 3.12 3.12 
SYLLR - gastro-intestinal 1498 25.42 0.01 87.62 0.43 10.86 10.48 3.59 3.58 
CARAN need index 1520 1.02 0.72 1.41 0.14 0.14 0.14 0.03 0.03 
All NHS expenditures are adjusted for unavoidable variations in costs by LA. These descriptives are unweighted averages across all ten years, but LAs are quite heterogeneous in terms of 
population size. CV, coefficient variation, is calculated by dividing the standard deviation by the mean – it gives a standardised measure of variability. SD (within – excluding uniform time 
effect) was calculated as the within standard deviation after the raw values had been adjusted for year effects using a regression of the variable under consideration against indicators for 
each of the years. 
 
The descriptive statistics reported in Table 1 indicate considerable variation in the key variables (mortality and expenditure) under consideration. The 
variation in CARAN need indicates considerable heterogeneity in the healthcare needs of LAs, although not to the extent of the key variables (comparing 
the coefficients of variation across variables). The standard deviation is broken down into between-variation (the variation between LAs) and within-
variation (the variation over time within LAs). In most cases the variation between LAs exceeds the within-variation, except for the expenditure variables. 
Since expenditure is measured in nominal terms, and because there are potentially other year-effects beyond inflation that affect all LAs, a second estimate 
of within-variation is calculated where the variable is first adjusted for general year effects using an unweighted regression of the variable under 
consideration against indicators for each of the years. Following this adjustment the within-variation for all variables is less than the between-variation, by 
quite some margin in some cases, therefore exhibiting high levels of persistence over time for each variable. 
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2.3 Econometric strategy 
Econometric analysis of the production of health can be informed by an explicit theoretical 
framework, which is useful in providing insight into an appropriate identification strategy. Many 
applications have in mind some model of individual health production, for example Gravelle & 
Backhouse (1987). Given that this analysis considers the English NHS with local administrative health 
bodies, we adopt the framework first described by Martin et al. (2008). In short, this model assumes 
that decision-makers allocate a fixed budget across programmes of care, in such a way that the 
health production function for each programme of care is considered, maximising a social welfare 
function that is a function of health outcomes. The key insight from this model is that the optimal 
level of spending for a given disease area is a function of overall expenditure, need for healthcare 
spending in that disease area, environmental factors that affect health in that disease area, as well 
as need for healthcare spending and environmental factors that affect health in other disease areas. 
Health within each disease area is assumed to be a function of healthcare expenditure within that 
specific disease area such that, for example, cancer outcomes do not depend upon expenditures on 
circulatory problems, and there are no direct health effects of cancer expenditures beyond cancer 
outcomes. In addition, following one of the insights of Gravelle & Backhouse (1987), expenditure 
within each outcome equation may be endogenous due to simultaneous equation bias, i.e. the level 
of healthcare expenditure within a disease area might reflect unobservable factors that influences 
the level of health outcome achieved in that disease area. 
 
The theoretical framework of Martin et al. (2008) suggests the specification and estimation of a 
system of equations, with an expenditure and health outcome equation for each of the 23 
programmes of care. However, this approach makes infeasible data demands, requiring variables to 
identify expenditure, need, environmental factors and health outcomes in each of the 23 
programmes of care. Moreover, mortality rates are available for less than half of the 23 
programmes. Rather than estimate a system of equations, we proceed on a programme-by-
programme basis, estimating health outcome and expenditure equations for those programmes for 
which mortality data are available following the strategy adopted in Claxton et al. (2015). 
 
In line with the theoretical framework summarised above, we specify the following expenditure (see 
Equation 1) and health outcome (see Equation 2) models for each of the 23 programmes of care. 
Accordingly, for the j-th programme of care we have: 
 𝑥𝑖 = 𝛽0 + 𝛽1𝑛𝑖 + 𝛽2𝑚𝑖 + 𝛽3𝑦𝑖 + 𝜀𝑖    (1) ℎ𝑖 = 𝛾0 + 𝛾1𝑛𝑖 + 𝛾2𝑥𝑖 +𝜔𝑖    (2) 
 
All variables are log-transformed prior to estimation. The 𝑖 subscript denotes the unit of observation, 
(LA), 𝑦 is overall expenditure, ℎ is mortality in the j-th PBC, 𝑥 is the expenditure on the j-th PBC, 𝑛 is 
the need for healthcare in the j-th PBC,  𝑚 is the need for care in other PBCs, 𝛽 and 𝛾 arguments are 
parameters to be estimated (𝛽3 is referred to as an ‘expenditure elasticity’ and 𝛾2 an outcome 
elasticity), and 𝜀 and 𝜔 are error terms. 
 
It may be the case that 𝑚 in equation 3 and 𝑥 in equation 4 are endogenous, since other programme 
need is proxied using mortality rates and expenditure by a LA on a disease area may be related to 
unobservable factors that influence the level of health outcomes. For this reason, OLS estimation of 
equations 1 and 2 would likely result in bias even if analysis controlled for observable healthcare 
need (𝑛). One approach to controlling for this endogeneity problem is to estimate IV regression 
using suitable IVs (Martin et al. 2008; Martin et al. 2012; Claxton, Martin, et al. 2015; Andrews et al. 
2017; L C Edney et al. 2018a). However, the underlying theory that suggests endogeneity is likely 
does not itself give any insight into specific instrumental variables that should be used. In general, 
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we need instruments that are associated with either PBC-specific expenditure or other-PBC mortality 
(this requirement is referred to as ‘instrument relevance’), but not PBC-specific mortality either 
directly or through some unobserved variable (this requirement is referred to as ‘instrument 
validity’). Instrument relevance can be directly tested, typically by requiring an F-test of excluded 
instruments in the first stage and requiring that the test statistic exceeds 10 (Staiger & Stock 1997). 
Instrument validity cannot be directly tested, and expert judgement is required, but when an 
equation is over-identified (there are more excluded instruments than endogenous variables) then 
an over-identification test can be helpful, although it may lack power in rejecting the null hypothesis 
of joint validity in some cases (Kovandzic et al. 2013).4 In some cases we can more appropriately 
invoke expert judgement than others. For example, given knowledge about social determinants of 
health, it would be not appropriate to rule out the possibility that socio-economic and demographic 
instruments are invalid in the context of an all-cause mortality where control variables are not used. 
Indeed there is a vast literature on the observed associations between socio-economic status and 
all-cause mortality e.g. Hauck et al. (2016). In the context of this paper, where control variables (𝑛) 
are used and it is not all-cause mortality but rather PBC-specific mortality, it is less clear the extent 
to which it is possible to know a priori which instrumental variables will be valid. Although for some 
PBCs there may be concern about the role of risk factors such as smoking and their association with 
socio-economic status, generally speaking the mechanisms of cause and effect underlying the 
observed associations between socio-economic status and PBC-specific mortalities are largely 
unknown. Nevertheless, the likely presence of endogeneity suggests that we should attempt to use 
some econometric approach beyond OLS, such as IV regression, in order to obtain consistent 
estimates of the causal effects. As such we rely on an approach where we are guided by statistical 
tests in addition to a priori plausibility that instruments could be valid. 
 
With 10 years of data available, a number of possible research avenues initially present themselves. 
It is observed in section 2.2 that there is greater between-variation than within-variation. This means 
that it will inevitably be challenging to isolate causal effects from within-variation. Any research 
strategy based on an IV approach given the available data is made even more difficult, since the IVs 
have only two different observed values over the 10 years (2001 and 2011). As such it is more 
appropriate to focus on the possibility of identifying the causal estimates using the between-
variation. Given that the patient population for each wave of data is, to some extent, different it 
makes sense that the model specification may vary between years with different determinants of 
PBC-specific mortality and PBC-specific expenditure. As such we analyse each wave of data 
separately as a cross-section. This approach enables the identification of any evolution over time in 
the relationships between overall budget and expenditures, and outcomes and expenditures for 
each PBC. 
 
2.4 Translating mortality effects into life-years and quality-adjusted life-years 
The same approach to using estimated elasticities to produce an overall estimate of cost per QALY 
for marginal productivity is adopted as in Claxton et al. (2015). This used additional information from 
WHO and ONS data sources in addition to assumptions about how the effect of expenditure can be 
estimated for improvements in health-related quality of life, in addition to reductions in mortality 
for PBCs without a mortality outcome variable. These assumptions, referred to as surrogacy and 
                                                          
4 The Hansen–Sargan J test of overidentifying restrictions calculates whether different instruments or different 
combinations of instruments generate significantly different values for the coefficient (𝛽2 in equation 1 and 𝛾2in equation 
2) on the endogenous variable in the equation of interest. If significant differences are detected then the test will reject the 
null hypothesis that all instruments are jointly valid. Even if all of the instruments are invalid in the sense that they are all 
correlated with the error term in the equation of interest, the test can detect this failure if the induced biases in the 
estimates of 𝛽2 or 𝛾2 differ across instruments. The test can have low power, i.e. not reject when IVs are not valid, if the 
biases induced in 𝛽2̂ or 𝛾2̂  by invalid instruments all coincide (i.e. the instruments all identify the same wrong parameter) 
(Kovandzic et al. 2013; Claxton et al. 2015). 
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extrapolation5 respectively have been the subject of critical discussion (Barnsley et al. 2013) with 
recent research by Soares et al. (2018) suggesting that on balance they are likely to underestimate 
the health effects of healthcare expenditure (and therefore overestimating cost per QALY). 
  
                                                          
5 The extrapolated elasticity is calculated differently in this paper compared to Claxton et al. (2015). Claxton et al. (2015) 
calculate a weighted average of the estimated outcome elasticities using change in expenditure to weight the different PBC 
elasticities. In contrast, we calculate an elasticity to extrapolating by simulating a 1% change in expenditure allocating 
across PBCs via the estimated expenditure elasticities and estimating the absolute reductions in mortality from the change 
in expenditure. This is then calculated as a percentage reduction in overall mortality and this value is used as the elasticity 
to be extrapolated to other PBCs without mortality indicators (Claxton et al. 2017a). 
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3. Methodological challenges 
The approach outlined in section 2.3 was followed for all of the 310 equations estimated for each of 
the ten years of data. In order to provide more detail on some of the methodological challenges, 
three key issues are highlighted here with additional description of the analysis undertaken.  
 
3.1 Determining an appropriate econometric specification 
Each wave of data was analysed separately, and the model was specified for each year according to 
the following method. In the first instance the econometric specification was taken from the most 
relevant precedent available beginning with 2009/10 drawing upon the 2008/09 specification 
derived in Claxton et al. (2015).6 This specification was then subjected to a battery of statistical tests: 
if IV specification - endogeneity test, Hansen-Sargan over-identification test (when multiple IVs 
used), Kleibergen-Paap LM test for instrument relevance and the Pesaran-Taylor test for 
misspecification; if OLS specification - RESET test. In addition, the model is assessed according to 
plausibility with respect to two priors: that expenditure reduces mortality (𝛾2̂ < 0) and that 
expenditure on a given PBC increases with overall budget (𝛽3̂ > 0) and decreases with other PBC 
need (𝛽2̂ < 0). If there was no evidence that the model was not appropriate based on these tests, 
then the estimate was used to form part of the overall result. If any of the tests indicated that the 
model was not appropriate, then the specification was first amended according to the specific test 
failed, and if this was not sufficient then the entire equation was re-estimated with covariates and 
instrumental variables selected using a step-wise procedure. In rare circumstances where outlier 
expenditure values were found, samples were trimmed as a final attempt to estimate a successful 
model. If this failed then either a value of zero is used if an outcome elasticity, or, if an expenditure 
elasticity, the preceding wave's specification was adopted and the estimate used irrespective of test 
results and coefficients not conforming to priors. The outcomes of this process were preferred 
outcome and expenditure specifications for each PBC for each year. More details of this process and 
are provided in the Appendix, section A1.1. 
 
3.2 Sensitivity of alternative OLS results to endogeneity 
As mentioned in section 3.1, a test for endogeneity is performed for estimated IV regression models, 
and a RESET test is performed for estimated OLS models. Both of these tests can be used to inform 
the presence of endogeneity. However, testing a variable within an IV regression model for 
endogeneity, with the null hypothesis that the variable is exogenous, relies upon the model being 
correctly specified. While there are tests for misspecification and the validity of IVs, it cannot be 
known with certainty that the model specification is correct. Likewise, the RESET test only provides 
an indication as to whether there is model misspecification or not, which in turn would indicate the 
presence of endogeneity. 
 
As a result the presence of endogeneity is not possible to detect using statistical tests alone, but 
instead a judgement informed by theory is required. In the context of estimating the relationship 
between mortality and healthcare expenditure, there is a long history of empirical work that has 
attempted to control for endogeneity (Gallet & Doucouliagos 2017) and theoretical papers that 
suggest that endogeneity is likely (Gravelle & Backhouse 1987). To illustrate the implications of not 
employing an IV approach, a sensitivity analysis is conducted where all equations are estimated 
using OLS. The results for 2012/13 are discussed in detail in the Appendix, section A1.2, and are 
briefly summarised here. In the analysis of the 2012/13 data, 10 expenditure equations and 5 
outcome equations were estimated using IV regression. In all cases, not using IVs and estimating 
                                                          
6 FY 2010/11 then drew upon the econometric specification from FY 2009/10, and so on, up to 2012/13.  The model 
specification for 2008/09 drew upon that for FY 2009/10, and then that for FY 2007/08 drew upon FY 2008/09 and so on 
until each an appropriate model was specified for each wave of data as far back as FY 2003/04 and up to FY 2012/13. 
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using OLS results in a reduction in the magnitude of the point estimate of the coefficient of interest. 
In addition, when using OLS, there is no evidence of a statistically significant effect of own-PBC 
healthcare spending on cancer, respiratory and gastro-intestinal mortality. Considering all of the 
elasticities from these models estimated by OLS as well as all other equations estimated using OLS in 
the main analysis, an estimate of the implied all-cause mortality elasticity can be calculated. The 
implied all-cause elasticity estimate from the main analysis for 2012/13 was -1.028, which is 
comparable in magnitude to other all-cause mortality elasticity estimates of -0.71 (Andrews et al. 
2017) and -1.089 (Claxton et al. 2018).7 On the other hand, when all equations are estimated by OLS 
the resulting implied all-cause mortality elasticity is -0.153. The difference between the 2012/13 
implied all-cause mortality elasticity estimate and the expected value from the existing literature 
reflects that OLS estimates underestimate the magnitude of effect of healthcare spending on 
mortality. 
 
3.3 Sensitivity of IV results to just-identified IV approach 
The issues caused by employing a weak set of IVs, with little relevance in the first-stage regression, 
are well-known, namely that it leads to bias in the IV regression coefficient. The approach adopted in 
this paper avoids this issue by choosing the model specification in accordance with statistical tests 
judged against conventional levels, i.e. first stage F-statistic of excluded instruments should be 
greater than 10 (Staiger & Stock 1997). In addition, it has been argued that a more parsimonious 
specification of IVs is better and that additional IVs, when individually adding little by way of 
explanatory power in the first-stage regression, increase large-sample bias of the IV regression 
coefficients (Breusch et al. 1999; Hahn & Hausman 2002; Andrews et al. 2017). As a rule, this paper 
does not include IVs in the first-stage regression if they are individually not significant and so does 
seek a parsimonious specification in this sense. More recently, some authors have gone further by 
saying that potential weak instrument bias can be mitigated by using a just-identified specification, 
i.e. including only a single IV in the case where there is a single endogenous regressor (Angrist & 
Pischke 2009). Specifically, Angrist and Pischke (2009) argue that just-identified IV is “approximately 
unbiased” with low median bias even with relatively weak instruments. In the main analysis of this 
paper, only IVs with significant individual and joint explanatory power are included in the first stage 
regressions of preferred specifications, but as a sensitivity analysis over-identified IV regression 
models were instead estimated using a just-identified approach. This resulted in negligible changes 
for the 2012/13 analysis of four large PBCs, results in Appendix section A1.3. 
 
                                                          
7 Both of these results are based on 2005/06 expenditure data and 2005/06/07 mortality data. These studies are not 
directly comparable, because they do not analyse individual PBCs, but instead estimate a model relating all-cause mortality 
and all healthcare expenditure. As such we might expect that there is an underestimate in the magnitudes of these 
resulting estimated elasticities due to ‘aggregation bias’, i.e. in these studies it is harder to obtain a clear signal from the 
noisy data. 
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4. Results 
Full regression results for the preferred outcome and expenditure equation specifications by PBC for 
each year, including specification test results, can be found in the Appendix section A2.2, Tables A2.1 
– A2.20. First stage regressions of IV models can be found in the Appendix section A2.3, Tables A2.21 
– A2.40. We summarise the outputs from each equation estimated by presenting the coefficient of 
interest in Table 2. 
 
These estimated elasticities are combined along with additional information about age, gender, life 
expectancy and burden of disease of the patient population to produce overall results that can be 
presented as either the amount of resource used to produce a unit of health benefit (cost per QALY) 
or as the amount of health benefits produced using a unit of resource (QALY per cost). For the latter, 
we present results as the number of QALYs gained for £10 million, which represents a small amount 
of money relative to the overall level of NHS expenditure, but is large enough to produce a large 
number of QALYs. All results are expressed in nominal terms, meaning that the 2009/10 estimate of 
marginal productivity is denominated in 2009/10 prices. The results can be found in Table 3 and in 
Figures 1 and 2. 
 
In Table 3 we present results in both formats. Results are generated first deterministically, where the 
point estimate of expenditure and outcome elasticities are used as inputs in the model that links 
these to ONS and WHO data in order to calculate overall estimates of marginal productivity. In the 
other columns, results are presented from a probabilistic analysis. For this, draws are taken from 
independent Normal distributions for each elasticity parameter with mean and variance taken from 
the estimated coefficient and standard error squared, respectively. In total, 20,000 iterations are 
conducted to generate a probability distribution for the overall result. The mean, 5th and 95th 
percentiles of the generated distribution are presented in the table above to reflect the point 
estimate and a 90% confidence interval.8 This confidence interval reflects the parameter uncertainty 
in the model that is driven by sampling uncertainty and is driven entirely by the standard errors of 
the estimated expenditure and outcome elasticities. To this extent it reflects the effect that 
variations in estimated elasticities would have on the overall estimates of marginal productivity. The 
confidence interval does not therefore reflect other sources of uncertainty arising from more 
structural matters such as assumptions relating the effect of expenditure on mortality to the effect 
of expenditure on morbidity, or indeed the bias resulting from IV regressions with contaminated IVs 
(IVs that are not perfectly valid). 
 
These same results are plotted visually in Figures 1 and 2. Figure 1 presents the deterministic point 
estimate in terms of cost per QALY along with the 90% confidence interval, while Figure 2 presents 
the deterministic point estimate in QALYs per £10 million along with the 90% confidence interval. 
 
 
                                                          
8 The deterministic and probabilistic point estimates differ because of the non-linear function that combines the estimated 
elasticities and additional information about survival and health-related quality of life. In particular, two features of the 
model are responsible for the non-linearity: the extrapolation assumption, and the adjustment to expenditure elasticities 
so that the changes in expenditure in all PBCs sum to the overall change in expenditure simulated (1% of total 
expenditure). 
12  CHE Research Paper 158 
 
Table 2 - Estimated outcome and expenditure elasticities, by PBC, 2003/04 to 2012/13 
PBC 2003/04 2004/05 2005/06 2006/07 2007/08 2008/09 2009/10 2010/11 2011/12 2012/13 
 
Out Exp Out Exp Out Exp Out Exp Out Exp Out Exp Out Exp Out Exp Out Exp Out Exp 
Infectious diseases -0.205 1.094*** -0.100 0.932*** -0.432 1.205*** -0.608 1.051*** -0.660** 1.387*** -0.549*** 1.471*** -0.310* 0.968*** -0.256 1.006*** -0.305*** 0.841*** -0.362*** 0.749*** 
Cancer -0.201** 1.711*** -0.224** 1.259*** -0.159* 1.592*** -0.239*** 1.219*** -0.273*** 1.626*** -0.287*** 0.784** -0.345*** 0.502** -0.220*** 0.438 -0.430*** 0.961** -0.361*** 1.027** 
Blood n/a 0.652* n/a 0.952*** n/a 1.486*** n/a 1.037*** n/a 1.374*** n/a 0.995*** n/a 1.060*** n/a 0.332 n/a 0.876*** n/a 1.119*** 
Endocrine 0 0.653*** -1.843 0.573*** -1.035 0.663*** -1.464 0.630*** -1.491 0.455*** -1.607** 0.498*** -1.075** 0.708*** -0.174 0.696*** -0.199 1.116*** -0.499 0.951*** 
Mental health n/a 1.333*** n/a 0.999*** n/a 0.991*** n/a 1.143*** n/a 1.103*** n/a 0.995*** n/a 0.899*** n/a 0.973*** n/a 1.194*** n/a 1.023*** 
Learning disability n/a 0.646* n/a 0.446* n/a 0.449* n/a 0.410 n/a 0.386 n/a 0.329 n/a 0.647** n/a 1.208** n/a 0.741* n/a 0.000 
Neurological -0.751* 1.408*** -0.968** 0.929*** -0.325 1.220*** -0.869* 0.382* -0.237* 0.733*** -0.304 0.897*** -1.357 0.850*** -0.374 0.557*** -1.415 0.703*** -0.009 0.856*** 
Vision n/a 0.833*** n/a 1.350*** n/a 1.127*** n/a 0.931*** n/a 1.106*** n/a 0.701*** n/a 0.934*** n/a 0.997*** n/a 1.279*** n/a 1.411*** 
Hearing n/a 0.694* n/a 0.526 n/a 0.762** n/a 0.989** n/a 0.951* n/a 1.637*** n/a 1.273*** n/a 0.808* n/a 1.231*** n/a 1.523*** 
Circulatory -1.202*** 1.873*** -1.375*** 1.652*** -1.637*** 1.477*** -1.404*** 1.578*** -1.315*** 1.614*** -1.384*** 1.784*** -1.842*** 0.494* -1.692*** 1.013*** -1.611*** 1.491*** -1.464*** 1.285*** 
Respiratory -1.666*** 1.661*** -2.494*** 1.253*** -2.217*** 1.225*** -2.281*** 1.287*** -1.564*** 1.555*** -1.671*** 0.752** -2.103*** 0.576*** -2.006** 1.192*** -1.743*** 1.360*** -1.704*** 0.928*** 
Dental n/a 0.717* n/a 0.848* n/a 1.224** n/a 0.835** n/a 0.420*** n/a 0.428** n/a 0.765*** n/a 0.229 n/a 0.843*** n/a 0.855*** 
Gastro-intestinal -1.493*** 1.409*** -1.253*** 0.928*** -1.014* 1.076*** -1.255** 1.014*** -0.837** 1.490*** -1.146** 0.520* -1.989* 0.387* -1.425** 1.040*** -2.000** 1.033*** -1.904** 0.997*** 
Skin n/a 0.700*** n/a 0.595*** n/a 0.840*** n/a 0.701*** n/a 0.787*** n/a 0.907*** n/a 0.890*** n/a 0.422* n/a 0.681*** n/a 1.158*** 
Musculo-skeletal n/a 1.014*** n/a 0.567*** n/a 0.935*** n/a 0.628* n/a 0.733*** n/a 0.738*** n/a 0.295 n/a 0.489** n/a 0.456** n/a 0.725*** 
Trauma and injuries 0 0.556*** 0 0.576** 0 0.897*** 0 0.705*** -0.638 1.328*** 0 1.344*** 0 1.090*** -0.064 0.589** 0 1.024*** 0 1.058*** 
Genito-urinary -0.063 0.934*** -0.931* 0.716*** -0.869* 1.079*** -0.588 0.988*** -1.977 1.015*** -0.024 0.733*** -2.997 0.878*** -2.83 0.631*** -0.494 0.598*** -0.160 0.855*** 
Maternity and 
neonates 
0 0.757*** -0.121 0.678*** -0.056 0.865*** -0.085 0.614** -0.057 0.563** -0.030 0.963*** -0.166* 0.653*** -0.04 0.342 -0.136 0.481*** -0.106 0.833*** 
Poisoning n/a 2.327*** n/a 1.674*** n/a 1.735*** n/a 1.107*** n/a 1.674*** n/a 2.102*** n/a 0.658** n/a 1.078** n/a 0.631** n/a 1.124*** 
Healthy individuals n/a 1.538** n/a 0.709* n/a 0.507 n/a 0.709 n/a 1.296** n/a 1.049 n/a 1.246** n/a 1.359** n/a 1.748*** n/a 1.172* 
Social care n/a 1.581*** n/a 1.313** n/a 1.069* n/a 1.702*** n/a 1.669** n/a 1.192* n/a 0.844 n/a 1.592** n/a 1.859*** n/a 1.613*** 
Other n/a 0.681*** n/a 0.337*** n/a 0.532*** n/a 0.447*** n/a 0.553*** n/a 0.338*** n/a 0.564*** n/a 0.520*** n/a 0.518*** n/a 0.585*** 
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5th percentile 95th percentile 
2003/04 
Cost per QALY £6,381 £6,381 £5,048 £8,534 
Health opportunity 
costs of £10mn (QALYs) 
1,567 1,567 1,172 1,981 
2004/05 
Cost per QALY £5,389 £5,377 £4,110 £7,517 
Health opportunity 
costs of £10mn (QALYs) 
1,856 1,860 1,330 2,433 
2005/06 
Cost per QALY £7,613 £7,635 £5,611 £11,619 
Health opportunity 
costs of £10mn (QALYs) 
1,314 1,310 861 1,782 
2006/07 
Cost per QALY £6,844 £6,838 £5,139 £9,878 
Health opportunity 
costs of £10mn (QALYs) 
1,461 1,462 1,012 1,946 
2007/08 
Cost per QALY £9,747 £9,765 £7,689 £13,043 
Health opportunity 
costs of £10mn (QALYs) 
1,026 1,024 767 1,301 
2008/09 
Cost per QALY £12,960 £13,271 £8,390 £32,881 
Health opportunity 
costs of £10mn (QALYs) 
772 754 304 1,192 
2009/10 
Cost per QALY £9,887 £9,920 £6,802 £17,296 
Health opportunity 
costs of £10mn (QALYs) 
1,011 1,008 578 1,470 
2010/11 
Cost per QALY £10,225 £10,214 £7,073 £17,153 
Health opportunity 
costs of £10mn (QALYs) 
978 979 583 1,414 
2011/12 
Cost per QALY £8,997 £8,985 £6,520 £13,945 
Health opportunity 
costs of £10mn (QALYs) 
1,112 1,113 717 1,534 
2012/13 
Cost per QALY £14,410 £14,411 £11,182 £19,861 
Health opportunity 
costs of £10mn (QALYs) 
694 694 504 894 
 
It can be seen from Table 3 and Figures 1 and 2 that the expected health opportunity costs of £10 
million have decreased between 2003/04 and 2012/13 and so the cost per QALY ratio has risen. 
Nevertheless, all point estimates are within the range £5,000 to £15,000 per QALY. In addition, 
changes in the overall estimates of health opportunity costs of £10 million do not decrease 
monotonically with time, despite these results being nominal and inflation in NHS price levels during 
this period9(Curtis 2014). From these results, where the uncertainty associated with these estimates 
is shown, it can be judged to what extent any changes in the point estimate between years should 
be interpreted as a signal of any trend. It is hard to conclude that there is a significant change in the 
health opportunity costs of £10mn expenditure, since there is a great deal of overlap between the 
90% confidence intervals of the years shown. It can also be seen from Figures 1 and 2 that while the 
confidence interval is far from symmetrically distributed around the point estimate of the cost per 
QALY ratio in Figure 1 (where uncertainty is reflected in the denominator), the distribution of 
uncertainty of health opportunity costs per £10mn is much more symmetric in Figure 2 (since 
uncertainty is reflected in the numerator). 
 
                                                          
9 HCHS index has grown over this period by 28%. 
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Figure 1 - Marginal productivity for 2003/04 to 2012/13 expressed as cost per QALY with 90% confidence 
intervals 
 
Figure 2 - Marginal productivity for 2003/04 to 2012/13 expressed as QALYs per £10 million with 90% 
confidence intervals  
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5. Discussion 
Broadly speaking the results here confirm those of Claxton et al. (2015), which showed that the point 
estimate of the marginal productivity of the NHS was between £10,000 and £15,000 per QALY for 
the years 2006/07 to 2008/09. This paper contributes to the literature by extending the number of 
years analysed including much more recent estimates for the marginal productivity of the NHS for 
2012/13. This is only possible due to work establishing the consistency in the unit of analysis to LA-
level. In addition, this paper uses more appropriate IVs, by combining values from the 2001 and the 
(more recently released) 2011 censuses. Finally this paper describes a process by which precedent in 
the literature addressing this research question can be taken and used to inform a model 
specification for newly available waves of data, in accordance with the appropriate econometric 
specification tests. 
 
Looking at the confidence intervals presented in Figures 1 and 2 it can also be seen that the results 
indicate that it can be said with some confidence that marginal productivity is above 300 QALYs for 
£10 million of NHS expenditure (£33,333 per QALY) where all years' results 5th percentile of QALYs 
per cost is above this value. Where resource allocation decisions have been made on the implicit 
basis that the estimate of marginal productivity of the NHS is £30,000, or even £40,000 per QALY, 
these decisions may have been sub-optimal as a result in terms of population QALYs (Claxton, 
Sculpher, et al. 2015). QALYs may of course not be the sole objective of healthcare expenditure, and 
decisions may be made that lead to reductions in health (as measured by QALYs), but are judged 
worthwhile because of other considerations. A framework for analysis to inform decisions such as 
these is illustrated in Sculpher et al. (2017). 
 
Comparisons of these results with the broader literature on productivity is problematic given the 
emphasis here is on the marginal productivity of the NHS and not the average productivity. Studies 
from other healthcare systems vary widely in terms of methods used, but produce results where the 
estimated marginal productivity is lower than the value implied by healthcare decision makers 
(Ochalek et al. 2015; Vallejo-Torres, García-Lorenzo, Castilla, et al. 2016; Vallejo-Torres, García-
Lorenzo & Serrano-Aguilar 2016). In this sense, this paper is consistent with the existing literature 
with marginal productivity estimated to be much lower than currently explicitly stated norms (NICE 
2013) or the values implied by actual decisions (Dakin et al. 2014). Looking at the results from this 
paper over time, the cost per QALY in 2012/13 is more than double that of 2003/04, but some of this 
increase is no doubt due to input price inflation faced by the NHS, roughly 28% over the same period 
(Curtis 2014). Nevertheless, this suggests that real productivity at the margin has fallen, which is 
consistent with diminishing marginal returns to health expenditure (expenditure has increased in 
nominal and real terms over most of the ten year period analysed) (Nuffield Trust 2015). This may 
appear counter-intuitive given the finding from Bojke et al. (2017) that average productivity has 
increased over the same period, but could be explained by a number of factors: first, Bojke et al. 
(2017) use a composite indicator of outputs, as opposed to focusing on outcomes; second, the 
difference in results may reflect the kinds of marginal activities that are subject to disinvestment and 
investment locally - where different productivity trends may exist compared to the average; third, 
the kinds of activities that are marginal may change over time due to changes in demand for 
healthcare; and fourth, falling marginal productivity and rising average productivity is consistent if 
marginal productivity remains above average productivity. The issue of factors that may affect 
marginal productivity over time is discussed in more general terms by Paulden et al. (2017), where 
the general productivity of the healthcare system is just one factor in determining the marginal 
productivity that is crucial for decisions around resource allocation. 
 
At the core of this analysis is the econometric estimation of expenditure and outcome elasticities. 
Since there are good reasons to believe that certain variables will be endogenous, a key component 
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is the use of IVs to identify a causal effect. It is generally impossible to know with certainty whether 
IVs are valid. Our theoretical model itself does not give insight into specific instrumental variables 
that should be used and their validity cannot be directly tested so judgement is required. In some 
cases we can more appropriately invoke expert judgement than others. For example, given 
knowledge about the social determinants of health, it would be not appropriate to rule out the 
possibility that instruments are invalid in the context of all-cause mortality where control variables 
are not used. Indeed we would argue that such instruments would not be valid with this setup, 
based on the literature on the observed associations between socio-economic status and mortality. 
In the context of this paper, where control variables are used and it is not all-cause but PBC-specific 
mortality that is being estimated, it is less clear the extent to which it is possible to know a priori 
which instrumental variables will be valid, i.e. those that are not part of the causal pathway. This is 
because the mechanisms of cause and effect on specific types of PBC mortality underlying the 
observed associations between socio-economic status and all-cause mortality are largely unknown.  
 
It is possible to conduct statistical tests that can guide model specification and these have been used 
throughout, as part of a clearly specified and documented protocol before the analysis is undertaken 
to avoid the danger of mining alternative specifications (see Appendix A1.1). Nonetheless, the tests 
for validity can lack power to reject the null that IVs are not appropriately excluded from the second 
stage of the IV regression, in particular when IVs might be thought to influence the endogenous 
regressor in the same kind of way. However, the results of the just-identified sensitivity analysis and 
the poor performance of an OLS strategy, combined with other related work provides some greater 
confidence and insight into how these considerations might influence a reasonable interpretation of 
the results in this paper. Firstly, Claxton, Martin, et al. (2015) a sensitivity analysis (based on Small, 
2007, and Conley et al., 2012) was undertaken to examine the impact of contaminated IVs (IVs that 
are not perfectly excluded from the second stage of the IV regression) which showed that 
contamination introduces additional uncertainty into the elasticity estimates, but not bias. Secondly, 
the implied all cause elasticities using the approach taken to identification in this paper are 
comparable with the directly estimated all cause elasticities in Andrews et al (2017) and Claxton et al 
(2018). The elasticities for key PBCs are also comparable with Claxton et al (2018). The fact that 
results are very similar when a very different approach to identification is taken gives some greater 
confidence that the census based instruments are plausibly valid and the results are not highly 
specific local average treatment effects. This is especially important in the more common context 
where the approach pioneered by Andrews et al (2017) is not possible. Taken together these 
considerations provide reassurance that an IV strategy is appropriate and that the estimates 
provided in this paper are not significantly biased in any particular direction. It does suggest that 
there is inevitably additional structural uncertainty that is not reflected in the confidence intervals 
reported in Table 2 and Figures 1 and 2. 
 
The approach taken here is to analyse each wave of data as an independent cross-section and to 
build on the model specification from the preceding wave. As a result, these models represent the 
best specification for the data given the results of the statistical tests and therefore have better 
econometric properties. For example, maximal bias in IV models is reduced with a higher magnitude 
of first stage F-statistic (Stock & Yogo 2002). Further, each wave of data represents a different 
patient population with different determinants of health and healthcare demand. As a result, it is 
reasonable to expect the most appropriate econometric specification to vary between different 
waves of data. Practically speaking however, there is limited within-variation in the key variables as 
seen from Table 1 and high persistence over time is exhibited. As such, it is no surprise that relatively 
few changes to model specifications are required and that the estimated elasticities are reasonably 
stable over time. 
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For future work, there are a number of benefits to estimating a model across multiple waves of data 
using panel data analysis. The benefits of increased precision from using both within and between 
variation in variables are likely to be limited given that there is little within-variation in this context. 
In particular, identifying a causal effect using a fixed effects panel model would seem highly 
challenging. However, there may be value in pooling the data and estimating a single model over the 
multiple years of data. One potential concern with the work that is undertaken in this paper is that 
overfitting is introduced by adjusting specifications between years where variations may reflect 
noise as opposed to signal. The consequence of such overfitting would be that parameter 
uncertainty is underestimated. A panel analysis could be used to inform a single specification that is 
then applied to each wave of data, without refinement, thus avoiding charges of overfitting the data. 
Further, it may be possible to estimate the time profile of the lagged relationships between health 
and expenditure, which cannot be estimated in a study such as this that restricts analysis to current 
expenditures and current health outcomes. 
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6. Conclusion 
Given the interest among economists in decision-making at the margin, and the longstanding 
interest in the productivity of publically funded institutions like the NHS, it is surprising that so few 
studies have sought to estimate the marginal productivity of the NHS. Its usefulness is not limited to 
decisions within the healthcare sector, but is essential to inform the allocation of scarce public 
resources across sectors too. This paper has shown how econometric analysis can be used to provide 
estimates of the outcome-based marginal productivity of the NHS, with results expressed as either 
cost per QALY or QALY per cost. The results themselves show that despite the inflation of prices that 
are faced by NHS providers, cost per QALY has remained relatively stable over time, with point 
estimates of the amount of resources, in nominal terms, to produce an additional unit of health 
benefit ranging from £5,000 to £15,000 per QALY over the period between 2003/04 and 2012/13. 
  
Estimating the marginal productivity of the English National Health Service from 2003/04 to 2012/13  19 
 
References 
Andrews, M. et al., 2017. Inference in the presence of redundant moment conditions and the impact 
of government health expenditure on health outcomes in England. Econometric Reviews, 36(1–3), 
pp.23–41. Available at: https://www.tandfonline.com/doi/full/10.1080/07474938.2016.1114205 
[Accessed July 24, 2017]. 
 
Angrist, J. & Pischke, J.S., 2009. A Note on Bias in Just Identi…ed IV with Weak Instruments. Available 
at: http://econ.lse.ac.uk/staff/spischke/mhe/josh/solon_justid_April14.pdf [Accessed July 30, 2018]. 
 
Barnsley, P. et al., 2013. Critique of CHE Research Paper 81: Methods for the Estimation of the NICE 
Cost Effectiveness Threshold. Available at: 
https://www.ohe.org/system/files/private/publications/392 - Critique of CHE Research Paper 81 
Barnsley 2013.pdf [Accessed May 16, 2017]. 
 
Bojke, C. et al., 2017. Productivity Growth in the English National Health Service from 1998/1999 to 
2013/2014. Health Economics, 26(5), pp.547–565. Available at: 
http://doi.wiley.com/10.1002/hec.3338 [Accessed January 18, 2018]. 
 
Breusch, T. et al., 1999. Redundancy of moment conditions. Journal of Econometrics, 91(1), pp.89–
111. Available at: https://www.sciencedirect.com/science/article/pii/S0304407698000505 [Accessed 
July 30, 2018]. 
 
Claxton, K., Sculpher, M., et al., 2015. Causes for concern: is NICE failing to uphold its responsibilities 
to all NHS patients? Health economics, 24(1), pp.1–7. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/25488707 [Accessed November 27, 2015]. 
 
Claxton, K., Martin, S., et al., 2015. Methods for the estimation of the National Institute for Health 
and Care Excellence cost-effectiveness threshold. Health technology assessment (Winchester, 
England). 
 
Claxton, K., Lomas, J. & Martin, S., 2017a. ESTIMATING EXPECTED HEALTH OPPORTUNITY COSTS IN 
THE NHS (Analysis of 2012/13 Expenditure Data). Available at: 
https://www.york.ac.uk/media/che/documents/Estimating_expected_health_opportunity_costs_in
_the_NHS_201213.pdf [Accessed January 18, 2018]. 
 
Claxton, K., Lomas, J. & Martin, S., 2017b. Switching to local authorities (LAs) as the unit of analysis 
(2008/09 expenditure). Available at: https://www.york.ac.uk/media/che/documents/PCT to Local 
Authority unit of analysis_08_09.pdf [Accessed January 18, 2018]. 
 
Claxton, K., Lomas, J. & Martin, S., 2018. The impact of NHS expenditure on health outcomes in 
England: Alternative approaches to identification in all-cause and disease specific models of 
mortality. Health Economics (United Kingdom). 
 
Conley, T.G., Hansen, C.B. & Rossi, P.E., 2012. Plausibly Exogenous. Review of Economics and 
Statistics, 94(1), pp.260–272. Available at: 
http://www.mitpressjournals.org/doi/10.1162/REST_a_00139 [Accessed July 31, 2018]. 
 
Culyer, A.J., 2018. Cost, Context and Decisions in Health Economics and Cost-Effectiveness Analysis. 
CHE Research Paper, 154. Available at: www.york.ac.uk/che [Accessed July 10, 2018]. 
 
20  CHE Research Paper 158 
 
Curtis, L., 2014. Unit Costs of Health and Social Care 2014. 
 
Dakin, H. et al., 2014. THE INFLUENCE OF COST-EFFECTIVENESS AND OTHER FACTORS ON NICE 
DECISIONS. Health economics. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25251336 
[Accessed December 2, 2015]. 
 
Edney, L.C. et al., 2018a. Estimating the Reference Incremental Cost-Effectiveness Ratio for the 
Australian Health System. PharmacoEconomics, 36(2), pp.239–252. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/29273843 [Accessed July 10, 2018]. 
 
Edney, L.C. et al., 2018b. Mortality reductions from marginal increases in public spending on health. 
Health Policy, 122(8), pp.892–899. Available at: http://www.ncbi.nlm.nih.gov/pubmed/29759682 
[Accessed August 9, 2018]. 
 
Gallet, C.A. & Doucouliagos, H., 2017. The impact of healthcare spending on health outcomes: A 
meta-regression analysis. Social Science & Medicine, 179, pp.9–17. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/28237460 [Accessed January 18, 2018]. 
 
Gravelle, H.S. & Backhouse, M.E., 1987. International cross-section analysis of the determination of 
mortality. Social science & medicine (1982), 25(5), pp.427–41. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/3499669 [Accessed January 18, 2018]. 
 
Hahn, J. & Hausman, J., 2002. Notes on bias in estimators for simultaneous equation models. 
Economics Letters, 75(2), pp.237–241. Available at: 
https://www.sciencedirect.com/science/article/pii/S0165176501006024 [Accessed July 31, 2018]. 
 
Hauck, K., Martin, S. & Smith, P.C., 2016. Priorities for action on the social determinants of health: 
Empirical evidence on the strongest associations with life expectancy in 54 low-income countries, 
1990–2012. Social Science & Medicine, 167, pp.88–98. Available at: 
https://www.sciencedirect.com/science/article/pii/S0277953616304713?via%3Dihub [Accessed July 
6, 2018]. 
 
Hollingsworth, B., 2008. The measurement of efficiency and productivity of health care delivery. 
Health Economics, 17(10), pp.1107–1128. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/18702091 [Accessed January 18, 2018]. 
 
Kovandzic, T. et al., 2013. Estimating the Causal Effect of Gun Prevalence on Homicide Rates: A Local 
Average Treatment Effect Approach. J Quant Criminol, 29, pp.477–541. Available at: 
https://link.springer.com/content/pdf/10.1007%2Fs10940-012-9185-7.pdf [Accessed July 26, 2018]. 
 
Martin, S., Rice, N. & Smith, P.C., 2012. Comparing costs and outcomes across programmes of health 
care. Health Economics, 21(3), pp.316–337. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/21322086 [Accessed July 24, 2017]. 
 
Martin, S., Rice, N. & Smith, P.C., 2008. Does health care spending improve health outcomes? 
Evidence from English programme budgeting data. Journal of health economics, 27(4), pp.826–42. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/18261812 [Accessed December 6, 2015]. 
 
McCarthy, N., 2015. The World’s Biggest Employers [Infographic]. Forbes. Available at: 
https://www.forbes.com/sites/niallmccarthy/2015/06/23/the-worlds-biggest-employers-
infographic/#48e61312686b [Accessed January 18, 2018]. 
Estimating the marginal productivity of the English National Health Service from 2003/04 to 2012/13  21 
 
Murray, C.J. & Frenk, J., 2000. A framework for assessing the performance of health systems. Bulletin 
of the World Health Organization, 78(6), pp.717–31. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/10916909 [Accessed January 18, 2018]. 
 
NICE, 2013. Guide to the methods of technology appraisal. Available at: 
https://www.nice.org.uk/process/pmg9/chapter/foreword [Accessed July 31, 2017]. 
 
Nuffield Trust, 2015. NHS in Numbers. Available at: https://www.nuffieldtrust.org.uk/resource/nhs-
in-numbers [Accessed January 18, 2018]. 
 
Ochalek, J., Lomas, J. & Claxton, K., 2015. Cost Per DALY Averted Thresholds for Low- and Middle-
Income Countries: Evidence From Cross Country Data, York. 
 
ONS, 2011. Life Expectancy at Birth and at Age 65 by Local Areas in the United Kingdom. Available at: 
https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/lifeexpectanci
es/bulletins/lifeexpectancyatbirthandatage65bylocalareasintheunitedkingdom/2011-10-19#tab-
National-life-expectancy [Accessed January 18, 2018]. 
 
Paulden, M., O’Mahony, J. & McCabe, C., 2017. Determinants of Change in the Cost-effectiveness 
Threshold. Medical Decision Making, 37(2), pp.264–276. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/27553208 [Accessed May 16, 2017]. 
 
Propper, C., 1995. Agency and incentives in the NHS internal market. Social Science & Medicine, 
40(12), pp.1683–1690. Available at: 
http://www.sciencedirect.com/science/article/pii/0277953694002852?via%3Dihub [Accessed 
January 18, 2018]. 
 
Propper, C. & Wilson, D., 2012. The use of performance measures in health care systems. In A. Jones, 
ed. The Elgar Companion to Health Economics. Edward Elgar, pp. 350–358. 
 
Sculpher, M., Claxton, K. & Pearson, S.D., 2017. Developing a Value Framework: The Need to Reflect 
the Opportunity Costs of Funding Decisions. Value in Health, 20(2), pp.234–239. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/28237201 [Accessed January 18, 2018]. 
 
Small, D.S., 2007. Sensitivity Analysis for Instrumental Variables Regression With Overidentifying 
Restrictions. Journal of the American Statistical Association, 102(479), pp.1049–1058. Available at: 
http://www.tandfonline.com/doi/abs/10.1198/016214507000000608 [Accessed July 31, 2018]. 
 
Smith, P. & Street, A., 2012. Concepts and challenges in measuring the performance of health care 
organizations. In A. Jones, ed. The Elgar Companion to Health Economics. Edward Elgar, pp. 341–349. 
Available at: https://pure.york.ac.uk/portal/en/publications/concepts-and-challenges-in-measuring-
the-performance-of-health-care-organizations(80f95591-69aa-4561-b6f2-
5f42159acecb)/export.html [Accessed January 18, 2018]. 
 
Soares, M.O., Sculpher, M.J. & Claxton, K., 2018. HEALTH OPPORTUNITY COSTS: ASSESSING THE 
IMPLICATIONS OF UNCERTAINTY USING ELICITATION METHODS WITH EXPERTS. Policy Research Unit 
in Economic Evaluation of Health and Care Interventions. Universities of Sheffield and York. Available 
at: http://www.eepru.org.uk/wp-content/uploads/2017/12/eepru-report-health-opp-costs-
elicitation-july-2018-revised.pdf [Accessed August 9, 2018]. 
 
 
22  CHE Research Paper 158 
 
Staiger, D. & Stock, J.H., 1997. Instrumental Variables Regression with Weak Instruments. 
Econometrica, 65(3), p.557. Available at: https://www.jstor.org/stable/2171753?origin=crossref 
[Accessed July 31, 2018]. 
 
Stock, J. & Yogo, M., 2002. Testing for Weak Instruments in Linear IV Regression, Cambridge, MA. 
Available at: http://www.nber.org/papers/t0284.pdf [Accessed January 18, 2018]. 
 
Vallejo-Torres, L., García-Lorenzo, B., Castilla, I., et al., 2016. On the Estimation of the Cost-
Effectiveness Threshold: Why, What, How? Value in Health, 19(5), pp.558–566. Available at: 
http://linkinghub.elsevier.com/retrieve/pii/S1098301516000693 [Accessed May 16, 2017]. 
 
Vallejo-Torres, L., García-Lorenzo, B. & Serrano-Aguilar, P., 2016. Estimating a cost-effectiveness 
threshold for the Spanish NHS, Madrid. 
 
WHO, 2008. The global burden of disease: 2004 update. Available at: 




Estimating the marginal productivity of the English National Health Service from 2003/04 to 2012/13  23 
 
Appendix 
This Appendix is divided into several sections. Reading through the main paper provides a guide for 
the reader to access the desired results in the Appendix. A1 provides additional detail on the 
methodology described in the main paper. A2 provides additional detail on results of specific 
equations that are estimated, which broadly correspond to purposes: 1. estimates to be used as 
inputs into the main results, which are presented in the main paper, and 2. estimates that are 
produced as sensitivity analyses that are described and discussed in the main paper, but are only 
presented in detail in the Appendix. 
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A1 Additional detail on methods 
A1.1 Determining an appropriate econometric specification 
In the main paper, the strategy for determining an appropriate econometric specification was only 
outlined, giving the types of tests used and an overview of the approach to analyse each wave of 
data separately. The process is described in greater detail in this section. 
 
1. The preferred specification for the preceding year analysed is used to re-estimate each outcome 
and expenditure equation for the year under consideration (if there is no precedent specification, 
this is denoted with a ‘*’ in Table A1.1). If this re-estimation produces a result which (a) passes the 
appropriate statistical tests and (b) generates coefficients in line with theoretical priors, use this 
result as our preferred result for the year under consideration.  This rule is applied to cases where 
the preferred specification for the preceding year is either IV or OLS.  If this re-estimation produces 
an acceptable result, this is denoted with a ‘--‘in Table A1.1. 
 
2. If the re-estimation produces a result which does not pass tests/have coefficients in line with 
priors, re-estimate the equation having adjusted the specification as suggested by the initial result.  
So, for example, if the initial estimation implies the presence of weak instruments and one of the 
instruments is insignificant in the first-stage regression, try re-estimating the equation without the 
insignificant instrument. And if, for example, one of the regressors in the second-stage regression is 
insignificant, try re-estimating without it. If this re-estimation produces an acceptable result, this is 
denoted with a ‘A‘ in Table A1.1. 
 
3. If a relatively minor adjustment to the preceding year’s specification does not generate a 
statistically and theoretically acceptable result, re-derive the IV equation to be estimated (again, this 
applies to cases where the preferred specification for the preceding year is either IV or OLS). That is, 
use OLS with backward stepwise regression to identify relevant covariates to be included in the 
second-stage regression having forced in the relevant variables throughout. For the outcome 
equation we force in own programme expenditure, and for the expenditure equation the other 
programme need variable and the total budget term are forced in throughout the stepwise 
procedure. 
 
Having identified relevant covariates for the second-stage regression, again use stepwise backward 
regression to identify relevant instruments for the first-stage conditioning on the covariates for the 
second-stage identified above. In other words, these second-stage covariates are forced in 
throughout stepwise procedure to identify relevant instruments. 
 
Having identified covariates for the second-stage and instruments for the first-stage, re-estimate the 
IV specification equation using these two sets of variables. If the endogeneity test suggests that a 
variable (eg own programme expenditure in the outcome equation) is clearly not endogenous then 
re-estimate using OLS.  If this re-estimation produces an acceptable result, this is denoted with a ‘B‘ 
in Table A1.1. 
 
4. If the above re-estimation approach produces a result which does not pass tests/have coefficients 
in line with priors, re-estimate the equation having adjusted the specification as suggested by the 
initial result (for example, if the result fails the misspecification test try adding the squared value of 
one of the regressors to the specification). If this re-estimation produces an acceptable result, this is 
denoted with a ‘C‘ in Table A1.1. 
 
5. If the above approaches fail to produce an acceptable result, consider excluding LAs with extreme 
values of expenditure per person. Only explore this option for programmes with small amounts of 
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expenditure and/or mortality. If this re-estimation approach produces an acceptable result, this is 
denoted with a ‘D‘ in Table A1.1. 
 
6. If all of the above fail then either use a value of zero if an outcome elasticity, or, if an expenditure 
elasticity, adopt the preceding wave's specification and use the estimate irrespective of test results 
and coefficients not conforming to priors. If this approach is used, it is denoted with a ‘E’ in Table 
A1.1. 
 
Table A1.1 Types of re-estimation undertaken 
PBC PBC description 2003/04 2004/05 2005/06 2006/07 2007/08 
  Out Exp Out Exp Out Exp Out Exp Out Exp 
1 Infectious diseases A A A A -- -- A A A -- 
2 Cancers and tumours -- A -- -- A A A -- -- A 
3 Diseases of the blood n/a B n/a A n/a -- n/a -- n/a -- 
4 Endocrine, nutritional, metabolic E A A A A -- A A D -- 
5 Mental health disorders n/a -- n/a -- n/a -- n/a -- n/a -- 
6 Learning disability n/a A n/a -- n/a D n/a B n/a -- 
7 Neurological problems A -- A -- A -- D A B A 
8 Vision problems n/a -- n/a -- n/a -- n/a -- n/a C 
9 Hearing problems n/a A n/a C n/a -- n/a -- n/a A 
10 Circulatory problems -- -- A -- A -- -- -- A -- 
11 Respiratory problems -- -- A -- A A -- -- A A 
12 Dental problems n/a A n/a E n/a E n/a C n/a D 
13 Gastro-intestinal problems A -- -- -- -- -- -- A -- A 
14 Skin problems n/a -- n/a A n/a A n/a A n/a -- 
15 Musculo-skeletal problems n/a -- n/a -- n/a -- n/a A n/a -- 
16 Trauma and injuries E A E A E A E -- * -- 
17 Genito-urinary problems B A -- A -- -- D A C A 
18&19 Maternity and reproductive health and 
neonates 
E A -- A -- -- C -- A -- 
20 Poisoning and adverse events n/a -- n/a -- n/a -- n/a -- n/a A 
21 Healthy individuals n/a A n/a A n/a B n/a B n/a C 
22 Social care needs n/a A n/a -- n/a -- n/a -- n/a C 
23 Other (includes GMS/PMS) n/a A n/a -- n/a -- n/a A n/a -- 
 
Table A1.1 continued Types of re-estimation undertaken 
PBC PBC description 2008/09 2009/10 2010/11 2011/12 2012/13 
  Out Exp Out Exp Out Exp Out Exp Out Exp 
1 Infectious diseases A -- A -- A -- B -- -- -- 
2 Cancers and tumours -- -- -- A -- -- A -- -- -- 
3 Diseases of the blood n/a -- n/a B n/a B n/a -- n/a -- 
4 Endocrine, nutritional, metabolic -- A A -- B C -- A B A 
5 Mental health disorders n/a -- n/a -- n/a -- n/a -- n/a -- 
6 Learning disability n/a -- n/a B n/a C n/a D n/a B 
7 Neurological problems C -- C -- C A C A B -- 
8 Vision problems n/a -- n/a A n/a -- n/a -- n/a -- 
9 Hearing problems n/a -- n/a C n/a -- n/a C n/a -- 
10 Circulatory problems -- A -- -- -- B -- -- -- A 
11 Respiratory problems -- -- B -- A A -- A A -- 
12 Dental problems n/a B n/a B n/a B n/a C n/a B 
13 Gastro-intestinal problems A -- A -- A A A A A -- 
14 Skin problems n/a -- n/a D n/a B n/a A n/a A 
15 Musculo-skeletal problems n/a C n/a B n/a C n/a C n/a -- 
16 Trauma and injuries E -- E -- * A E A E -- 
17 Genito-urinary problems C -- B -- B A A -- C -- 
18&19 Maternity and reproductive health and neonates A -- B -- B -- A A -- -- 
20 Poisoning and adverse events n/a -- n/a -- n/a A n/a -- n/a -- 
21 Healthy individuals n/a -- n/a -- n/a A n/a -- n/a A 
22 Social care needs n/a -- n/a B n/a -- n/a -- n/a A 
23 Other (includes GMS/PMS) n/a -- n/a B n/a -- n/a A n/a -- 
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A1.2 Sensitivity of alternative OLS results to endogeneity 
In the main paper we summarise the results for 2012/13. In this section we present summary results 
from all waves of data as well as more detailed results for 2012/13. 
 
The existing literature provides two estimates of the all-cause mortality elasticity estimate for the 
English NHS: -0.71 (Andrews et al. 2017) and -1.089 (Claxton et al. 2018). In Table A1.2, we present 
the implied all-cause mortality elasticity estimates for all waves of data. Two estimates are provided, 
first the results from the main analysis where an IV approach is used, where judged appropriate on 
the basis of statistical tests, and second an alternative analysis where OLS is used for all equations. 
 
Table A1.2 Implied all-cause mortality elasticity estimates: main analysis and all OLS approaches 
 
Implied all-cause mortality 
 
IV + OLS 
(main analysis) 
ALL OLS 
03/04 -1.246 -0.189 
04/05 -1.615 -0.293 
05/06 -1.372 -0.144 
06/07 -1.496 -0.209 
07/08 -1.269 -0.167 
08/09 -0.795 -0.154 
09/10 -0.941 -0.067 
10/11 -1.328 -0.066 
11/12 -1.386 -0.177 
12/13 -1.028 -0.153 
 
Taken together these results reinforce the interpretation of the result in the main paper for 2012/13 
only, which is that using only OLS underestimates the magnitude of the implied overall elasticity in 
line with the theoretical arguments about why this is likely to be the case. Note that some years’ 
estimates from the main analysis have higher magnitudes of implied all-cause mortality elasticities 
than the exiting literature, which is to be expected, because the cited studies from the existing 
literature do not analyse individual PBCs, but instead estimate a model relating all-cause mortality 
and all healthcare expenditure. As such we might expect that there is an underestimate in the 
magnitudes of these resulting estimated elasticities due to ‘aggregation bias’, i.e. in these studies it 
is harder to obtain a clear signal from the noisy data. 
 
The results for specific equations from 2012/13 are presented in Table A1.3 
 
Table A1.3 PBC expenditure and outcome elasticities, 2012/13: main analysis and all OLS approaches  
 Expenditure Outcome 
 IV elasticity OLS elasticity IV elasticity OLS elasticity 
Cancer 1.027** 0.220 -0.361*** -0.042 
Circulatory 1.285*** 0.869*** -1.464*** -0.380*** 
Respiratory 0.928*** 0.602*** -1.704*** -0.121 
Gastro-intestinal 0.997*** 0.656*** -1.904** -0.062 
Endocrine 0.951*** 0.657*** -0.499 -0.409** 
Neurological 0.856*** 0.474*** N/a (already OLS) N/a (already OLS) 
Vision 1.411*** 0.923*** N/a N/a 
Dental 0.855*** 0.737*** N/a N/a 
Skin 1.158*** 0.704*** N/a N/a 
Poisoning 1.124*** 0.588*** N/a N/a 
*** p<0.01, ** p<0.05, * p<0.1 
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In the analysis of the 2012/13 data, 10 expenditure equations and 5 outcome equations were 
estimated using IV regression. In all cases, not using IVs and estimating using OLS results in a 
reduction in the magnitude of the point estimate of the coefficient of interest. In addition, when 
using OLS, there is no evidence of a statistically significant effect of own-PBC healthcare spending on 
cancer, respiratory and gastro-intestinal mortality. 
 
A1.3 Sensitivity of IV results to just-identified IV approach 
Recent theory suggests that potential weak instrument bias can be mitigated to some extent by 
including only a single instrument (Angrist & Pischke 2009). To examine the impact of this approach 
on our results, we have re-estimated those specifications that are over-identified, replacing the 
multiple instruments with only the strongest one. Tables A1.6 and A1.7 report the results of this 
analysis for the ‘big four’ programmes using our preferred outcome and expenditure specifications 
for 2012/13 (note that variable names are described in section A2.1). These results are summarised 
in Tables A1.4 and A1.5.   
 
The preferred outcome equations for cancer and gastro-intestinal problems are already just 
identified.  Re-estimation of the preferred outcome equations for circulatory disease and respiratory 
problems using only a single instrument reduces the absolute size of the outcome elasticity by just 





The preferred expenditure equation for gastro-intestinal problems is already just identified. Re-
estimation of the preferred expenditure equation for the cancer programme increases the 
expenditure elasticity marginally, but re-estimation has no effect on the elasticity in both the 
circulatory and respiratory PBCs. 
 
Table A1.5 
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Table A1.6 Re-estimation of preferred multi-instrument outcome specifications using only a single instrument for the big four programmes for 2012/13
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Table A1.7 Re-estimation of preferred multi-instrument expenditure specifications using only a single instrument for the big four programmes for 2012/13
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A2 Results for specific equations underpinning main results 
In this section we provide the regression results for the preferred outcome and expenditure 
equations for each wave of data, in addition to the results of all relevant specification tests.  
 
A2.1 Description of variable names  
The census based variables used in this study have the following names: 
 
Short variable 
name Long variable name 
  
BORNEXEU Proportion of residents born outside the European Union 
WHITEEG Proportion of population in white ethnic group 
PCWALLTI Proportion of population of working age (16-74) with a limiting 
long-term illness 
POPPUCAR Proportion of population providing unpaid care 
NQUAL174 Proportion of population aged 16-74 with no qualifications 
HHNOCAR Proportion of households without a car 
OWNOCC Proportion of owner occupied households 
LONEPENH Proportion of lone pensioner households 
LONEPARH Proportion of one parent households 
PERMSICK Proportion of population aged 16-74 that are permanently sick 
PC74LTUN Proportion of population aged 16-74 are long-term 
unemployed 
WORKAGRI Proportion of 16-74 in employment that are in agriculture 
PROFOCCU Proportion of those aged 16-74 that are in professional 
occupations 
  
The short variable names are augmented with both a prefix and suffix in the preferred specifications 
reported below. An ‘L’ in the prefix denotes that the log value of the variable has been used in the 
estimation, and the numeric suffix denotes the year to which the variable relates. To obtain values 
for non-census years we interpolated values between the 2001 and 2011 censuses. We used census 
values for 2011 when estimating specifications for 2012.  
 
Other (non-census based) indicators used in this study include:   
IMD2007 Index of Multiple Deprivation 2007 
IMD2010 Index of Multiple Deprivation 2010 
needCARAN Need index (incorporates CARAN or other relevant needs 
formula) 
DIAPREV Diabetes prevalence rate 
EPIPREV Epilepsy prevalence rate 
HIVNEEDPH HIV need index  
CKDPREV Chronic kidney disease prevalence rate 
MATNEEDPP Maternity need index 
 
As is the case for the census-based variables, the short variable names for these other indicators are 
augmented with both a prefix and suffix in the preferred specifications reported below. An ‘L’ in the 
prefix denotes that the log value of the variable has been used in the estimation, and the numeric 
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suffix denotes the year to which the variable relates. Thus ‘lLAhivneedph’ denotes the log of the 
value of the HIV need index at local authority level. Sometimes, specifications ‘fail’ the reset test and 
we add the square of one of the indicators. These variables are denoted either with a ‘2’ as a suffix 
(for example, ‘lLAhivneedph2’ is the square of the HIV need index, and ‘lLAneedCARAN342’ is the 
square of the need index for 2003/4) or with `SQ’ as a suffix (for example, ‘LPERMSICK07SQ’ is the 
square of the ‘permanently sick’ variable for 2007). 
 
The programme specific expenditure variables have names like ‘lLAg1_34’ where ‘l’ denotes that the 
log value has been used, ‘LA’ denotes that expenditure has been mapped to a local authority 
geography, ‘g1’ denotes expenditure in PBC 1, and ‘34’ denotes expenditure in the financial year 
2003/4. The variable name ‘lLAgall_34’ relates to expenditure across all PBCs in 2003/4. Sometimes, 
we combine expenditure across two PBCs. Thus the variable name ‘lLAg1819_78’ relates to 
expenditure across PBC 18 and PBC 19 combined in 2007/8. 
 
The mortality variables have names like ‘lSYLLRallcause345’ where ‘l’ denotes that the log value has 
been used, ‘SYLLR’ denotes that the standardised years of life lost rate has been used, ‘all cause’ 
relates to the disease coverage, and ‘345’ denotes that the data relate to 2003, 2004, and 2005 
combined. A further example is ‘lSYLLRacExIandP345’; this is a proxy for ‘other PBC need’ in the 
expenditure equation for the infectious and parasitic diseases PBC and ‘acExIandP’ refers to all-cause 
mortality excluding infectious and parasitic diseases. Another example is ‘lSYLLRacExDIA345’; this is 
a proxy for ‘other PBC need’ in the expenditure equation for the diabetes PBC, and ‘acExDIA’ refers 
to all-cause mortality excluding diabetes. 
 
All regressions are weighted regressions where analytical weights are constructed using the 
populations of the LAs. 
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A2.2 Second stage of IV regressions and OLS regressions results tables 
Table A2.1 Preferred outcome specifications for 2003/04 
 
Table A2.2 Preferred expenditure specifications for 2003/04 
 
Table A2.3 Preferred outcome specifications for 2004/05 
 
Table A2.4 Preferred expenditure specifications for 2004/05 
 
Table A2.5 Preferred outcome specifications for 2005/06 
 
Table A2.6 Preferred expenditure specifications for 2005/06 
 
Table A2.7 Preferred outcome specifications for 2006/07 
 
Table A2.8 Preferred expenditure specifications for 2006/07 
 
Table A2.9 Preferred outcome specifications for 2007/08 
 
Table A2.10 Preferred expenditure specifications for 2007/08 
 
Table A2.11 Preferred outcome specifications for 2008/09 
 
Table A2.12 Preferred expenditure specifications for 2008/09 
 
Table A2.13 Preferred outcome specifications for 2009/10 
 
Table A2.14 Preferred expenditure specifications for 2009/10 
 
Table A2.15 Preferred outcome specifications for 2010/11 
 
Table A2.16 Preferred expenditure specifications for 2010/11 
 
Table A2.17 Preferred outcome specifications for 2011/12 
 
Table A2.18 Preferred expenditure specifications for 2011/12 
 
Table A2.19 Preferred outcome specifications for 2012/13 
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Table A2.1 Preferred outcome specifications for 2003/04 
  (1) (2) (3) (4) (5) (6) (7)  
PBC 1 PBC 2 PBC 7 PBC 10 PBC 11 PBC 13 PBC 17  
infectious cancer neurological circulatory respiratory gastro genito-urinary  
2003/4 spend 2003/4 spend 2003/4 spend 2003/4 spend 2003/4 spend 2004/5 spend 2003/4 spend  
SYLLR 2003/4/5 SYLLR 2003/4/5 SYLLR 2003/4/5 SYLLR 2003/4/5 SYLLR 2003/4/5 SYLLR 2003/4/5 SYLLR 2003/4/5  
outcome model outcome model outcome model outcome model outcome model outcome model outcome model  
instrument spend instrument spend instrument spend instrument spend instrument spend instrument spend instrument spend  
weighted weighted weighted weighted weighted weighted weighted  
IV second stage IV second stage IV second stage IV second stage IV second stage IV second stage IV second stage  
GMM2S GMM2S GMM2S GMM2S GMM2S GMM2S GMM2S  
LA-level LA-level LA-level LA-level LA-level LA-level LA-level  
actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality  
actual census 03 actual census 03 actual census 03 actual census 03 actual census 03 actual census 03 actual census 03 
VARIABLES 04/05 revised 04/05 specification 04/05 revised 04/05 specification 04/05 specification 04/05 revised re-derived 
                
lLAg1_34 -0.205 
      
 
[0.343] 
      
lLAhivneedph 0.067 
      
 
[0.072] 









    
LWHITEEG03 -0.796*** 
     
-1.822***  
[0.213] 
     
[0.352] 
LPOPPUCAR03 -1.241*** 
      
 
[0.421] 




     
  
[0.094] 















    
   
[0.426] 




    
   
[0.054] 




    
   
[1.856] 
    
lLAg10_34 
   
-1.202*** 
   
    
[0.182] 
   
LPERMSICK03 











    
-1.666*** 
  




     
-1.493*** 
 




      
-0.063 
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[0.674] 
LNQUAL17403 
      
1.321***        
[0.371] 
Constant -1.843* 5.893*** 3.239** 12.254*** 9.747*** 12.635*** 1.263  
[1.082] [0.393] [1.296] [1.023] [1.777] [2.414] [2.895]         
Observations 144 151 135 151 151 151 151 
Endogeneity test statistic 0.928 4.945 2.165 32.851 28.292 11.906 0.038 
Endogeneity p-value 0.336 0.026 0.141 0.000 0.000 0.001 0.846 
Kleibergen-Paap LM test statistic 7.931 16.583 12.542 19.283 13.403 14.162 17.836 
Kleibergen-Paap p-value 0.005 0.000 0.002 0.000 0.000 0.000 0.000 
Kleibergen-Paap F statistic 9.795 10.257 10.043 55.862 28.447 24.260 24.694 
Pesaran-Taylor reset statistic 0.641 0.047 0.834 0.009 1.210 0.000 0.177 
Pesaran-Taylor p-value 0.423 0.828 0.361 0.924 0.271 0.995 0.674 
Hansen-Sargan test statistic 
 
0.971 0.501 
    
Hansen-Sargan p-value   0.324 0.479         
Robust standard errors in brackets 
       
*** p<0.01, ** p<0.05, * p<0.1 
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Table A2.2 Preferred expenditure specifications for 2003/04 
  (1) (2) (3) (4) (5) (6) (7) (8) (9) (10)  
PBC 1 PBC 2 PBC 3 PBC 4 PBC 5 PBC 6 PBC 7 PBC 8 PBC 9 PBC 10  
infectious cancer blood endocrine mental health LDisability neurological vision hearing circulatory  
2003/4 spend 2003/4 spend 2003/4 spend 2003/4 spend 2003/4 spend 2003/04 spend 2003/04 spend 2003/4 spend 2003/4 spend 2003/4 spend  
SYLLR 
2003/4/5 








SYLLR 2003/4/5 SYLLR 2003/4/5 SYLLR 2003/4/5 
 
spend model spend model spend model spend model spend model spend model spend model spend model spend model spend model  
instrument n/a instrument 
o/need 






weighted weighted weighted weighted weighted weighted weighted weighted weighted weighted  
OLS IV second stage OLS OLS OLS OLS OLS IV second stage IV second stage IV second stage   
GMM2S 
     
GMM2S GMM2S GMM2S  
LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level  
actual 
mortality 












actual census 03 actual census 03 actual census 03 actual census 03 actual census 03 actual census 03 
VARIABLES 04/05 revised 04/05 
specification 
re-derived OLS 04/05 revised 04/05 
specification 




04/05 revised 04/05 
specification 
                      
lLAgall_34 1.094*** 1.711*** 0.652* 0.653*** 1.333*** 0.646* 1.408*** 0.833*** 0.694* 1.873***  
[0.254] [0.294] [0.381] [0.113] [0.162] [0.331] [0.205] [0.276] [0.407] [0.288] 
lLAhivneedph 0.274*** 
         
 
[0.033] 
         
lSYLLRacExIandP345 -0.075 
         
 
[0.183] 
         
lLAhivneedph2 0.138*** 
         
 
[0.027] 




        
  
[0.237] 




        
  
[0.126] 



















       
   
[0.036] 




       
   
[0.420] 
       
LNQUAL17403 
   
0.274*** 
   
0.744*** 
 
0.907***     
[0.061] 





   
-0.162* 
      
    
[0.090] 
      
lSYLLRacExDIA345 
   
-0.234** 
      
    
[0.112] 
      
lLAmhneedindexpp 
    
0.308* 
     
     
[0.157] 
     
LPOPPUCAR03 
    
-0.597*** 
   
0.865*** 
 
     
[0.107] 
   
[0.259] 
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LHHNOCAR03 
     
-0.426*** 
    
      
[0.142] 
    
lLAneedCARAN342 
     
1.262 
    
      
[1.176] 
    
           
lLAepiprev0304 
      
0.319*** 
   
       
[0.114] 
   
lSYLLRacExEPI345 
      
-0.492*** 
   
       
[0.139] 
   
LLONEPENH03 
        
-0.646** 
 




        
-0.463*** 
 




        
-0.428 
 




        
0.423** 
 




         
-1.759***           
[0.335] 
Constant -4.412*** -2.084 -3.602 0.584 -4.828*** -2.782 -1.831 2.111* -11.683*** 3.212**  
[1.181] [1.347] [2.926] [0.797] [1.559] [2.716] [1.298] [1.225] [3.401] [1.305]            
Observations 147 151 150 149 151 137 151 151 151 151 
R-squared 0.623 
 
0.244 0.366 0.665 0.098 0.330 
   
Ramsey reset F statistic 1.280 
 
1.021 2.043 1.403 0.678 0.144 
   
Probability > F 0.284 
 
0.386 0.111 0.244 0.567 0.934 
   
Endogeneity test statistic 
 
9.775 
     




     
0.046 0.609 0.000 




     




     
0.000 0.000 0.000 
Kleibergen-Paap F statistic 
 
45.579 
     
35.891 28.335 19.117 
Pesaran-Taylor reset statistic 
 
0.185 
     




     
0.509 0.446 0.165 
Hansen-Sargan test statistic 
       
0.101 0.129 0.288 
Hansen-Sargan p-value               0.751 0.720 0.592 
Robust standard errors in brackets 
         
*** p<0.01, ** p<0.05, * p<0.1 
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Table A2.2 continued Preferred expenditure specifications for 2003/04 
  (1) (2) (3) (4) (5) (6) (7) (8) (9)  
PBC 11 PBC 12 PBC 13 PBC 14 PBC 15 PBC 16 PBC 17 PBC 1819 PBC 20  
respiratory dental gastro skin problems musculo-skeletal trauma genito- mat/neonates poisoning  
2003/4 spend 2003/4 spend 2004/5 spend 2003/04 spend 2003/04 spend 2003/4 spend 2003/4 spend 2003/04 spend 2003/4 spend  




spend model spend model spend model spend model spend model spend model spend model spend model spend model  
instrument 
o/need 
instrument n/a instrument 
o/need 
instrument n/a instrument n/a instrument n/a instrument n/a o/need exogenous instrument 
o/need  
weighted weighted weighted weighted weighted weighted weighted weighted weighted  




     
GMM2S  
LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level  
actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality  
actual census 03 actual census 03 actual census 03 actual census 
04 











04/05 revised 04/05 
specification 
04/05 revised 04/05 revised 04/05 revised 04/05 
specification 





0.131 -0.327** 0.091 
 
0.136 -1.909***   
[0.448] 
 
[0.113] [0.164] [0.122] 
 
[0.230] [0.412] 
lLAgall_34 1.661*** 0.717* 1.409*** 0.700*** 1.014*** 0.556*** 0.934*** 0.757*** 2.327***  




       
  
[0.454] 
       
LNQUAL17403 0.605*** -0.878*** 0.706*** 0.178** 
    
0.860***  
[0.103] [0.293] [0.100] [0.072] 





       
  
[0.045] 
       
lSYLLRacExResp345 -0.857*** 
        
 
[0.274] 




      
   
[0.239] 
      
LPC74LTUN03 
    
-0.165** 
    
     
[0.072] 
    
LPROFOCCU03 
    
-0.365*** 
    
     
[0.082] 
    
LLONEPENH03 
     
0.551*** 
   
      
[0.117] 
   
lSYLLRacExrenal345 
      
-0.097 
  




      
-0.403*** 
  




       
0.468*** 
 
        
[0.145] 
 
Constant -1.549 -6.011** 2.171* -2.418*** -2.161 0.783 -2.077** -1.977 -1.079  
[1.126] [2.659] [1.212] [0.859] [1.684] [0.900] [0.921] [1.790] [1.587]           
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0.391 0.265 0.346 0.498 0.326 
 
Endogeneity test statistic 10.155 
 
9.194 
     
9.308 
Endogeneity p-value 0.001 
 
0.002 
     
0.002 
Kleibergen-Paap LM test statistic 26.355 
 
25.192 
     
30.213 
Kleibergen-Paap p-value 0.000 
 
0.000 
     
0.000 
Kleibergen-Paap F statistic 48.934 
 
96.403 
     
35.169 
Pesaran-Taylor reset statistic 0.177 
 
0.021 
     
0.010 
Pesaran-Taylor p-value 0.674 
 
0.886 
     
0.919 




1.640 0.560 1.379 1.993 0.301 
 




0.183 0.642 0.251 0.118 0.824 
 
Hansen-Sargan test statistic 
        
0.584 
Hansen-Sargan p-value                 0.445 
Robust standard errors in 
brackets 
         
*** p<0.01, ** p<0.05, * p<0.1 
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Table A2.2 continued Preferred expenditure specifications for 2003/04 
  (1) (2) (3)  
PBC 21 PBC 22 PBC 23  
HI social care GMS  
2003/4 spend 2003/04 spend 2003/4 spend  
SYLLR 2003/04/05 SYLLR 2003/04/05 SYLLR 2003/4/5  
spend model spend model spend model  
instrument o/need o/need exogenous instrument n/a  
weighted weighted weighted  




LA-level LA-level LA-level  
actual mortality actual mortality actual mortality  
actual census 03 actual census 03 actual census 03 
VARIABLES 04/05 IV revised 04/05 revised 04/05 revised 
        
lSYLLRallcause345 -2.190** -1.539*** -0.117  
[0.983] [0.381] [0.116] 
lLAgall_34 1.538** 1.581*** 0.681***  








-0.423***    
[0.083] 
Constant 8.683 1.534 0.831  
[5.661] [2.555] [0.876]     




Endogeneity test statistic 7.348 
  
Endogeneity p-value 0.007 
  
Hansen-Sargan test statistic 3.994 
  
Hansen-Sargan p-value 0.136 
  
Kleibergen-Paap LM test statistic 32.122 
  
Kleibergen-Paap p-value 0.000 
  
Kleibergen-Paap F statistic 19.387 
  
Pesaran-Taylor reset statistic 0.000 
  
Pesaran-Taylor p-value 0.985 
  
Ramsey reset F statistic 
 
2.020 0.584 
Probability > F   0.114 0.627 
Robust standard errors in brackets 
   
*** p<0.01, ** p<0.05, * p<0.1 
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Table A2.3 Preferred outcome specifications for 2004/05 
  (1) (2) (3) (4) (5) (6) (7) (8) (9)  
PBC 1 PBC 2 PBC 4 PBC 7 PBC 10 PBC 11 PBC 13 PBC 17 PBC 1819  
infectious cancer endocrine neurological circulatory respiratory gastro genito- mat/neonates  
2004/5 
spend 




















instrument spend instrument n/a spend exogenous 
 
weighted weighted weighted weighted weighted weighted weighted weighted weighted  
OLS IV second stage IV second stage IV second stage IV second stage IV second stage IV second stage OLS OLS   
GMM2S GMM2S GMM2S GMM2S GMM2S GMM2S 
  
 
LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level  
actual 
mortality 




actual census 04 actual census 04 actual census 04 actual census 04 actual census 04 actual census 04 actual census 
04 





05/06 revised 05/06 revised 05/06 revised 05/06 revised 05/06 
specification 
05/06 revised 05/06 specification 
                    
lLAhivneedph 0.112** 
        
 
[0.054] 









    
[0.072] 
LOWNOCC04 -0.414* 
        
 
[0.242] 
        
LWHITEEG04 -0.941*** 









        
 
[0.107] 




       
  
[0.111] 















      
   
[1.126] 




      
   
[0.297] 




      
   
[1.905] 
      
lLAg7_45 
   
-0.968** 
     
    
[0.484] 
     
LWORKAGRI04 
   
0.126** 
     
    
[0.057] 
     
lLAg10_45 
    
-1.375*** 
    
     
[0.205] 
    
LPERMSICK04 
    
0.518*** 
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[0.104] 
    
lLAg11_45 
     
-2.494*** 
   
      
[0.832] 
   
lLAg13_45 
      
-1.253*** 
  




       
-0.931* 
 




       
2.156*** 0.638***         
[0.477] [0.166] 
lLAg1819_45 
        
-0.121          
[0.101] 
LLONEPENH04 
        
-0.409**          
[0.206] 
LBORNEXEU04 
        
0.070*          
[0.040] 
Constant 1.106*** 6.008*** 8.364** 4.082** 12.804*** 13.346*** 8.469*** 5.829** 1.210*  
[0.344] [0.481] [3.974] [1.722] [1.042] [3.439] [1.872] [2.597] [0.631]           
Observations 145 151 136 137 151 151 151 137 151 
R-squared 0.565 
      
0.211 0.457 
Ramsey reset F statistic 0.698 
      
0.803 1.023 
Probability > F 0.555 
      
0.494 0.384 
Endogeneity test statistic 
 




0.089 0.067 0.091 0.000 0.000 0.009 
  











     
Kleibergen-Paap LM test statistic 
 




0.001 0.008 0.000 0.000 0.006 0.000 
  
Kleibergen-Paap F statistic 
 
9.441 10.808 14.107 67.065 13.553 33.424 
  
Pesaran-Taylor reset statistic 
 
2.454 2.713 2.393 0.150 0.551 0.534 
  
Pesaran-Taylor p-value   0.293 0.100 0.122 0.699 0.458 0.465     
Robust standard errors in brackets 
         
*** p<0.01, ** p<0.05, * p<0.1 
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Table A2.4 Preferred expenditure specifications for 2004/05 
  (1) (2) (3) (4) (5) (6) (7) (8) (9) (10)  
PBC 1 PBC 2 PBC 3 PBC 4 PBC 5 PBC 6 PBC 7 PBC 8 PBC 9 PBC 10  
infectious cancer blood endocrine mental health LDisability neurological vision hearing circulatory  
2004/5 spend 2004/5 spend 2004/5 spend 2004/5 spend 2004/5 spend 2004/05 spend 2004/05 spend 2004/5 spend 2004/5 spend 2004/5 spend  
SYLLR 
2004/5/6 








SYLLR 2004/5/6 SYLLR 2004/5/6 SYLLR 2004/5/6 
 
spend model spend model spend model spend model spend model spend model spend model spend model spend model spend model  
instrument n/a instrument 
o/need 






weighted weighted weighted weighted weighted weighted weighted weighted weighted weighted  
OLS IV second stage OLS OLS OLS OLS OLS IV second stage IV second stage IV second stage   
GMM2S 
     
GMM2S GMM2S GMM2S  
LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level  
actual 
mortality 












actual census 04 actual census 04 actual census 04 actual census 04 actual census 04 actual census 04 
VARIABLES 05/06 revised 05/06 
specification 
05/06 revised 05/06 revised 05/06 
specification 




                      
lLAgall_45 0.932*** 1.259*** 0.952*** 0.573*** 0.999*** 0.446* 0.929*** 1.350*** 0.526 1.652***  
[0.210] [0.278] [0.355] [0.111] [0.170] [0.260] [0.212] [0.319] [0.412] [0.247] 
lLAhivneedph 0.252*** 
         
 
[0.028] 
         
lSYLLRacExIandP456 -0.125 
         
 
[0.158] 
         
lLAhivneedph2 0.092*** 
         
 
[0.024] 




        
  
[0.495] 




        
  
[0.275] 




       
  
[0.281] [0.180] 

















   
0.172** 
   
0.635*** 
 
0.667***     
[0.068] 





   
-0.215*** 
      
    
[0.082] 
      
lSYLLRacExDIA456 
   
-0.103 
      
    
[0.106] 
      
lLAmhneedindexpp 
    
0.356* 
     
     
[0.182] 
     
LPOPPUCAR04 
    
-0.743*** 
   
1.026*** 
 
     
[0.099] 




     
3.141** 
    
      
[1.563] 
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lLAepiprev0405 
      
0.196* 
   
       
[0.106] 
   
lSYLLRacExEPI456 
      
-0.306** 
   
       
[0.136] 
   
LLONEPENH04 
        
-0.458 
 




        
-0.239* 
 




        
-0.006 
 




         
-1.390***           
[0.283] 
Constant -2.947*** 3.265* -4.090** 0.224 -3.165* 1.448 -0.206 -0.380 -6.905* 2.137**  
[1.015] [1.973] [1.814] [0.792] [1.786] [1.613] [1.367] [1.119] [3.779] [1.064]            
Observations 145 151 151 151 151 137 151 151 151 151 
R-squared 0.584 
 
0.371 0.369 0.667 0.073 0.200 
   
Ramsey reset F statistic 0.330 
 
0.444 1.478 1.235 0.612 1.654 
   
Probability > F 0.803 
 
0.722 0.223 0.299 0.609 0.180 
   
Endogeneity test statistic 
 
13.951 
     




     
0.036 0.825 0.000 




     




     
0.000 0.000 0.000 
Kleibergen-Paap F statistic 
 
14.608 
     
41.912 40.253 23.031 
Pesaran-Taylor reset statistic 
 
0.442 
     




     
0.726 0.835 0.877 
Hansen-Sargan test statistic 
       
2.023 1.404 1.474 
Hansen-Sargan p-value               0.155 0.236 0.225 
Robust standard errors in 
brackets 
          
*** p<0.01, ** p<0.05, * p<0.1 
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Table A2.4 continued  Preferred expenditure specifications for 2004/05 
  (1) (2) (3) (4) (5) (6) (7) (8)  
PBC 11 PBC 13 PBC 14 PBC 15 PBC 16 PBC 17 PBC 1819 PBC 20  
respiratory gastro skin problems musculo-skeletal trauma genito- mat/neonates poisoning  
2004/5 spend 2004/5 spend 2004/05 spend 2004/05 spend 2004/5 spend 2004/5 spend 2004/05 spend 2004/5 spend  
SYLLR 2004/5/6 SYLLR 2004/5/6 SYLLR 2004/5/6 SYLLR 2004/5/6 SYLLR 2004/5/6 SYLLR 2004/5/6 infant mort rate 2004/05/06 SYLLR 2004/5/6  
spend model spend model spend model spend model spend model spend model spend model spend model  
instrument o/need instrument o/need instrument n/a instrument n/a instrument n/a instrument n/a o/need exogenous instrument o/need  
weighted weighted weighted weighted weighted weighted weighted weighted  
IV second stage IV second stage OLS OLS OLS OLS OLS IV second stage  
GMM2S GMM2S 
     
GMM2S  
LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level  
actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality  
actual census 04 actual census 04 actual census 04 actual census 04 actual census 04 actual census 04 actual census 04 actual census 04 
VARIABLES 05/06 specification 05/06 specification 05/06 specification 05/06 specification 05/06 revised 05/06 revised 05/06 revised 05/06 specification 
                  
lSYLLRacExResp456 -0.377* 
       
 
[0.205] 
       
lLAgall_45 1.253*** 0.928*** 0.595*** 0.567*** 0.576** 0.716*** 0.678*** 1.674***  
[0.186] [0.167] [0.203] [0.164] [0.235] [0.242] [0.156] [0.297] 
LNQUAL17404 0.430*** 0.467*** 0.176* 
    
0.706***  
[0.080] [0.066] [0.101] 





      
  
[0.203] 
      
lSYLLRallcause456 
  
0.114 -0.023 -0.244 
 
-0.025 -1.414***    






     
   
[0.020] 
     
LPC74LTUN04 











   
-0.390*** 
    
    
[0.097] 
    
lLAneedCARAN45 
    
0.618** 
   
     
[0.278] 
   
lSYLLRacExrenal456 
     
-0.160 
  




     
0.154* 
  




      
0.600*** 
 




      
-0.276* 
 
       
[0.144] 
 
Constant -1.899** 0.749 -1.639 -1.025 1.679 3.734 -0.983 0.219  
[0.802] [0.746] [1.055] [1.468] [1.957] [2.268] [0.998] [1.395]          
Observations 151 151 151 151 151 151 151 151 
Endogeneity test statistic 5.586 1.528 
     
12.795 
Endogeneity p-value 0.018 0.216 
     
0.000 
Kleibergen-Paap LM test statistic 28.181 33.441 
     
33.481 
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Kleibergen-Paap p-value 0.000 0.000 
     
0.000 
Kleibergen-Paap F statistic 58.442 112.795 
     
40.539 
Pesaran-Taylor reset statistic 0.021 0.845 
     
1.118 
Pesaran-Taylor p-value 0.885 0.358 
     
0.290 
Hansen-Sargan test statistic 
       
1.316 
Hansen-Sargan p-value 




0.362 0.249 0.363 0.366 0.523 
 
Ramsey reset F statistic 
  
1.547 1.891 0.676 1.843 1.850 
 
Probability > F     0.205 0.134 0.568 0.142 0.141   
Robust standard errors in brackets 
        
*** p<0.01, ** p<0.05, * p<0.1 
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Table A2.4 continued  Preferred expenditure specifications for 2004/05 
  (1) (2) (3)  
PBC 21 PBC 22 PBC 23a  
HI social care GMS  
2004/05 spend 2004/05 spend 2004/5 spend  
SYLLR 2004/05/06 SYLLR 2004/05/06 SYLLR 2004/5/6  
spend model spend model spend model  
o/need exogenous o/need exogenous instrument n/a  
weighted weighted weighted  
OLS OLS OLS     
 
LA-level LA-level LA-level  
actual mortality actual mortality actual mortality  
actual census 04 actual census 04 actual census 04 
VARIABLES 05/06 revised OLS 05/06 OLS 05/06 specification 
        
lLAgall_45 0.709* 1.313** 0.337***  









-0.170***    
[0.046] 
lSYLLRallcause456 0.323 -0.940** 0.071  
[0.277] [0.427] [0.062] 
Constant -4.176** -0.206 2.166***  
[1.881] [3.050] [0.487]     
Observations 151 98 146 
R-squared 0.174 0.076 0.259 
Ramsey reset F statistic 1.780 1.085 1.314 
Probability > F 0.154 0.360 0.272 
Robust standard errors in brackets 
   
*** p<0.01, ** p<0.05, * p<0.1 
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Table A2.5 Preferred outcome specifications for 2005/06 
  (1) (2) (3) (4) (5) (6) (7) (8) (9)  
PBC 1 PBC 2 PBC 4 PBC 7 PBC 10 PBC 11 PBC 13 PBC 17 PBC 1819  
infectious cancer endocrine neurological circulatory respiratory gastro genito- mat/neonates  
2005/6 spend 2005/6 spend 2005/6 spend 2005/6 spend 2005/6 spend 2005/6 spend 2005/6 spend 2005/6 spend 2005/06 spend  
SYLLR 2005/6/7 SYLLR 2005/6/7 SYLLR 2005/6/7 SYLLR 2005/6/7 SYLLR 2005/6/7 SYLLR 2005/6/7 SYLLR 2005/6/7 SYLLR 2005/6/7 infant mort rate 2005/6/7  
outcome model outcome model outcome model outcome model outcome model outcome model outcome model outcome model outcome model  
instrument spend instrument spend instrument spend instrument spend instrument spend instrument spend instrument spend instrument n/a spend exogenous  
weighted weighted weighted weighted weighted weighted weighted weighted weighted  
IV second stage IV second stage IV second stage IV second stage IV second stage IV second stage IV second stage OLS OLS  
GMM2S GMM2S GMM2S GMM2S GMM2S GMM2S GMM2S 
  
 
LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level  
actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality  
actual census 05 actual census 05 actual census 05 actual census 05 actual census 05 actual census 05 actual census 05 actual census 05 actual census 05 
VARIABLES 6/7 specification 06/07 revised 06/07 specification 6/7 revised+ 06/07 revised+ 06/07 revised 06/07 specification 6/7 revised 5/95% rederived OLS 
                    
lLAg1_56 -0.432 
        
 
[0.377] 
        
lLAhivneedph 0.478*** 
        
 
[0.142] 
        
lLAhivneedph2 0.085 
        
 
[0.084] 














       
  
[0.086] 















      
   
[1.002] 




      
   
[0.371] 
      
lLAg7_56 
   
-0.325 
     
    
[0.434] 
     
LPOPPUCAR05 
   
10.101 
   
-2.979** 
 
    
[8.381] 




   
1.971 
     
    
[1.781] 
     
lLAg10_56 
    
-1.637*** 
    
     
[0.354] 
    
LPERMSICK05 
    
0.737*** 
    
     
[0.135] 
    
lLAg11_56 
     
-2.217*** 
   
      
[0.827] 
   
lLAneedCARAN562 
     
1.629 
   
      
[1.293] 
   
lLAg13_56 
      
-1.014* 
  




       
-0.869* 
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2.533*** 0.719***         
[0.711] [0.146] 
LOWNOCC05 
       
-0.849 
 




       
-0.822 
 




        
-0.056          
[0.089] 
LLONEPENH05 
        
-0.404*          
[0.233] 
LBORNEXEU05 
        
0.078*          
[0.043] 
Constant 2.241** 5.730*** 6.349 14.837 14.726*** 12.403*** 7.559*** -0.941 1.289**  
[0.925] [0.381] [4.263] [10.345] [1.927] [3.496] [2.294] [2.829] [0.608]           
Observations 149 151 136 136 151 151 151 136 151 
R-squared 
       
0.228 0.407 
Endogeneity test statistic 1.680 3.078 0.937 1.490 28.751 20.370 6.411 
  
Endogeneity p-value 0.195 0.079 0.333 0.222 0.000 0.000 0.011 
  
Kleibergen-Paap LM test statistic 12.475 18.668 8.162 20.976 14.371 7.453 16.180 
  
Kleibergen-Paap p-value 0.000 0.000 0.004 0.000 0.001 0.006 0.000 
  
Kleibergen-Paap F statistic 19.089 15.860 9.794 15.137 14.185 12.876 29.084 
  
Pesaran-Taylor reset statistic 0.046 0.912 0.194 0.079 0.330 0.784 0.510 
  
Pesaran-Taylor p-value 0.830 0.340 0.660 0.779 0.566 0.376 0.475 
  











    
Ramsey reset F statistic 
       
0.538 0.003 
Probability > F               0.657 1.000 
Robust standard errors in brackets 
         
*** p<0.01, ** p<0.05, * p<0.1 
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Table A2.6 Preferred expenditure specifications for 2005/06 
  (1) (2) (3) (4) (5) (6) (7) (8) (9) (10)  
PBC 1 PBC 2 PBC 3 PBC 4 PBC 5 PBC 6 PBC 7 PBC 8 PBC 9 PBC 10  
infectious cancer blood endocrine mental health LDisability neurological vision hearing circulatory  
2005/6 spend 2005/6 spend 2005/6 spend 2005/6 spend 2005/6 spend 2005/06 spend 2005/06 spend 2005/6 spend 2005/6 spend 2005/6 spend  




SYLLR 2005/6/7 SYLLR 2005/6/7 SYLLR 2005/6/7 
 
spend model spend model spend model spend model spend model spend model spend model spend model spend model spend model  
instrument n/a instrument 
o/need 
instrument n/a instrument n/a instrument n/a instrument n/a instrument n/a instrument 
o/need 
instrument n/a instrument 
o/need  
weighted weighted weighted weighted weighted weighted weighted weighted weighted weighted  
OLS IV second stage OLS OLS OLS OLS OLS IV second stage OLS IV second stage   
GMM2S 




LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level  
actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality  
actual census 05 actual census 06 actual census 05 actual census 05 actual census 05 actual census 05 actual census 05 actual census 05 actual census 05 actual census 05 
VARIABLES 06/07 
specification 












                      
lLAgall_56 1.205*** 1.592*** 1.486*** 0.663*** 0.991*** 0.449* 1.220*** 1.127*** 0.762** 1.477***  
[0.208] [0.282] [0.410] [0.126] [0.142] [0.266] [0.239] [0.278] [0.346] [0.206] 
lLAhivneedph 0.374*** 
         
 
[0.025] 
         
lSYLLRacExIandP567 -0.410*** 
         
 
[0.154] 
         
lLAhivneedph2 0.174*** 
         
 
[0.022] 




        
  
[0.440] 















        
  
[0.249] 



















       
   
[0.198] 
       
LNQUAL17405 
   
0.281*** 
   
0.643*** 
 
0.566***     
[0.069] 





   
-0.060 
      
    
[0.109] 
      
lLAmhneedindexpp 
    
0.542*** 
     
     
[0.141] 
     
LPOPPUCAR05 
    
-0.801*** 
     
     
[0.100] 
     
lLAneedCARAN562 
     
1.844 
    
      
[1.223] 
    
lLAepiprev0506 
      
0.330*** 
   
       
[0.089] 
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lSYLLRacExEPI567 
      
-0.446*** 
   
       
[0.161] 
   
lSYLLRacExCirc567 
         
-1.190***           
[0.256] 
Constant -3.136*** -0.270 0.095 -0.417 -1.681 0.915 -0.722 1.527 -3.186* 1.952*  
[1.008] [1.991] [2.383] [0.844] [1.496] [1.474] [1.304] [0.987] [1.801] [1.147]            
Observations 149 151 151 151 151 137 151 151 151 151 
R-squared 0.780 
 




Ramsey reset F statistic 2.114 
 




Probability > F 0.101 
 




Endogeneity test statistic 
 
8.069 


























Kleibergen-Paap F statistic 
 
15.505 




Pesaran-Taylor reset statistic 
 
0.048 











Hansen-Sargan test statistic 




Hansen-Sargan p-value               0.733   0.806 
Robust standard errors in brackets 
         
*** p<0.01, ** p<0.05, * 
p<0.1 
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Table A2.6 continued  Preferred expenditure specifications for 2005/06 
  (1) (2) (3) (4) (5) (6) (7) (8)  
PBC 11 PBC 13 PBC 14 PBC 15 PBC 16 PBC 17 PBC 1819 PBC 20  
respiratory gastro skin problems musculo-skeletal trauma genito- mat/neonates poisoning  
2005/6 spend 2005/6 spend 2005/06 spend 2005/06 spend 2005/6 spend 2005/6 spend 2005/06 spend 2005/6 spend  
SYLLR 2005/6/7 SYLLR 2005/6/7 SYLLR 2005/6/7 SYLLR 2005/6/7 SYLLR 2005/6/7 SYLLR 2005/6/7 infant mort rate 2005/06/07 SYLLR 2005/6/7  
spend model spend model spend model spend model spend model spend model spend model spend model  
instrument o/need instrument o/need instrument n/a instrument n/a instrument n/a instrument n/a o/need exogenous instrument o/need  
weighted weighted weighted weighted weighted weighted weighted weighted  
IV second stage IV second stage OLS OLS OLS OLS OLS IV second stage  
GMM2S GMM2S 
     
GMM2S  
LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level  
actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality  
actual census 05 actual census 05 actual census 05 actual census 05 actual census 05 actual census 05 actual census 05 actual census 05 
VARIABLES 06/07 revised 06/07 specification 06/07 revised 06/07 specification 06/07 revised 06/07 specification 06/07 specification 06/07 specification 
                  
lSYLLRacExResp567 -0.381* 
       
 
[0.207] 
       
lLAgall_56 1.225*** 1.076*** 0.840*** 0.935*** 0.897*** 1.079*** 0.865*** 1.735***  
[0.191] [0.154] [0.190] [0.205] [0.250] [0.264] [0.157] [0.264] 
LNQUAL17405 0.414*** 0.416*** 0.175** 
    
0.449***  
[0.075] [0.059] [0.079] 





      
  
[0.199] 
      
lSYLLRallcause567 
  
0.033 0.038 -0.170 
 
-0.127 -1.235***    















   
-0.418*** 
    
    
[0.092] 
    
LWORKAGRI05 
    
0.047*** 
   
     
[0.013] 
   
lLAneedCARAN56 
    
0.376 
   
     
[0.315] 
   
lSYLLRacExrenal567 
     
-0.326* 
  




      
0.734*** 
 
       
[0.119] 
 
Constant -1.704** -0.274 -2.722*** -4.523*** -0.836 -0.755 -1.145 -1.676  
[0.779] [0.721] [0.924] [1.593] [2.201] [2.014] [0.869] [1.299]          
Observations 151 151 151 151 151 151 151 151 
Endogeneity test statistic 4.593 1.596 
     
15.227 
Endogeneity p-value 0.032 0.206 
     
0.000 
Kleibergen-Paap LM test statistic 27.275 34.219 
     
33.883 
Kleibergen-Paap p-value 0.000 0.000 
     
0.000 
Kleibergen-Paap F statistic 57.822 107.256 
     
40.297 
Pesaran-Taylor reset statistic 0.002 1.800 
     
0.260 
Pesaran-Taylor p-value 0.964 0.180 
     
0.610 
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Hansen-Sargan test statistic 
       
1.785 
Hansen-Sargan p-value 




0.412 0.395 0.464 0.441 0.497 
 
Ramsey reset F statistic 
  
1.493 2.060 1.611 1.397 0.840 
 
Probability > F     0.219 0.108 0.190 0.246 0.474   
Robust standard errors in brackets 
        
*** p<0.01, ** p<0.05, * p<0.1 
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Table A2.6 continued  Preferred expenditure specifications for 2005/06 
 (1) (2) (3)  
PBC 21 PBC 22 PBC 23a  
HI social care GMS  
2005/6 spend 2005/6 spend 2005/6 spend  
SYLLR 2005/6/7 SYLLR 2005/6/7 SYLLR 2005/6/7  
spend model spend model spend model  
instrument o/need instrument o/need instrument n/a  
weighted weighted weighted  




LA-level LA-level LA-level  
actual mortality actual mortality actual mortality  
actual census 05 actual census 05 actual census 05 
VARIABLES re-derived 06/07 specification 06/07 specification 
lSYLLRallcause567 0.413 -0.893* -0.102*  
[0.342] [0.532] [0.052] 
lLAgall_56 0.507 1.069* 0.532***  



















-0.194***    
[0.045] 
Constant -5.832*** 1.173 1.929***  
[2.224] [2.588] [0.347]     




Endogeneity test statistic 0.304 0.599 
 
Endogeneity p-value 0.581 0.439 
 
Hansen-Sargan test statistic 1.658 3.943 
 
Hansen-Sargan p-value 0.646 0.268 
 
Kleibergen-Paap LM test statistic 36.779 33.298 
 
Kleibergen-Paap p-value 0.000 0.000 
 
Kleibergen-Paap F statistic 50.792 38.220 
 
Pesaran-Taylor reset statistic 0.527 0.000 
 
Pesaran-Taylor p-value 0.468 0.984 
 
Ramsey reset F statistic 
  
0.691 
Probability > F     0.559 
Robust standard errors in brackets 
   
*** p<0.01, ** p<0.05, * p<0.1 
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Table A2.7 Preferred outcome specifications for 2006/07 
  (1) (2) (3) (4) (5) (6) (7) (8) (9)  
PBC 1 PBC 2 PBC 4 PBC 7 PBC 10 PBC 11 PBC 13 PBC 17 PBC 1819  
infectious cancer endocrine neurological circulatory respiratory gastro genito-urinary mat/neonates  
2006/7 spend 2006/7 spend 2006/7 spend 2006/7 spend 2006/7 spend 2006/7 spend 2006/7 spend 2006/7 spend 2006/7 spend  
SYLLR 2006/7/8 SYLLR 2006/7/8 SYLLR 2006/7/8 SYLLR 2006/7/8 SYLLR 2006/7/8 SYLLR 2006/7/8 SYLLR 2006/7/8 SYLLR 2006/7/8 mortality rate 2006/7/8  
outcome model outcome model outcome model outcome model outcome model outcome model outcome model outcome model outcome model  
instrument spend instrument spend instrument spend instrument spend instrument spend instrument spend instrument spend instrument n/a instrument spend  
weighted weighted weighted weighted weighted weighted weighted weighted weighted  
IV second stage IV second stage IV second stage IV second stage IV second stage IV second stage IV second stage OLS IV second stage  
GMM2S GMM2S GMM2S GMM2S GMM2S GMM2S GMM2S 
 
GMM2S  
LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level  
actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality  
actual census 06 actual census 06 actual census 06 actual census 06 actual census 06 actual census 06 actual census 06 actual census 06 actual census 06 
VARIABLES 07/08 revised 07/08 revised 07/08 revised+ re-derived++ 07/08 specification 07/08 specification 07/08 specification re-derived  5%/95% OLS re-derived+ 
                    
lLAg1_67 -0.608 
        
 
[0.402] 
        
lLAhivneedph 0.478*** 
        
 
[0.142] 
        
lLAhivneedph2 0.114 
        
 
[0.076] 














       
  
[0.083] 





2.296*** 2.781** 4.015*** 
 
0.917**   
[0.085] 
  






       
  
[0.280] 




      
   
[0.976] 




      
   
[0.428] 
      
lLAg7_67 
   
-0.869* 
     
    
[0.494] 
     
LPOPPUCAR06 
   
1.492*** 
   
-2.849** 
 
    
[0.371] 




    
-1.404*** 
    
     
[0.218] 
    
LPROFOCCU06 
    
-0.508*** 
    
     
[0.140] 
    
lLAg11_67 
     
-2.281*** 
   
      
[0.801] 
   
LPERMSICK06 
     
2.745** 
   
      
[1.385] 
   
LPERMSICK06SQ 
     
0.285 
   
      
[0.203] 
   
lLAg13_67 
      
-1.255** 
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-0.588 
 




       
2.140*** 
 




       
-0.973* 
 




        
-0.085          
[0.205] 
LBORNEXEU06 
        
0.120***          
[0.039] 
LHHNOCAR06 
        
-0.708***          
[0.140] 
LPC74LTUN06 
        
0.489***          
[0.125] 
Constant 2.248** 6.052*** 8.080* 7.442*** 10.621*** 18.286*** 8.505*** -2.020 2.104  
[0.944] [0.364] [4.157] [2.483] [1.006] [5.109] [2.703] [2.908] [1.481]           
Observations 148 150 136 117 150 150 149 135 149 
Endogeneity test statistic 1.915 8.416 2.828 2.516 35.080 24.628 6.928 
 
0.824 
Endogeneity p-value 0.166 0.004 0.093 0.113 0.000 0.000 0.008 
 
0.364 
Kleibergen-Paap LM test statistic 9.043 19.866 7.931 16.288 35.077 6.770 10.318 
 
14.757 
Kleibergen-Paap p-value 0.003 0.000 0.005 0.001 0.000 0.009 0.001 
 
0.001 
Kleibergen-Paap F statistic 15.331 16.380 9.502 7.767 30.494 12.140 15.426 
 
9.216 
Pesaran-Taylor reset statistic 0.248 0.358 0.044 0.615 0.039 1.756 0.054 
 
1.239 
Pesaran-Taylor p-value 0.618 0.550 0.834 0.433 0.843 0.185 0.817 
 
0.266 












   
0.105 
R-squared 
       
0.222 
 
Ramsey reset F statistic 
       
0.752 
 
Probability > F               0.523   
Robust standard errors in brackets 
         
*** p<0.01, ** p<0.05, * p<0.1 
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Table A2.8 Preferred expenditure specifications for 2006/07 
  (1) (2) (3) (4) (5) (6) (7) (8) (9)  
PBC 1 PBC 2 PBC 3 PBC 4 PBC 5 PBC 6 PBC 7 PBC 8 PBC 9  
infectious cancer blood endocrine mental health LDisability neurological vision hearing  
2006/7 spend 2006/7 spend 2006/7 spend 2006/7 spend 2006/7 spend 2006/07 spend 2006/07 spend 2006/7 spend 2006/7 spend  
SYLLR 2006/7/8 SYLLR 2006/7/8 SYLLR 2006/7/8 SYLLR 2006/7/8 SYLLR 2006/7/8 SYLLR 2006/7/8 SYLLR 2006/7/8 SYLLR 2006/7/8 SYLLR 2006/7/8  
spend model spend model spend model spend model spend model spend model spend model spend model spend model  
instrument n/a instrument o/need instrument n/a instrument n/a instrument n/a instrument n/a instrument n/a instrument o/need instrument n/a  
weighted weighted weighted weighted weighted weighted weighted weighted weighted  
OLS IV second stage OLS OLS OLS OLS OLS IV second stage OLS   
GMM2S 




LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level  
actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality  
actual census 06 actual census 06 actual census 06 actual census 06 actual census 06 actual census 06 actual census 06 actual census 06 actual census 06 
VARIABLES 07/08 spec revised 07/08 specification 07/08 specification 07/08 revised 07/08 specification re-derived OLS 7/8 revised OLS 07/08 specification 07/08 revised 
                    
lLAgall_67 1.051*** 1.219*** 1.037*** 0.630*** 1.143*** 0.410 0.382* 0.931*** 0.989**  
[0.258] [0.263] [0.330] [0.168] [0.204] [0.488] [0.220] [0.329] [0.458] 
lLAhivneedph 0.364*** 
        
 
[0.040] 
        
lSYLLRacExIandP678 -0.043 
        
 
[0.288] 
        
lLAhivneedph2 0.165*** 
        
 
[0.026] 
        
LPROFOCCU06 0.647* -0.527*** 

























       
  
[0.204] 
















      
   
[0.194] 
      
lSYLLRacExDIA678 
   
0.051 
     
    
[0.137] 
     
lLAmhneedindexpp 
    
0.560*** 
    
     
[0.148] 
    
LPOPPUCAR06 
    
-0.837*** 
    
     
[0.118] 
    
LBORNEXEU06 
     
0.279*** 
   
      
[0.083] 
   
LWHITEEG06 
     
0.838*** 
   
      
[0.303] 
   
lLAepiprev0607 
      
0.417*** 
  




      
0.119 
  
       
[0.159] 
  
Constant -3.116 -0.773 0.769 -1.014 -2.637 4.214* 2.561* 1.677 -5.653** 
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[2.237] [1.188] [2.461] [1.017] [1.850] [2.513] [1.334] [1.537] [2.581]           
Observations 148 150 150 150 150 150 150 150 150 
R-squared 0.698 
 
0.162 0.371 0.739 0.111 0.283 
 
0.253 
Ramsey reset F statistic 1.801 
 
0.305 0.553 1.380 0.238 0.219 
 
0.601 
Probability > F 0.150 
 
0.822 0.647 0.252 0.870 0.883 
 
0.615 
Endogeneity test statistic 
 
12.742 






     
0.172 
 
Hansen-Sargan test statistic 
 
0.194 






     
0.848 
 
Kleibergen-Paap LM test statistic 
 
33.956 






     
0.000 
 
Kleibergen-Paap F statistic 
 
46.177 
     
74.593 
 
Pesaran-Taylor reset statistic 
 
0.014 
     
0.007 
 
Pesaran-Taylor p-value   0.906           0.931   
Robust standard errors in brackets 
         
*** p<0.01, ** p<0.05, * p<0.1 
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Table A2.8 continued  Preferred expenditure specifications for 2006/07 
  (1) (2) (3) (4) (5) (6) (7) (8) (9) (10)  
PBC 10 PBC 11 PBC 12 PBC 13 PBC 14 PBC 15 PBC 16 PBC 17 PBC 1819 PBC 20  
circulatory respiratory dental gastro skin problems musculo-skeletal trauma genito- mat/neonates poisoning  
2006/7 spend 2006/7 spend 2006/7 spend 2006/7 spend 2006/7 spend 2006/7 spend 2006/7 spend 2006/7 spend 2006/07 spend 2006/7 spend  
SYLLR 2006/7/8 SYLLR 2006/7/8 SYLLR 
2006/7/8 
SYLLR 2006/7/8 SYLLR 
2006/7/8 
SYLLR 2006/7/8 SYLLR 2006/7/8 SYLLR 
2006/7/8 















instrument n/a instrument n/a instrument 
n/a 
spend exogenous instrument 
spend  
weighted weighted weighted weighted weighted weighted weighted weighted weighted weighted  




     
GMM2S  
LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level  
actual mortality actual mortality actual 
mortality 
actual mortality actual 
mortality 
actual mortality actual mortality actual 
mortality 
actual mortality real mortality 
 
actual census 06 actual census 06 actual census 
07 
actual census 06 actual census 
06 
actual census 06 actual census 06 actual census 
06 










07/08 revised 07/08 specification 07/08 revised 
                      
lLAgall_67 1.578*** 1.287*** 0.835** 1.014*** 0.701*** 0.628** 0.705*** 0.988*** 0.614** 1.107***  





-0.124 0.341 0.273 
 
0.167 -0.667***    
[0.382] 
 






       
   
[0.284] 




       
   
[1.704] 




       
   
[0.324] 




       
   
[0.302] 
       
lSYLLRacExCirc678 -1.203*** 
         
 
[0.247] 
         
LNQUAL17406 0.553*** 0.273*** 
 
0.402*** 










        
  
[0.221] 
        
lSYLLRacExGast678 
   
-0.363 
      
    
[0.224] 
      
LPROFOCCU06 
    
-0.287*** -0.504*** 
    
     
[0.100] [0.182] 
    
LPC74LTUN06 











      
0.080*** 
   
       
[0.026] 
   
lSYLLRacExrenal678 
       
-0.229 
  
        
[0.184] 
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lLAmatneedindexpp 
        
0.561*** 
 
         
[0.123] 
 
Constant 1.221 -3.159*** -9.116 -0.291 -1.325 -5.128*** -2.329** -0.867 -1.203 -1.069  
[1.349] [1.195] [5.559] [1.014] [1.338] [1.863] [1.041] [1.298] [1.307] [1.571]            
Observations 150 150 150 150 150 150 150 150 150 150 
Endogeneity test statistic 26.058 7.261 
 
4.381 
     
11.024 
Endogeneity p-value 0.000 0.007 
 
0.036 
     
0.001 
Hansen-Sargan test statistic 0.158 0.478 
       
1.866 
Hansen-Sargan p-value 0.691 0.489 
       
0.172 





     
35.141 
Kleibergen-Paap p-value 0.000 0.000 
 
0.000 
     
0.000 
Kleibergen-Paap F statistic 33.179 56.202 
 
85.706 
     
59.640 
Pesaran-Taylor reset statistic 0.140 0.314 
 
0.004 
     
0.024 
Pesaran-Taylor p-value 0.708 0.575 
 
0.949 






0.286 0.277 0.230 0.358 0.391 
 




1.670 0.503 0.759 1.568 1.269 
 
Probability > F     0.083   0.176 0.681 0.519 0.200 0.287   
Robust standard errors in brackets 
         
*** p<0.01, ** p<0.05, * 
p<0.1 
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Table A2.8 continued  Preferred expenditure specifications for 2006/07 
  (1) (2) (3)  
PBC 21 PBC 22 PBC 23a  
HI social care GMS  
2006/7 spend 2006/07 spend 2006/7 spend  
SYLLR 2006/7/8 SYLLR 2006/7/8 SYLLR 2006/7/8  
spend model spend model spend model  
spend exogenous spend exogenous instrument n/a  
weighted weighted weighted  
OLS OLS OLS     
 
LA-level LA-level LA-level  
actual mortality actual mortality actual mortality  
actual census 07 actual census 06 actual census 06 
VARIABLES re-derived 07/08 specification OLS 07/08 specification 
        
lLAgall_67 0.709 1.702*** 0.447***  
[0.432] [0.489] [0.112] 
lSYLLRallcause678 -0.318 -0.817* 0.056  






















-0.225***    
[0.049] 
Constant -4.143 -3.938* 1.621***  
[3.699] [2.367] [0.452]     
Observations 150 103 145 
R-squared 0.134 0.102 0.367 
Ramsey reset F statistic 1.695 0.312 0.757 
Probability > F 0.171 0.817 0.520 
Robust standard errors in brackets 
   
*** p<0.01, ** p<0.05, * p<0.1 
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Table A2.9 Preferred outcome specifications for 2007/08 
  (1) (2) (3) (4) (5) (6) (7) (8) (9) (10)  
PBC 1 PBC 2 PBC 4 PBC 7 PBC 10 PBC 11 PBC 13 PBC 16 PBC 17 PBC 1819  
infectious cancer endocrine Neurological circulatory respiratory gastro trauma genito-urinary mat/neonates  
2007/8 spend 2007/8 spend 2007/8 spend 2007/08 spend 2007/8 spend 2008/9 spend 2007/8 spend 2007/8 spend 2007/8 spend 2007/08 spend  
SYLLR 2007/8/9 SYLLR 2007/8/9 SYLLR 2007/8/9 SYLLR 
2007/08/09 
SYLLR 2007/8/9 SYLLR 
2008/9/10 
SYLLR 2007/8/9 SMR 2007/8/9 SMR 2007/8/9 infant mort rate 
2007/08/09  



















weighted weighted weighted weighted weighted weighted weighted weighted weighted weighted  
IV second stage IV second stage IV second stage OLS IV second stage IV second stage IV second stage IV second stage IV second stage OLS  
GMM2S GMM2S GMM2S 
 
GMM2S GMM2S GMM2S GMM2S GMM2S 
 
 
LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level  
actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality  
actual census 
07 












actual census 07 
VARIABLES 08/09 revised 08/09 
specification 
08/09 revised re-derived, OLS 08/09 revised 08/09 revised 08/09 
specification 
re-derived re-derived 08/09 specification+ 
                      
lLAg1_78 -0.660** 
         
 
[0.290] 
         
lLAhivneedph 0.515*** 
         
 
[0.119] 
         
lLAhivneedph2 0.157** 
         
 
[0.065] 













        
  
[0.084] 





2.168*** 1.838*** 3.565*** 3.822*** 3.887** 1.494***   
[0.092] 
  




       
   
[1.274] 
       
LPROFOCCU07 
  
-0.830* -0.701*** -0.598*** 
     
   
[0.494] [0.175] [0.139] 
     
lLAg7_78 
   
-0.237* 
      
    
[0.131] 
      
LPOPPUCAR07 
   
0.542* 
      
    
[0.300] 
      
lLAg10_78 
    
-1.315*** 
     
     
[0.172] 
     
lLAg11_78 
     
-1.564*** 
    
      
[0.448] 
    
LPERMSICK07 
     
3.244*** 
    
      
[1.183] 
    
LPERMSICK07SQ 
     
0.364** 
    
      
[0.168] 
    
lLAg13_78 
      
-0.837** 
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[0.425] 
   
lLAg16_78 
       
-0.638 
  




       
-0.605** 
 





        
-1.977 
 




        
0.368*** 0.178***          
[0.106] [0.045] 
lLAg1819_78 
         
-0.057           
[0.084] 
LHHNOCAR07 
         
-0.641***           
[0.125] 
Constant 2.369*** 6.221*** 4.252 2.837*** 10.071*** 16.150*** 6.713*** 0.585 8.451 3.206***  
[0.697] [0.380] [3.874] [0.998] [0.837] [3.573] [1.824] [1.158] [7.152] [0.601]            
Observations 148 152 133 150 152 152 151 151 152 151 
R-squared 
   
0.182 
     
0.404 
Endogeneity test statistic 3.991 12.271 1.372 
 
37.856 18.331 6.454 1.100 1.226 
 
Endogeneity p-value 0.046 0.000 0.241 
 
0.000 0.000 0.011 0.294 0.268 
 












Kleibergen-Paap LM test 
statistic 
19.326 20.419 8.726 
 
31.136 9.921 12.416 11.511 10.176 
 
Kleibergen-Paap p-value 0.000 0.000 0.003 
 
0.000 0.002 0.000 0.003 0.006 
 
Kleibergen-Paap F statistic 9.757 19.300 9.375 
 
43.326 20.194 18.138 8.192 6.291 
 
Pesaran-Taylor reset statistic 1.118 1.587 0.184 
 
1.828 1.547 0.018 0.049 0.910 
 
Pesaran-Taylor p-value 0.290 0.208 0.668 
 
0.176 0.214 0.892 0.825 0.340 
 
Ramsey reset F statistic 
   
1.220 
     
0.766 
Probability > F       0.305           0.515 
Robust standard errors in 
brackets 
          
*** p<0.01, ** p<0.05, * p<0.1 
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Table A2.10 Preferred expenditure specifications for 2007/08 
  (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11)  
PBC 1 PBC 2 PBC 3 PBC 4 PBC 5 PBC 6 PBC 7 PBC 8 PBC 9 PBC 10 PBC 11  
infectious cancer blood endocrine mental health LDisability neurological vision hearing circulatory respiratory  
2007/8 spend 2007/8 spend 2007/8 spend 2007/8 spend 2007/8 spend 2007/08 spend 2007/8 spend 2007/8 spend 2007/8 
spend 
2007/8 spend 2008/9 spend 
 




SYLLR 2007/8/9 SYLLR 
2007/8/9 
SYLLR 2007/8/9 SYLLR 
2008/9/10  
spend model spend model spend model spend model spend model spend model spend model spend model spend model spend model spend model  
instrument n/a instrument 
o/need 










weighted weighted weighted weighted weighted weighted weighted weighted weighted weighted weighted  
OLS IV second stage OLS OLS OLS OLS IV second stage IV second stage OLS IV second stage IV second stage   
GMM2S 
    
GMM2S GMM2S 
 
GMM2S GMM2S  
LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level  
actual mortality actual 
mortality 













































                        
lLAgall_78 1.387*** 1.626*** 1.374*** 0.455*** 1.103*** 0.386 0.733*** 1.106*** 0.951* 1.614*** 1.555***  
[0.252] [0.314] [0.386] [0.129] [0.123] [0.393] [0.243] [0.277] [0.572] [0.294] [0.245] 
lLAhivneedph 0.440*** 
          
 
[0.024] 
          
lSYLLRacExIandP789 -0.536** 
          
 
[0.233] 
          
lLAhivneedph2 0.181*** 
          
 
[0.021] 




         
  
[0.216] 


































        
   
[0.162] 
        
LNQUAL17407 
   
0.721 
   
0.545*** 
 
0.721*** 0.382***     
[0.527] 





   
0.120 
       
    
[0.183] 
       
lLAdiaprev0708 
   
0.114 
       
    
[0.116] 
       
lSYLLRacExDIA789 
   
-0.060 
       
    
[0.096] 
       
lLAmhneedindexpp 
    
0.598*** 
      
     
[0.107] 
      
LPOPPUCAR07 
    
-0.684*** 
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[0.089] 
      
lLAneedCARAN782 
     
3.601** 
     
      
[1.615] 
     
lSYLLRacExEPI789 
      
-0.354 
    
       
[0.249] 
    
lLAepiprev0708 
      
0.512*** 
    
       
[0.077] 
    
LPERMSICK07 
      
0.191 
    
       
[0.120] 
    
lSYLLRacExCirc789 
         
-1.395*** 
 




          
-0.621***            
[0.202] 
Constant -3.903*** -1.505 -1.767 1.812 -2.007* 4.456* 4.038* 0.021 -5.920* 2.204 -2.864**  
[1.044] [1.535] [2.716] [1.118] [1.202] [2.439] [2.136] [1.235] [3.073] [1.357] [1.307]             
Observations 150 152 152 152 152 152 152 152 152 152 152 
R-squared 0.731 
 




Ramsey reset F statistic 0.873 
 




Probability > F 0.457 
 




Endogeneity test statistic 
 
18.550 









































Kleibergen-Paap F statistic 
 
49.406 












Pesaran-Taylor p-value   0.442         0.559 0.283   0.967 0.303 
Robust standard errors in brackets 
          
*** p<0.01, ** p<0.05, * 
p<0.1 
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Table A2.10 continued  Preferred expenditure specifications for 2007/08 
  (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11)  
PBC 12 PBC 13 PBC 14 PBC 15 PBC 16 PBC 17 PBC 1819 PBC 20 PBC 21 PBC 22 PBC 23a  
dental gastro skin problems musculo-
skeletal 




2007/8 spend 2007/08 spend 2007/08 spend 2007/8 spend 2007/8 
spend 





























instrument n/a instrument n/a instrument n/a instrument 
n/a 








weighted weighted weighted weighted weighted weighted weighted weighted weighted weighted weighted  
OLS IV second 
stage 
OLS OLS OLS OLS OLS IV second 
stage 
























actual mortality real mortality actual 
mortality 






































                        
lLAgall_78 0.420*** 1.490*** 0.787*** 0.733*** 1.328*** 1.015*** 0.563** 1.674*** 1.296** 1.669** 0.553***  
[0.150] [0.296] [0.203] [0.198] [0.293] [0.218] [0.242] [0.382] [0.544] [0.804] [0.110] 
LLONEPARH07 0.179** 
          
 
[0.079] 
          
LNQUAL17407 0.094 0.390*** 
 
0.057 












-0.062 0.278 0.041 
 
0.230 -1.095*** -0.078 -0.423 -0.062  
[0.146] 
 
[0.134] [0.186] [0.225] 
 




         
  
[0.273] 




        
   
[0.107] 




        
   
[0.086] 
        
LPC74LTUN07 
   
-0.357*** 
       
    
[0.080] 
       
LPOPPUCAR07 
   
0.695*** 
       
    
[0.252] 
       
LWORKAGRI07 
    
0.125*** 
      
     
[0.018] 
      
lSYLLRacExrenal789 
     
-0.087 
     
      
[0.153] 
     
lLAmatneedindexpp 
      
0.597*** 
    
       
[0.093] 
    
LWHITEEG07 
        
0.697** 
  
         
[0.296] 
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LLONEPENH07 
        
-0.789* 
  
         
[0.468] 
  
Constant 0.328 -1.286 -3.063** -2.570 -5.264*** -2.654*** -1.238 -2.162 -7.075* -6.170** 1.347***  
[1.039] [1.375] [1.174] [1.597] [1.084] [0.916] [1.382] [1.918] [3.584] [2.758] [0.453]             
Observations 135 152 152 152 152 152 152 152 152 110 151 
R-squared 0.485 
 





Ramsey reset F statistic 1.996 
 





Probability > F 0.118 
 





Endogeneity test statistic 
 
6.175 













Hansen-Sargan test statistic 
 
2.634 






























Kleibergen-Paap F statistic 
 
50.766 














Pesaran-Taylor p-value   0.719           0.914   0.664   
Robust standard errors in 
brackets 
           
*** p<0.01, ** p<0.05, * 
p<0.1 
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Table A2.11 Preferred outcome specifications for 2008/09 
  (1) (2) (3) (4) (5) (6) (7) (8) (9)  
PBC 1 PBC 2 PBC 4 PBC 7 PBC 10 PBC 11 PBC 13 PBC 17 PBC 1819  
infectious cancer endocrine neurological circulatory respiratory gastro genito-urinary mat/neonates  
2008/9 spend 2009/10 spend 2008/9 spend 2008/9 spend 2008/9 spend 2008/9 spend 2008/9 spend 2008/9 spend 2008/09 spend  
SYLLR 2008/9/10 SYLLR 2009/10/11 SYLLR 2008/9/10 SYLLR 2008/9/10 SYLLR 2008/9/10 SYLLR 2008/9/10 SYLLR 2008/9/10 SYLLR 
2008/9/10 
infant mort rate 
2008/09/10  
outcome model outcome model outcome model outcome model outcome model outcome model outcome model spend model outcome model  
instrument 
spend 
instrument spend instrument spend instrument spend instrument spend instrument spend instrument 
spend 
instrument n/a spend exogenous 
 
weighted weighted weighted weighted weighted weighted weighted weighted weighted  
IV second stage IV second stage IV second stage IV second stage IV second stage IV second stage IV second stage OLS OLS  
GMM2S GMM2S GMM2S GMM2S GMM2S GMM2S GMM2S 
  
 
LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level  
actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality  
actual census 08 actual census08 actual census 08 actual census 08 actual census 08 actual census 08 actual census 08 actual census 
08 
actual census 08 
VARIABLES 09/10 revised 09/10 
specification 




09/10 revised PCT 
specification 
09/10 specification+ 
                    
lLAg1_89 -0.549*** 
        
 
[0.201] 
        
lLAhivneedph 0.472*** 
        
 
[0.086] 
        
lLAhivneedph2 0.168*** 
        
 
[0.046] 













       
  
[0.076] 





1.254 2.924*** 1.913* 3.774*** 
 
1.630***   
[0.092] 
 






      
   
[0.802] 




      
   
[0.368] 
      
lLAg7_89 
   
-0.304 
     
    
[0.641] 
     
lLAg10_89 
    
-1.384*** 
    
     
[0.209] 
    
lLAg11_89 
     
-1.671*** 
   
      
[0.504] 
   
LPERMSICK08 
     
3.922*** 
   
      
[1.287] 
   
LPERMSICK08SQ 
     
0.457** 
   
      
[0.192] 
   
lLAg13_89 
      
-1.146** 
  




       
1.455*** 
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-0.024 
 




        
-0.030          
[0.091] 
LBORNEXEU08 
        
0.228***          
[0.043] 
LHHNOCAR08 
        
-0.527***          
[0.105] 
LPC74LTUN08 
        
0.354***          
[0.114] 
Constant 1.873*** 6.277*** 4.188* 2.757 11.178*** 18.058*** 8.100*** 3.126 2.582***  
[0.488] [0.349] [2.205] [2.697] [1.018] [3.907] [1.957] [2.877] [0.633]           
Observations 148 152 149 148 152 151 150 143 151 
R-squared 
       
0.134 0.442 
Endogeneity test statistic 3.777 10.300 4.581 0.931 25.219 15.773 11.326 
  
Endogeneity p-value 0.052 0.001 0.032 0.334 0.000 0.000 0.001 
  
Hansen-Sargan test statistic 2.602 0.523 
 
3.587 0.566 2.626 
   
Hansen-Sargan p-value 0.272 0.470 
 
0.166 0.452 0.105 
   
Kleibergen-Paap LM test statistic 22.335 25.882 9.327 16.084 24.567 11.562 13.871 
  
Kleibergen-Paap p-value 0.000 0.000 0.002 0.001 0.000 0.003 0.000 
  
Kleibergen-Paap F statistic 10.459 32.476 10.515 10.630 43.471 14.269 28.799 
  
Pesaran-Taylor reset statistic 0.028 0.123 0.911 1.459 0.017 0.154 0.627 
  
Pesaran-Taylor p-value 0.867 0.726 0.340 0.227 0.897 0.695 0.429 
  
Ramsey reset F statistic 
       
0.731 0.339 
Probability > F               0.535 0.797 
Robust standard errors in 
brackets 
         
*** p<0.01, ** p<0.05, * p<0.1 
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Table A2.12 Preferred expenditure specifications for 2008/09 
  (1) (2) (3) (4) (5) (6) (7) (8)  
PBC 1 PBC 2 PBC 3 PBC 4 PBC 5 
 
PBC 7 PBC 8  
infectious cancer blood endocrine mental health PBC 6 neurological vision  
2008/9 spend 2008/9 spend 2008/9 spend 2008/9 spend 2008/9 spend LDisability 2008/9 spend 2008/9 spend  
SYLLR 2008/9/10 SYLLR 2008/9/10 SYLLR 2008/9/10 SYLLR 2008/9/10 SYLLR 2008/9/10 2008/09 spend SYLLR 2008/9/10 SYLLR 2008/9/10  
spend model spend model spend model spend model spend model SYLLR 2008/09/10 spend model spend model  
instrument n/a instrument o/need instrument n/a instrument n/a instrument n/a spend model instrument o/need instrument o/need  
weighted weighted weighted weighted weighted instrument n/a weighted weighted  
OLS IV second stage OLS OLS OLS weighted IV second stage IV second stage   
GMM2S 
   
OLS GMM2S GMM2S  
LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level  
actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality  
actual census 08 actual census 08 actual census 08 actual census 08 actual census 08 actual census 08 actual census 08 actual census 08 
VARIABLES 09/10 specification 09/10 specification 09/10 specification 09/10 revised OLS 09/10 specification 09/10 specification 09/10 specification 09/10 specification 
                  
lLAgall_89 1.471*** 0.784** 0.995*** 0.498*** 0.995*** 0.329 0.897*** 0.701***  
[0.261] [0.335] [0.272] [0.147] [0.192] [0.351] [0.204] [0.223] 
lLAhivneedph 0.456*** 
       
 
[0.026] 
       
lSYLLRacExIandP890 -0.429** 
       
 
[0.214] 
       
lLAhivneedph2 0.181*** 
       
 
[0.023] 




      
  
[0.168] 




      
  
[0.468] 



























     
   
[0.152] 
     
LNQUAL17408 
   
1.217*** 
   
0.664***     
[0.398] 
   
[0.079] 
LNQUAL17408SQ 
   
0.347*** 
    
    
[0.129] 
    
lLAdiaprevinover17 
   
0.285** 
    
    
[0.116] 
    
lSYLLRacExDIA890 
   
0.097 
    
    
[0.105] 
    
lLAmhneedindexpp 
    
0.658*** 
   
     
[0.143] 
   
LPOPPUCAR08 
    
-0.618*** 
   
     
[0.104] 
   
lLAneedCARAN2 
     
3.556** 
  




      
-0.132 
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0.382*** 
 
       
[0.068] 
 
Constant -5.190*** 5.048* 1.139 0.073 -1.644 3.663* -1.466 2.541**  
[1.130] [2.695] [1.594] [0.976] [1.724] [2.101] [0.992] [1.057]          
Observations 150 152 152 150 152 152 150 152 
R-squared 0.783 
 
0.194 0.579 0.789 0.104 
  
Ramsey reset F statistic 1.513 
 
1.512 1.186 0.465 1.764 
  
Probability > F 0.214 
 
0.214 0.317 0.707 0.157 
  
Endogeneity test statistic 
 
19.732 





    
0.003 0.040 
Hansen-Sargan test statistic 
 
1.028 





    
0.776 0.442 
Kleibergen-Paap LM test statistic 
 
36.285 





    
0.000 0.000 
Kleibergen-Paap F statistic 
 
56.425 
    
82.270 51.873 
Pesaran-Taylor reset statistic 
 
0.002 
    
0.809 0.143 
Pesaran-Taylor p-value   0.968         0.368 0.705 
Robust standard errors in brackets 
        
*** p<0.01, ** p<0.05, * p<0.1 
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Table A2.12 continued  Preferred expenditure specifications for 2008/09 
  (1) (2) (3) (4) (5) (6) (7) (8)  
PBC 9 PBC 10 PBC 11 PBC 12 PBC 13 PBC 14 PBC 15 PBC 16  
hearing circulatory respiratory dental gastro skin problems musculo-skeletal trauma  
2008/9 spend 2008/9 spend 2008/9 spend 2008/9 spend 2008/9 spend 2008/09 spend 2008/09 spend 2008/9 spend  
SYLLR 2008/9/10 SYLLR 2008/9/10 SYLLR 2008/9/10 SYLLR 2008/9/10 SYLLR 2008/9/10 SYLLR 2008/09/11 SYLLR 2008/09/10 SYLLR 2008/9/10  
spend model spend model spend model spend model spend model spend model spend model spend model  
instrument n/a instrument o/need instrument o/need instrument n/a instrument o/need instrument n/a instrument n/a instrument n/a  
weighted weighted weighted weighted weighted weighted weighted weighted  




   
 
LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level  
actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality  
actual census 08 actual census 08 actual census 08 actual census 08 actual census 08 actual census 08 actual census 08 actual census 08 
VARIABLES 09/10 specification 09/10 spec revised 09/10 specification rederived OLS 09/10 specification 09/10 specification re-derived+ OLS 09/10 specification 
                  
lLAgall_89 1.637*** 1.784*** 0.752** 0.428** 0.520* 0.907*** 0.738*** 1.344***  



























      
  
[0.236] 















     
   
[0.285] 






   








     
   
[0.530] 
     
lLAimd_2007exexpobook 











    
-1.309*** 
   
     
[0.323] 
   
LHHNOCAR08 
     
-0.222*** 
  




      
-0.305*** 
 




      
0.681*** 
 




      
0.271 
 




       
0.084***         
[0.018] 
Constant -10.672*** -0.118 5.422* -1.183 8.403*** -4.278*** -2.206 -3.653***  
[1.776] [1.402] [2.892] [1.513] [2.751] [1.256] [1.617] [0.989]          
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0.495 0.541 0.348 




1.203 1.296 0.793 




0.311 0.278 0.500 











   











   











   





   





   
Pesaran-Taylor p-value   0.630 0.761   0.532       
Robust standard errors in brackets 
        
*** p<0.01, ** p<0.05, * p<0.1 
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Table A2.12 continued  Preferred expenditure specifications for 2008/09 
  (1) (2) (3) (4) (5) (6)  
PBC 17 PBC 1819 PBC 20 PBC 21 PBC 22 PBC 23a  
genito- maternity poisoning HI social care GMS  
2008/9 spend 2008/9 spend 2008/9 spend 2008/9 spend 2008/9 spend 2008/9 spend  
SYLLR 2008/9/10 SYLLR 2008/9/10 SYLLR 2008/9/10 SYLLR 2008/9/10 SYLLR 2008/9/10 SYLLR 2008/9/10  
spend model spend model spend model spend model spend model spend model  
instrument n/a instrument o/need instrument o/need instrument n/a instrument n/a instrument n/a  
weighted weighted weighted weighted weighted weighted  
OLS IV second stage IV second stage OLS OLS OLS   
GMM2S GMM2S 
   
 
LA-level LA-level LA-level LA-level LA-level LA-level  
actual mortality actual mortality real mortality actual mortality actual mortality actual mortality  
actual census 08 actual census 08 actual census 08 
  
actual census 08 
VARIABLES 09/10 specification 09/10 specification 09/10 specification 09/10 specification 09/10 specification 09/10 specification 
              
LBORNEXEU08 0.037** 
     
 
[0.016] 
     
lSYLLRacExrenal890 -0.040 
     
 
[0.130] 










lLAgall_89 0.733*** 0.963*** 0.674* 0.952 1.192* 0.338***  
[0.213] [0.339] [0.366] [0.699] [0.605] [0.089] 
lSYLLRallcause890 
 
-0.299 -1.433*** 0.076 -0.463 -0.028   




    
  
[0.135] 
    
Constant -0.747 -0.903 6.637* -3.945 -2.416 2.672***  
[1.897] [0.819] [3.581] [5.837] [3.223] [0.350]        
Observations 152 152 152 152 106 150 
R-squared 0.491 
  
0.368 0.049 0.228 
Ramsey reset F statistic 1.741 
  
0.317 0.331 0.753 
Probability > F 0.161 
  
0.813 0.803 0.522 
Endogeneity test statistic 
 
1.649 19.393 




   
Hansen-Sargan test statistic 
 
2.648 0.006 




   
Kleibergen-Paap LM test statistic 
 
15.039 33.275 




   
Kleibergen-Paap F statistic 
 
11.224 33.862 
   
Pesaran-Taylor reset statistic 
 
0.215 0.029 
   
Pesaran-Taylor p-value   0.643 0.865       
Robust standard errors in brackets 
      
*** p<0.01, ** p<0.05, * p<0.1 
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Table A2.13 Preferred outcome specifications for 2009/10 
  (1) (2) (3) (4) (5) (6) (7) (8) (9) (10)  
PBC 1 PBC 2 PBC 04 PBC 07 PBC 10 PBC 11 PBC 13 PBC 17 PBC 1819 PBC 16  
infectious 
diseases 
cancer endocrine etc neurological circulatory respiratory gastro-
intestinal 
genito-urinary mat/neonates trauma/injuries 
 





















outcome model outcome 
model 




























o/need exogenous spend exogenous 
 
weighted weighted weighted weighted weighted weighted weighted weighted weighted weighted  
IV second stage IV second 
stage 












GMM2S GMM2S GMM2S GMM2S GMM2S GMM2S GMM2S GMM2S 
  
 
LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level  
actual mortality actual 
mortality 


























actual census 09 actual census 09 
VARIABLES Re-derived 08/09 version 08/09 revised 
v2(SI) 
Re-derived(SI)+ 08/09 version Re-derived 08/09 
revised(SI) 
Re-derived Re-derived, OLS Re-derived, OLS 
                      
lLAg1_0910 -0.310* 
         
 
[0.169] 
         
lLAhivneedph 0.362*** 
         
 
[0.071] 
         
lLAhivneedphSQ 0.123*** 
         
 
[0.037] 













        
  
[0.127] 





1.191 3.041*** 1.433** 4.291*** 
 
2.019*** 1.163***   
[0.113] 
 






       
   
[0.462] 




       
   
[0.178] 
       
lLAg7_0910 
   
-1.357 
      
    
[0.845] 
      
lLAepiprev0910 
   
1.413*** 
      
    
[0.384] 
      
LBORNEXEU09 
   
0.187*** 
    
0.319*** 
 
    
[0.065] 




    
-1.842*** 
     
     
[0.380] 
     
lLAg11_0910 
     
-2.103*** 
    
      
[0.794] 
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LPERMSICK09 
     
4.493*** 
    
      
[1.676] 
    
LPERMSICK09SQ 
     
0.508** 
    
      
[0.239] 
    
lLAg13_0910 
      
-1.989* 
   
       
[1.111] 
   
lLACARANneed910SQ 
      
3.833*** 
   
       
[1.473] 
   
lLAg17_0910 
       
-2.997 
  




       
2.662*** 
  




       
-4.052*** 
  




       
-3.945*** 
  




       
0.522** 
  




        
-0.166* 
 




        
-0.340*** 
 




         
0.041           
[0.141] 
LPC74LTUN09 
         
-0.259**           
[0.123] 
Constant 1.418*** 6.559*** 2.834** 14.608*** 13.415*** 21.341*** 11.868** 20.235** 2.152*** -0.876  
[0.505] [0.594] [1.404] [5.131] [1.873] [6.014] [4.923] [9.485] [0.462] [0.585]            
Observations 147 150 148 140 150 148 148 150 149 143 
R-squared 
        
0.413 0.141 
Endogeneity test statistic 1.862 5.166 6.368 3.034 34.858 13.820 8.584 2.256 
  
Endogeneity p-value 0.172 0.023 0.012 0.082 0.000 0.000 0.003 0.133 
  












Kleibergen-Paap LM test 
statistic 
25.041 23.944 13.637 7.203 14.621 11.432 6.617 26.731 
  
Kleibergen-Paap p-value 0.000 0.000 0.000 0.007 0.001 0.003 0.010 0.000 
  




1.073 0.329 2.068 0.575 0.000 1.083 0.251 1.449 
  
Pesaran-Taylor p-value 0.300 0.566 0.150 0.448 0.995 0.298 0.616 0.229 
  
Ramsey reset F statistic 
        
1.439 0.050 
Probability > F                 0.234 0.985 
Robust standard errors in brackets 
         
*** p<0.01, ** p<0.05, * 
p<0.1 
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Table A2.14 Preferred expenditure specifications for 2009/10 
  (1) (2) (3) (4) (5) (6) (7) (8) (9)  







infectious cancer PBC 3 diabetes PBC 5 PBC 6 epilepsy PBC 8 PBC 9  




SYLLR 2009/10/11 2009/10 spend all causeSYLLR 
2009/10/11 
2009/10 spend 2009/10 spend all causeSYLLR 
2009/10/11 
2009/10 spend 2009/10 spend 
 
spend model spend model SYLLR 
2009/10/11 








instrument n/a instrument other 
needs 
spend model instrument o/need spend model spend model instrument o/need spend model spend model 
 




OLS IV second stage weighted IV second stage weighted weighted IV second stage weighted weighted   
GMM2S OLS GMM2S OLS OLS GMM2S GMM2S OLS  
LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level  
actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality  
actual census 09 actual census09 actual census 09 actual census 09 actual census 09 actual census 09 actual census 09 actual census 09 actual census 09 
VARIABLES 08/09 version revised(XR) Re-derived, OLS 08/09 version 08/09 version Re-derived, OLS 08/09 version 08/09 revised Re-derived, OLS 
                    
lLAgall_0910 0.968*** 0.502** 1.060*** 0.708*** 0.899*** 0.647** 0.850*** 0.934*** 1.273***  
[0.288] [0.245] [0.277] [0.214] [0.225] [0.295] [0.225] [0.258] [0.359] 
lLAhivneedph 0.413*** 
        
 
[0.022] 
        
lSYLLRacExIandP901 -0.169 
        
 
[0.229] 
        
lLAhivneedphSQ 0.147*** 
        
 
[0.026] 




       
  
[0.173] 















   
-0.338** 
   
  
[0.098] 
   
[0.139] 
















      
   
[0.132] 
      
lSYLLRacExDIA901 
   
-0.167 
     
    
[0.258] 
     
lLACARANneed910SQ 




   




   
lLAdiaprev0910 
   
0.189* 
     
    
[0.103] 
     
lLAmhneedindexpp 
    
0.510*** 
    
     
[0.170] 
    
LPOPPUCAR09 
    
-0.465*** 
    
     
[0.104] 
    




      
-0.080 
  




      
0.394*** 
  




       
0.489*** 
 




        
0.297*          
[0.168] 
Constant -2.991** 6.566*** 2.197 0.164 -1.794 2.204 0.406 0.262 -8.969***  
[1.338] [1.661] [1.634] [1.976] [2.060] [1.477] [0.977] [0.967] [1.774]           























































































Pesaran-Taylor p-value   0.838   0.362     0.787 0.866   
Robust standard errors in brackets 
        
*** p<0.01, ** p<0.05, * p<0.1 
         
          
  
78  CHE Research Paper 158 
 
Table A2.14 continued  Preferred expenditure specifications for 2009/10 
  (1) (2) (3) (4) (5) (6) (7) (8) (9)  
PBC 10 PBC 11 
 
PBC 13 
   
PBC 17 PBC 1819  
circulatory respiratory PBC 12 gastro PBC 14 PBC 15 PBC 16 renal maternity/neonates  
2009/10 spend 2009/10 spend dental problems 2009/10 spend skin problems musculo-skeletal trauma/injuries 2009/10 spend 2009/10 spend  
SYLLR 
2009/10/11 




spend model spend model SYLLR 
2009/10/11 












spend model instrument other 
needs 
spend model spend model spend model instrument n/a instrument o/need 
 
weighted weighted instrument n/a weighted instrument n/a instrument n/a instrument n/a weighted weighted  
IV second stage IV second stage weighted IV second stage weighted weighted weighted OLS IV second stage  
GMM2S GMM2S OLS GMM2S OLS OLS OLS 
 
GMM2S  
LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level  
actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality  
actual census09 actual census09 actual census 09 actual census09 actual census 09 actual census 09 actual census 09 actual census 09 actual census 09 
VARIABLES 08/09 version 08/09 version Re-derived, OLS 08/09 version Re-derived, OLS Re-derived, OLS 08/09 version 08/09 version 08/09 version 




       
  
[0.273] 
       
lLAgall_0910 0.494* 0.576*** 0.765*** 0.387* 0.890*** 0.295 1.090*** 0.878*** 0.653***  
[0.267] [0.218] [0.188] [0.231] [0.192] [0.263] [0.215] [0.207] [0.233] 




















      
  
[0.472] [0.538] 
      
lSYLLRacExCirc901 -1.965*** 
        
 
[0.460] 





-0.046 0.180 -0.219 
 
-0.405*    
[0.131] 
 






   
0.069*** 
  
   
[0.018] 








   




   
lSYLLRacExGast901 
   
-0.612*** 
     
    
[0.211] 
     
lLAIMD2010 
    
0.278** 
    
     
[0.133] 
    
LHHNOCAR09 
    
-0.176** 
    
     
[0.074] 
    
LPC74LTUN09 
     
-0.317*** 
   
      
[0.077] 
   
LBORNEXEU09 
       
0.051*** 
 




       
-0.171 
 




        
0.963***          
[0.088] 
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Constant 12.640*** 3.491 -2.268** 5.218** -3.817** 0.574 -2.171* -0.939 2.072***  
[3.154] [2.136] [0.977] [2.254] [1.517] [2.551] [1.157] [1.794] [0.704]           
Observations 150 148 150 148 148 150 150 150 150 
Endogeneity test statistic 23.688 7.777 
 
9.122 
    
1.253 
Endogeneity p-value 0.000 0.005 
 
0.003 
    
0.263 
Hansen-Sargan test statistic 0.267 0.024 
 
0.389 
    
0.212 
Hansen-Sargan p-value 0.606 0.877 
 
0.533 
    
0.899 





    
35.340 
Kleibergen-Paap p-value 0.000 0.000 
 
0.000 
    
0.000 
Kleibergen-Paap F statistic 11.755 22.221 
 
29.989 
    
69.224 
Pesaran-Taylor reset statistic 0.022 0.171 
 
2.482 
    
0.050 
Pesaran-Taylor p-value 0.883 0.679 
 
0.115 






0.496 0.564 0.236 0.487 
 




1.358 1.392 0.948 1.995 
 
Probability > F     0.244   0.258 0.248 0.419 0.117   
Robust standard errors in brackets 
        
*** p<0.01, ** p<0.05, * p<0.1 
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Table A2.14 continued  Preferred expenditure specifications for 2009/10 
  (1) (2) (3) (4)  
PBC 20 PBC 21 PBC 22 PBC 23a  
poisoning HI social care GMS  
2009/10 spend 2009/10 spend 2009/10 spend 2009/10 spend  
SYLLR 2009/10/11 SYLLR 2009/10/11 SYLLR 2009/10/11 SYLLR 2009/10/11  
spend model spend model spend model spend model  
instrument o/need instrument n/a instrument n/a instrument n/a  
weighted weighted weighted weighted  
GMM2S OLS OLS OLS  
LA-level LA-level LA-level LA-level  
actual mortality actual mortality actual mortality actual mortality  
actual census 09 actual census 09 actual census 09 actual census 09 
VARIABLES 08/09 version 08/09 version Re-derived, OLS Re-derived, OLS 
          
lSYLLRallcause901 -0.816*** 0.232 -0.177 0.010  
[0.302] [0.323] [0.432] [0.071] 
lLAgall_0910 0.658** 1.246** 0.844 0.564***  
[0.304] [0.506] [0.563] [0.085] 





Constant 3.017 -7.085* -1.640 0.751**  
[2.692] [4.068] [2.855] [0.369]      
Observations 150 150 97 148 
R-squared 
 
0.385 0.035 0.463 
Endogeneity test statistic 12.352 
   
Endogeneity p-value 0.000 
   
Hansen-Sargan test statistic 0.078 
   
Hansen-Sargan p-value 0.781 
   
Kleibergen-Paap LM test statistic 25.438 
   
Kleibergen-Paap p-value 0.000 
   
Kleibergen-Paap F statistic 21.297 
   
Pesaran-Taylor reset statistic 0.008 
   
Pesaran-Taylor p-value 0.928 
   
Ramsey reset F statistic 
 
0.507 1.066 0.112 
Probability > F   0.678 0.368 0.953 
Robust standard errors in brackets 
    
*** p<0.01, ** p<0.05, * p<0.1 
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Table A2.15 Preferred outcome specifications for 2010/11 
  (1) (2) (3) (4) (5) (6) (7) (8) (9) (10)  
PBC 1 PBC 2 PBC 04 PBC 07 PBC 10 PBC 11 PBC 13 PBC 17 PBC 1819 PBC 16  
infectious 
diseases 
cancer endocrine etc neurological 
etc 




2010/11 spend 2010/11 spend 2010/11 spend 2010/11 spend 2010/11 spend 2010/11 spend 2010/11 spend 20010/11 
spend 


























outcome model outcome model outcome model outcome 
model 


















weighted weighted weighted weighted weighted weighted weighted weighted weighted weighted  






IV second stage IV second stage IV second stage IV second 
stage 
IV second stage OLS 
 
GMM2S GMM2S GMM2S GMM2S GMM2S GMM2S GMM2S GMM2S GMM2S 
 
 
LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level  






actual mortality actual mortality actual mortality actual 
mortality 












actual census 10 actual census 10 actual census 
10 
actual census 10 actual census 10 








Re-derived Re-derived 09/10 version & Re-
derived, OLS 
                      
lLAg1_1011 -0.256 
         
 
[0.285] 
         
lLAhivneedph 0.305*** 
         
 
[0.107] 
         
lLAIMD2010 0.590*** 
         
 
[0.125] 




        
  
[0.079] 




















       
   
[0.175] 




       
   
[0.136] 




       
   
[0.125] 
       
lLAg7_1011 
   
-0.374 
      
    
[0.515] 
      
lLAg10_1011 
    
-1.692*** 
     
     
[0.395] 
     
lLAg11_1011 
     
-2.006** 
    
      
[0.821] 
    
LPERMSICK10 
     
7.423*** 
    
      
[2.212] 
    
LPERMSICK10SQ 
     
0.905*** 
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[0.300] 
    
lLAg13_1011 
      
-1.425** 
   
       
[0.631] 
   
lLACARANneed1011SQ 
      
4.413*** 
   
       
[1.579] 
   
lLAg17_1011 
       
-2.830 
  




       
-2.567* 
  




       
-1.802** 
  




       
3.130*** 
  




        
-0.040 
 




        
-0.454*** 
 




        
0.326*** 
 




         
-0.064           
[0.129] 
Constant 0.927 6.119*** 0.468 2.968 12.742*** 26.332*** 9.358*** 9.693 1.389 0.618  
[0.638] [0.369] [0.611] [2.232] [1.931] [7.442] [2.781] [11.907] [1.212] [0.548]            
Observations 147 150 149 150 150 150 150 152 149 134 
R-squared 
         
0.157 
Endogeneity test statistic 0.845 6.251 
 
1.359 28.477 21.491 13.803 1.615 0.121 
 
Endogeneity p-value 0.358 0.012 
 
0.244 0.000 0.000 0.000 0.204 0.728 
 
Hansen-Sargan test statistic 0.162 0.882 
  
1.843 
     
Hansen-Sargan p-value 0.688 0.348 
  
0.175 
     




11.334 16.195 8.269 6.906 10.628 18.511 
 
Kleibergen-Paap p-value 0.001 0.000 
 
0.001 0.000 0.004 0.009 0.001 0.000 
 
Kleibergen-Paap F statistic 9.561 25.020 
 
16.653 12.595 10.897 8.704 11.406 23.729 
 
Pesaran-Taylor reset statistic 2.067 0.468 
 
0.312 0.117 0.000 0.128 1.600 0.129 
 
Pesaran-Taylor p-value 0.150 0.494 
 
0.576 0.732 0.994 0.721 0.206 0.719 
 
Ramsey reset F statistic 
  
0.324 
      
0.049 
Probability > F     0.808             0.985 
Robust standard errors in 
brackets 
          
*** p<0.01, ** p<0.05, * 
p<0.1 
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Table A2.16 Preferred expenditure specifications for 2010/11 
  (1) (2) (3) (4) (5) (6) (7) (8) (9)  







infectious cancer PBC 3 diabetes PBC 5 PBC 6 epilepsy PBC 8 PBC 9  




SYLLR 2010/11/12 2010/11 spend SYLLR 2010/11/12 2009/10 spend 2010/11 spend all cause SYLLR 
2010/11/12 
2010/11 spend 2010/11 spend 
 
spend model spend model SYLLR 
2010/11/12 
spend model SYLLR 
2009/10/11 
SYLLR 2010/11/12 spend model SYLLR 2010/11/12 SYLLR 
2010/11/12  
instrument n/a instrument other 
needs 
spend model instrument 
o/need 
spend model spend model instrument o/need spend model spend model 
 






OLS IV second stage weighted IV second stage weighted weighted IV second stage weighted weighted   
GMM2S OLS GMM2S OLS GMM2S GMM2S GMM2S OLS  
LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level  
actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality  
actual census 10 actual census10 actual census 10 actual census 1- actual census 09 actual census 10 actual census 10 actual census 10 actual census 10 
VARIABLES 09/10 version 09/10 version Re-derived, OLS Re-derived +XR 09/10 version Re-derived plus Re-derived 09/10 version 09/10 version 
                    
lLAgall_1011 1.006*** 0.438 0.332 0.696*** 0.973*** 1.208** 0.557*** 0.997*** 0.808*  
[0.294] [0.380] [0.302] [0.175] [0.285] [0.500] [0.193] [0.234] [0.417] 
lLAhivneedph 0.409*** 
        
 
[0.018] 
        
lSYLLRacExIandP012 0.140 
        
 
[0.210] 
        
lLAhivneedphSQ 0.051** 
        
 
[0.022] 




       
  
[0.262] 




       
  
[0.480] 




   
-1.067*** 
   
  
[0.167] 
   
[0.326] 
















      
   
[0.024] 
      
lSYLLRacExDIA012 
   
-0.215 
     
    
[0.152] 
     
LNQUAL17410 
   
0.903* 
   
0.439*** 
 
    
[0.485] 




   
0.204 
     
    
[0.161] 
     
LWHITEEG10 




   




   
lLAmhneedindexpp 
    
0.530*** 
    
     
[0.185] 
    
LPOPPUCAR10 
    
-0.435*** 
    
     
[0.151] 
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LLONEPENH10 
     
-0.911** -0.307* 
  




     
-0.181*** 
   
      
[0.044] 
   
LPC74LTUN10 
     
-0.449** -0.272*** 
  




      
0.348 
  




      
0.537*** 
  




        
0.503***          
[0.165] 
Constant -5.084*** 9.093*** -0.747 0.904 -2.280 -1.164 -1.088 0.526 -7.387***  
[1.584] [2.751] [1.445] [1.034] [2.392] [3.074] [1.998] [0.928] [2.104]           






   
0.168 





   
0.627 





   
0.599 














0.049 0.153 0.057 
 














0.833 0.578 0.603 
 














0.000 0.000 0.000 
 






20.440 22.773 18.701 
 






0.205 0.551 0.051 
 
Pesaran-Taylor p-value   0.923   0.123   0.651 0.458 0.821   
Robust standard errors in 
brackets 
         
*** p<0.01, ** p<0.05, * p<0.1 
         
          
  
Estimating the marginal productivity of the English National Health Service from 2003/04 to 2012/13  85 
 
Table A2.16 continued  Preferred expenditure specifications for 2010/11 
  (1) (2) (3) (4) (5) (6) (7) (8) (9)  
PBC 10 PBC 11 
     
PBC 17 PBC 1819  
circulatory respiratory PBC 12 PBC 13 PBC 14 PBC 15 PBC 16 renal maternity/neonates  
2010/11 spend 2010/11 spend dental problems gastro problems skin problems musculo-skeletal trauma/injuries 2010/11 spend 2010/11 spend  
SYLLR 
2010/11/12 
SYLLR 2010/11/12 2010/11 spend 2010/11 spend 2010/11 spend 2010/11 spend 2010/11 spend SYLLR 2010/11/12 all causeSYLLR 
2010/11/12  












instrument o/need spend model spend model spend model spend model spend model instrument n/a instrument o/need 
 




instrument n/a instrument n/a weighted weighted 
 
IV second stage IV second stage weighted weighted weighted weighted weighted OLS IV second stage  
GMM2S GMM2S OLS GMM2S GMM2S OLS OLS 
 
GMM2S  
LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level  
actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality  
actual census10 actual census10 actual census 10 actual census 10 actual census 10 actual census 10 actual census 10 actual census 10 actual census 10 
VARIABLES Re-derived 09/10 version 
revised 







                    
lSYLLRacExCirc012 -0.979*** 
        
 
[0.252] 
        
lLAgall_1011 1.013*** 1.192*** 0.229 1.040*** 0.422* 0.489** 0.589** 0.631*** 0.342  
[0.223] [0.268] [0.192] [0.315] [0.235] [0.226] [0.250] [0.135] [0.233] 
















       
  
[0.320] 





-0.285 0.341 -0.032 
 
-0.253    
[0.154] 
 






      
   
[0.273] 




      
   
[0.082] 
      
lSYLLRacExGast012 
   
-0.691** 
     
    
[0.334] 
     
LPC74LTUN10 
    
0.385*** -0.359*** 
   
     
[0.129] [0.090] 
   
LBORNEXEU10 
    
-0.085*** 
    
     
[0.030] 
    
LOWNOCC10 
     
0.258** 
   
      
[0.130] 
   
LWORKAGRI10 
      
0.069*** 
  




      
0.083 
  




       
-0.099* 
 




       
0.105 
 
        
[0.119] 
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lLAmatneedindexpp 
        
1.049***          
[0.093] 
Constant 3.705*** -0.718 2.190 1.298 3.586 -1.983 0.523 -0.928 3.394***  
[0.979] [1.102] [1.812] [1.395] [2.551] [1.812] [1.605] [0.577] [0.909]           
Observations 150 150 150 150 147 150 150 150 150 
Endogeneity test statistic 14.309 8.904 
 
5.635 2.987 
   
0.593 
Endogeneity p-value 0.000 0.003 
 
0.018 0.084 
   
0.441 
Hansen-Sargan test statistic 0.689 0.101 
  
3.182 
   
3.084 
Hansen-Sargan p-value 0.406 0.751 
  
0.204 
   
0.214 





   
32.544 
Kleibergen-Paap p-value 0.000 0.000 
 
0.000 0.000 
   
0.000 
Kleibergen-Paap F statistic 20.267 17.314 
 
73.904 23.609 
   
75.024 
Pesaran-Taylor reset statistic 2.257 1.617 
 
0.342 0.087 
   
0.876 
Pesaran-Taylor p-value 0.133 0.204 
 
0.559 0.769 






0.417 0.181 0.388 
 




1.833 1.758 0.307 
 
Probability > F     0.101     0.144 0.158 0.821   
Robust standard errors in 
brackets 
         
*** p<0.01, ** p<0.05, * p<0.1 
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Table A2.16 continued  Preferred expenditure specifications for 2010/11 
  (1) (2) (3) (4)  
PBC 20 PBC 21 PBC 22 PBC 23a  
poisoning HI social care GMS  
2010/11 spend 2010/11 spend 2010/11 spend 2010/11 spend  
SYLLR 2010/11/12 SYLLR 2010/11/12 SYLLR 2010/11/12 SYLLR 2010/11/12  
spend model spend model spend model spend model  
instrument o/need instrument n/a instrument n/a instrument n/a  
weighted weighted weighted weighted  
GMM2S OLS OLS OLS  
LA-level LA-level LA-level LA-level  
actual mortality actual mortality actual mortality actual mortality  
actual census 10 actual census 10 actual census 10 actual census 10 
VARIABLES 09/10 version revised 09/10 version revised 09/10 version 09/10 version 
          
lSYLLRallcause012 -1.109** 0.258 -0.260 0.050  
[0.500] [0.461] [0.539] [0.104] 
lLAgall_1011 1.078** 1.359** 1.592** 0.520***  
[0.457] [0.594] [0.673] [0.120] 





Constant 2.149 -7.612* -6.686** 0.790  
[1.650] [4.097] [2.913] [0.585]      
Observations 150 149 93 150 
R-squared 
 
0.200 0.119 0.365 
Endogeneity test statistic 6.385 
   
Endogeneity p-value 0.012 
   
Hansen-Sargan test statistic 1.613 
   
Hansen-Sargan p-value 0.204 
   
Kleibergen-Paap LM test statistic 23.506 
   
Kleibergen-Paap p-value 0.000 
   
Kleibergen-Paap F statistic 18.701 
   
Pesaran-Taylor reset statistic 0.128 
   
Pesaran-Taylor p-value 0.720 
   
Ramsey reset F statistic 
 
1.080 0.437 1.133 
Probability > F   0.360 0.727 0.338 
Robust standard errors in brackets 
    
*** p<0.01, ** p<0.05, * p<0.1 
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Table A2.17 Preferred outcome specifications for 2011/12 
  (1) (2) (3) (4) (5) (6) (7) (8) (9) (10)  
PBC 1 PBC 2 PBC 04 PBC 07 PBC 10 PBC 11 PBC 13 PBC 17 PBC 1819 PBC 16  




renal mat/neonates trauma/injuries 
 



















SMR<75 skull fracture 
 














outcome model outcome model 
 
instrument n/a instrument 
spend 








instrument n/a spend exogenous spend exogenous 
 
weighted weighted weighted weighted weighted weighted weighted weighted weighted weighted  
OLS IV second 
stage 












GMM2S GMM2S GMM2S GMM2S 
   
 












































10/11 version 10/11 version & Re-
derived, OLS 
                      
lLAg1_1112 -0.305*** 
         
 
[0.094] 
         
lLAhivneedph 0.172*** 
         
 
[0.049] 









      
LLONEPENH11 -0.666*** 
         
 
[0.182] 




        
  
[0.157] 




















       
   
[0.196] 




       
   
[0.147] 




       
   
[0.139] 
       
lLAg7_1112 
   
-1.415 
      
    
[1.125] 
      
LWORKAGRI11 
   
0.039 
      
    
[0.051] 
      
lLAepiprev1112 
   
1.271 
      
    
[0.779] 
      
lLAg10_1112 
    
-1.611*** 
     
     
[0.343] 
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lLAg11_1112 
     
-1.743*** 
    
      
[0.598] 
    
LPERMSICK11 
     
6.198*** 
    
      
[1.592] 
    
LPERMSICK11SQ 
     
0.727*** 
    
      
[0.220] 
    
lLAg13_1112 
      
-2.000** 
   
       
[0.984] 
   
lLACARANneed1112SQ 
      
4.644*** 
   
       
[1.513] 
   
LWHITEEG11 
       
-2.062*** 
  




       
1.246*** 
  




       
-0.494 
  




        
-0.136 
 




        
0.298*** 
 




        
-0.357*** 
 




         
0.143           
[0.180] 
Constant -0.523 7.072*** 0.581 12.713 12.292*** 23.178*** 11.964*** 2.395 1.830*** -0.140  
[0.454] [0.727] [0.735] [8.281] [1.675] [5.233] [4.389] [3.962] [0.579] [0.773]            




    
0.113 0.245 0.196 
Ramsey reset F statistic 0.313 
 
0.806 
    
0.273 0.835 0.443 
Probability > F 0.816 
 
0.492 
    
0.845 0.477 0.723 




2.857 25.774 14.703 10.016 





0.091 0.000 0.000 0.002 
   





8.458 17.541 15.098 7.239 





0.004 0.000 0.000 0.007 
   




8.746 17.472 18.118 9.678 
   




0.015 0.009 2.624 0.177 





0.902 0.925 0.105 0.674 
   
Hansen-Sargan test statistic 
    
2.060 
     
Hansen-Sargan p-value         0.151           
Robust standard errors in 
brackets 
          
*** p<0.01, ** p<0.05, * 
p<0.1 
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Table A2.18 Preferred expenditure specifications for 2011/12 
  (1) (2) (3) (4) (5) (6) (7) (8) (9)  
PBC 1 PBC 2 PBC 3 PBC 4 PBC 5 PBC 6 PBC 7 PBC 8 PBC 9  
infectious cancer Blood disorders diabetes Mental health LDisability epilepsy Vision hearing problems  
2011/12 spend 2011/12 spend 2011/12 spend 2011/12 spend 2011/12 spend 2011/12 spend 2011/12 spend 2011/12 spend 2011/12 spend  
SYLLR 2011/12/13 SYLLR 2011/12/13 SYLLR 2011/12/13 SYLLR 2011/12/13 SYLLR 2011/12/13 SYLLR 2011/12/13 SYLLR 2011/12/13 SYLLR 2011/12/13 SYLLR 2011/12/13  
spend model spend model spend model spend model spend model spend model spend model spend model spend model  
instrument n/a instrument other needs instrument n/a instrument o/need instrument n/a instrument n/a instrument o/need instrument o/need instrument n/a  
weighted weighted weighted weighted weighted weighted weighted weighted weighted  








LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level  
actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality  
actual census 11 actual census11 actual census 11 actual census 11 actual census 11 actual census 11 actual census 11 actual census 11 actual census 11 
VARIABLES 10/11 version 10/11 version 10/11 version 10/11 revised 10/11 version Re-derived, OLS 10/11 revised 10/11 version Re-derived,OLS2 
                    
lLAgall_1112 0.841*** 0.961** 0.876*** 1.116*** 1.194*** 0.741* 0.703*** 1.279*** 1.231***  
[0.266] [0.384] [0.248] [0.133] [0.212] [0.398] [0.177] [0.241] [0.395] 
lLAhivneedph 0.409*** 
        
 
[0.016] 
        
lSYLLRacExIandP123 0.115 
        
 
[0.207] 
        
lLAhivneedphSQ 0.075*** 
        
 
[0.023] 




       
  
[0.292] 




       
  
[0.423] 




   
-0.691*** 
  
-0.280   
[0.146] 



















      
   
[0.026] 
      
lSYLLRacExDIA123 
   
-0.415*** 
     
    
[0.122] 
     
LNQUAL17411 
   
0.275*** 
   
0.622*** 
 
    
[0.065] 




   
-0.221*** 
     
    
[0.044] 
     
lLAmhneedindexpp 
    
0.338** 
    
     
[0.147] 
    
LPOPPUCAR11 
    
-0.496*** 
    
     
[0.120] 
    
LPC74LTUN11 
     
-0.609*** 
   
      
[0.187] 
   
lSYLLRacExEPI123 
 
      
-0.164 
  
       
[0.146] 
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lLAepiprev1112 
      
0.531*** 
  




        
0.665***          
[0.209] 
Constant -3.654*** 4.919* -3.419*** -1.452* -4.244** -5.250 2.711** 1.685* -9.391***  
[1.391] [2.611] [1.204] [0.825] [1.920] [3.403] [1.098] [0.920] [2.474]           






















































































Pesaran-Taylor p-value   0.562   0.125     0.617 0.866   
Robust standard errors in brackets 
         
*** p<0.01, ** p<0.05, * p<0.1 
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Table A2.18 continued  Preferred expenditure specifications for 2011/12 
  (1) (2) (3) (4) (5) (6) (7) (8) (9)  
PBC 10 PBC 11 PBC 12 PBC 13 PBC 14 PBC 15 PBC 16 PBC 17 PBC 1819  
circulatory respiratory dental problems gastro problems skin problems musculo-skeletal trauma/injuries renal maternity/neonates  
2011/12 spend 2011/12 spend 2011/12 spend 2011/12 spend 2011/12 spend 2011/12 spend 2011/12 spend 2011/12 spend 2011/12 spend  
SYLLR 2011/12/13 SYLLR 2011/12/13 SYLLR 2011/12/13 SYLLR 2011/12/13 SYLLR 2011/12/13 SYLLR 2011/12/13 SYLLR 2011/12/13 SYLLR 2011/12/13 SYLLR 2011/12/13  
spend model spend model spend model spend model spend model spend model spend model spend model spend model  
instrument o/need instrument o/need instrument o/need instrument o/need instrument o/need instrument n/a instrument n/a instrument n/a instrument n/a  
weighted weighted weighted weighted weighted weighted weighted weighted weighted  
IV second stage IV second stage IV second stage IV second stage IV second stage OLS OLS OLS OLS  
GMM2S GMM2S GMM2S GMM2S GMM2S 
    
 
LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level  
actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality  
actual census 11 actual census 11 actual census 11 actual census 11 actual census 11 actual census 11 actual census 11 actual census 11 actual census 11 
VARIABLES 10/11 version 10/11 revised Re-derived+ 10/11 version+ 10/11 version+ 10/11 version+ 10/11 version+ 10/11 version 10/11 version OLS 




       
  
[0.213] 
       
lLAgall_1112 1.491*** 1.360*** 0.843*** 1.033*** 0.681*** 0.456** 1.024*** 0.598*** 0.481***  
[0.234] [0.177] [0.181] [0.210] [0.225] [0.222] [0.193] [0.124] [0.180] 












   
lLACARANneed1112SQ 
 
2.439*** -1.260 1.173** 
     
  
[0.562] [0.789] [0.541] 
     
lSYLLRacExCirc123 -1.202*** 
        
 
[0.236] 





-0.259 0.215 -0.154 
 
-0.217    
[0.300] 
 








   








      
   
[0.122] 
      
lSYLLRacExGast123 
   
-0.593** 
     
    
[0.254] 
     
LPC74LTUN11 
    
0.248** -0.226*** 
   
     
[0.099] [0.077] 
   
LWHITEEG11 











     
0.513*** 
   
      
[0.113] 
   
LHHNOCAR11 
      
-0.147*** 
  




       
0.088 
 




        
1.108***          
[0.099] 
Constant 1.354 -0.873 -2.750* 0.802 1.193 -1.132 -2.656** -0.550 2.147**  
[1.022] [0.777] [1.531] [0.834] [1.652] [1.368] [1.111] [0.563] [0.858]           
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Observations 148 148 148 148 145 148 148 148 148 
R-squared 
     
0.499 0.242 0.434 0.601 
Endogeneity test statistic 22.129 15.086 1.201 6.134 1.993 
    
Endogeneity p-value 0.000 0.000 0.273 0.013 0.158 
    
Hansen-Sargan test statistic 0.892 0.027 1.361 
 
1.197 
    
Hansen-Sargan p-value 0.345 0.870 0.243 
 
0.274 
    
Kleibergen-Paap LM test statistic 20.617 22.588 24.305 29.448 25.703 
    
Kleibergen-Paap p-value 0.000 0.000 0.000 0.000 0.000 
    
Kleibergen-Paap F statistic 19.918 19.840 51.658 94.008 35.963 
    
Pesaran-Taylor reset statistic 0.545 0.836 2.153 0.127 0.000 
    
Pesaran-Taylor p-value 0.460 0.360 0.142 0.722 0.992 
    
Ramsey reset F statistic 
     
1.326 0.561 0.514 1.711 
Probability > F           0.268 0.642 0.673 0.168 
Robust standard errors in brackets 
         
*** p<0.01, ** p<0.05, * p<0.1 
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Table A2.18 continued  Preferred expenditure specifications for 2011/12 
  (1) (2) (3) (4) 
 PBC 20 PBC 21 PBC 22 PBC 23a 
 poisoning HI social care GMS 
 2011/12 spend 2011/12 spend 2011/12 spend 2011/12 spend 
 SYLLR 2011/12/13 SYLLR 2011/12/13 SYLLR 2011/12/13 SYLLR 2011/12/13 
 spend model spend model spend model spend model 
 instrument o/need instrument n/a instrument n/a instrument n/a 
 weighted weighted weighted weighted 
 IV second stage OLS OLS OLS 
 GMM2S    
 LA-level LA-level LA-level LA-level 
 actual mortality actual mortality actual mortality actual mortality 
 actual census 11 actual census 11 actual census 11 actual census 11 
VARIABLES 10/11 version 10/11 version 10/11 version 10/11 version + 
          
lSYLLRallcause123 -0.206 0.570 -0.698* -0.096 
 [0.286] [0.388] [0.400] [0.103] 
lLAgall_1112 0.631** 1.748*** 1.859*** 0.518*** 
 [0.297] [0.515] [0.532] [0.113] 
LNQUAL17411 0.298*** -0.008   
 [0.090] [0.240]   
LPROFOCCU11    -0.186*** 
    [0.065] 
Constant -0.147 -12.970*** -5.898** 1.496** 
 [1.023] [3.136] [2.922] [0.719] 
     
Observations 148 147 102 148 
R-squared  0.319 0.121 0.430 
Endogeneity test statistic 1.908    
Endogeneity p-value 0.167    
Hansen-Sargan test statistic 0.020    
Hansen-Sargan p-value 0.887    
Kleibergen-Paap LM test statistic 22.743    
Kleibergen-Paap p-value 0.000    
Kleibergen-Paap F statistic 19.191    
Pesaran-Taylor reset statistic 0.753    
Pesaran-Taylor p-value 0.385    
Ramsey reset F statistic  0.458 0.864 1.273 
Probability > F   0.712 0.462 0.286 
Robust standard errors in brackets     
*** p<0.01, ** p<0.05, * p<0.1     
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Table A2.19 Preferred outcome specifications for 2012/13 
  (1) (2) (3) (4) (5) (6) (7) (8) (9)  
PBC 1 PBC 2 PBC 4 PBC 7 PBC 10 PBC 11 PBC 13 PBC 17 PBC 1819  
infectious cancer endocrine etc neurological etc circulatory respiratory gastro-intestinal renal mat/neonates  
2012/13 spend 2012/13 spend 2012/13 spend 2012/13 spend 2012/13 spend 2012/13 spend 2012/13 spend 2012/13 spend 2012/13 spend  
SYLLR 2012/13/14 SYLLR 2012/13/14 SYLLR 2012/13/14 SYLLR 2012/13/14 SYLLR 2012/13/14 SYLLR 2012/13/14 SYLLR 2012/13/14 SYLLR 2012/13/14 infant m/rate 2012/13/14  
spend model outcome model outcome model outcome model outcome model outcome model outcome model outcome model outcome model  
instrument n/a instrument spend instrument spend instrument n/a instrument spend instrument spend instrument spend instrument n/a spend exogenous  
weighted weighted weighted weighted weighted weighted weighted weighted weighted  
OLS IV second stage IV second stage OLS IV second stage IV second stage IV second stage OLS OLS   
GMM2S GMM2S 
 
GMM2S GMM2S GMM2S 
  
 
LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level  
actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality  
actual census 11 actual census11 actual census 11 actual census 11 actual census 11 actual census 11 actual census 11 actual census 11 actual census 11 
VARIABLES 11/12 version 11/12 version Re-derived Re-derived, OLS 11/12 version 11/12 revised 11/12 revised Re-derived+ 11/12 version 
                    
lLAg1_1213 -0.362*** 
        
 
[0.089] 
        
lLAhivneedph 0.276*** 
        
 
[0.045] 









     
LLONEPENH11 -0.177 
        
 
[0.183] 




       
  
[0.149] 
















      
   
[0.349] 




    
3.875*** 
 
   
[0.165] 




   
-0.009 
     
    
[0.188] 
     
LBORNEXEU11 
   
-0.169*** 
    
0.247***     
[0.050] 
    
[0.064] 
lLAg10_1213 
    
-1.464*** 
    
     
[0.268] 
    
lLAg11_1213 
     
-1.704*** 
   
      
[0.459] 
   
LPERMSICK11 
     
6.265*** 
   
      
[1.189] 
   
LPERMSICK11SQ 
     
0.742*** 
   
      
[0.166] 
   
lLAg13_1213 
      
-1.904** 
  




      
3.735*** 
  




       
-0.160 
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3.888*** 
 




       
-3.045*** 
 




        
-0.106          
[0.129] 
LHHNOCAR11 
        
-0.365***          
[0.102] 
Constant 0.698 6.744*** 1.118 -0.032 11.541*** 23.203*** 11.547*** 9.081* 1.529**  
[0.437] [0.691] [1.164] [0.782] [1.302] [3.903] [4.024] [4.938] [0.671]           




   
0.233 0.229 
Ramsey reset F statistic 1.139 
  
1.414 
   
2.110 1.064 
Probability > F 0.336 
  
0.241 
   
0.102 0.366 










0.000 0.000 0.003 
  










0.000 0.000 0.001 
  




19.517 16.644 10.363 
  










0.769 0.757 0.843 
  





   
Hansen-Sargan p-value     0.490   0.368 0.136       
Robust standard errors in brackets 
         
*** p<0.01, ** p<0.05, * p<0.1 
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Table A2.20 Preferred expenditure specifications for 2012/13 
  (1) (2) (3) (4) (5) (6) (7) (8) (9)  
PBC 1 PBC 2 PBC 3 PBC 4 PBC 5 PBC 6 PBC 7 PBC 8 PBC 9  
infectious cancer blood disorders diabetes mental health LDisability epilepsy vision hearing issues  
2011/12 spend 2012/13 spend 2012/13 spend 2012/13 spend 2012/13 spend 2012/13 spend 2012/13 spend 2012/13 spend 2012/13 spend  
SYLLR 
2011/12/13 














spend model spend model spend model spend model spend model spend model spend model spend model spend model  
instrument n/a instrument o/ 
need 
instrument n/a instrum o/need instrument n/a instrument n/a instrum o/need instrum o/need instrument n/a 
 
weighted weighted weighted weighted weighted weighted weighted weighted weighted  








LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level  
actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality  
actual census 11 actual census11 actual census 11 actual census 11 actual census 11 actual census 11 actual census 11 actual census 11 actual census 11 
VARIABLES 11/12 revised 11/12 version 11/12 version 11/12 revised 11/12 version Re-derived, OLS 11/12 version 11/12 version 11/12 version 
                    
lLAgall_1213 0.749*** 1.027** 1.119*** 0.951*** 1.023*** 0.000 0.856*** 1.411*** 1.523***  
[0.252] [0.522] [0.253] [0.128] [0.221] [0.451] [0.168] [0.234] [0.357] 
lLAhivneedph 0.342*** 
        
 
[0.028] 
        
lSYLLRacExIandP234 0.160 
        
 
[0.193] 
        
lLAhivneedphSQ 0.087*** 
        
 
[0.019] 













       
  
[0.326] 




       
  
[0.599] 




      
-0.060   
[0.173] 



















   




   
SYLLRacExDIA234 
   
-0.440*** 
     
    
[0.138] 
     
LNQUAL17411 
   
0.359*** 
   
0.607*** 
 
    
[0.062] 




    
0.334** 
    
     
[0.146] 
    
LPOPPUCAR11 
    
-0.408*** 
    
     
[0.116] 
    
lSYLLRacExEPI234 
      
-0.326** 
  




      
0.489*** 
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0.587***          
[0.204] 
Constant -3.303** 5.169 -2.932** 0.056 -3.512* 1.414 2.362** 0.395 -11.656***  
[1.322] [3.768] [1.213] [0.737] [1.994] [2.473] [1.205] [0.930] [2.388]           






















































































Pesaran-Taylor p-value   0.124   0.281     0.422 0.391   
Robust standard errors in 
brackets 
         
*** p<0.01, ** p<0.05, * p<0.1 
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Table A2.20 continued  Preferred expenditure specifications for 2012/13 
  (1) (2) (3) (4) (5) (6) (7) (8) (9)  
PBC 10 PBC 11 PBC 12 PBC 13 PBC 14 PBC 15 PBC 16 PBC 17 PBC 1819  
circulatory respiratory dental problems gastro problems skin problems musculo-skeletal trauma/injuries renal maternity/neonates  
2012/13 spend 2011/12 spend 2012/13 spend 2012/13 spend 2012/13 spend 2012/13 spend 2012/13 spend 2012/13 spend 2012/13 spend  
SYLLR 2012/13/14 SYLLR 2011/12/13 SYLLR 2012/13/14 SYLLR 2012/13/14 SYLLR 2012/13/14 SYLLR 2012/13/14 SYLLR 2012/13/14 SYLLR 2012/13/14 SYLLR 2012/13/14  
spend model spend model spend model spend model spend model spend model spend model spend model spend model  
instrument o/need instrument o/need instrument o/need instrument o/need instrument o/need instrument n/a instrument n/a instrument n/a instrument n/a  
weighted weighted weighted weighted weighted weighted weighted weighted weighted  
IV second stage IV second stage IV second stage IV second stage IV second stage OLS OLS OLS OLS  
GMM2S GMM2S GMM2S GMM2S GMM2S 
    
 
LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level LA-level  
actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality actual mortality  
actual census 11 actual census 11 actual census 11 actual census 11 actual census 11 actual census 11 actual census 11 actual census 11 actual census 11 
VARIABLES 11/12 revised 11/12 version Re-derived 11/12 version 11/12 revised 11/12 version 11/12 version 11/12 version 11/12 version 
                    
lSYLLRacExCirc234 -0.908*** 
        
 
[0.159] 
        
lLAgall_1213 1.285*** 0.928*** 0.855*** 0.997*** 1.158*** 0.725*** 1.058*** 0.855*** 0.833***  
[0.161] [0.163] [0.158] [0.171] [0.322] [0.184] [0.171] [0.119] [0.159] 












   
LWHITEEG11 0.191*** 















       
  
[0.193] 
















-0.976* 0.210 -0.270** 
 
-0.472***    
[0.158] 
 






      
   
[0.017] 




      
   
[0.083] 
      
lSYLLRacExGast234 
   
-0.570*** 
     
    
[0.218] 
     
LPC74LTUN11 
    
0.277* -0.378*** 
   
     
[0.158] [0.076] 
   
LPROFOCCU11 
    
-0.308* 
    
     
[0.175] 
    
LOWNOCC11 
     
0.384*** 
   
      
[0.103] 
   
lLAIMD2010 
     
0.136 
   
      
[0.107] 
   
LHHNOCAR11 
      
-0.129*** 
  




       
-0.093 
 




        
1.129*** 
100  CHE Research Paper 158 
 
         
[0.083] 
Constant 1.110 0.296 0.237 0.942 1.704 -3.635** -2.230** -1.375** 1.035  
[0.993] [0.744] [1.060] [0.872] [2.538] [1.403] [0.961] [0.623] [0.783]           
Observations 149 149 149 149 147 149 149 149 149 
R-squared 
     
0.594 0.240 0.505 0.676 
Endogeneity test statistic 12.964 6.507 2.711 7.495 4.994 
    
Endogeneity p-value 0.000 0.011 0.100 0.006 0.025 
    
Hansen-Sargan test statistic 2.162 0.000 2.463 
      
Hansen-Sargan p-value 0.141 0.985 0.482 
      
Kleibergen-Paap LM test statistic 31.331 23.711 43.690 29.937 15.054 
    
Kleibergen-Paap p-value 0.000 0.000 0.000 0.000 0.000 
    
Kleibergen-Paap F statistic 65.251 23.538 50.773 122.358 20.121 
    
Pesaran-Taylor reset statistic 0.807 0.484 0.354 0.023 0.002 
    
Pesaran-Taylor p-value 0.369 0.487 0.552 0.878 0.964 
    
Ramsey reset F statistic 
     
0.257 1.071 0.879 0.323 
Probability > F           0.856 0.363 0.454 0.809 
Robust standard errors in brackets 
         
*** p<0.01, ** p<0.05, * p<0.1 
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Table A2.20 continued  Preferred expenditure specifications for 2012/13 
  (1) (2) (3) (4) 
 
 
PBC 20 PBC 21 PBC 22 PBC 23a 
 
 
poisoning HI social care GMS 
 
 
2012/13 spend 2012/13 spend 2012/13 spend 2012/13 spend 
 
 
SYLLR 2012/13/14 SYLLR 2012/13/14 SYLLR 2012/13/14 SYLLR 2012/13/14 
 
 
spend model spend model spend model spend model 
 
 
instrument o/need instrument n/a instrument n/a instrument n/a 
 
 
weighted weighted weighted weighted 
 
 




    
 
LA-level LA-level LA-level LA-level 
 
 
actual mortality actual mortality actual mortality actual mortality 
 
 
actual census 11 actual census 11 actual census 11 actual census 11 
 
VARIABLES 11/12 version 11/12 revised 11/12 revised 11/12 version 
 
          
 
lSYLLRallcause234 -0.601*** -0.455 -0.852** -0.113 
 
 
[0.229] [0.488] [0.408] [0.088] 
 
lLAgall_1213 1.124*** 1.172* 1.613*** 0.585*** 
 
 
[0.252] [0.645] [0.430] [0.095] 
 
LNQUAL17411 0.142 
    
 
[0.111] 




   
  
[0.312] 





   
[0.246] [0.063] 
 
Constant -1.673 1.059 -3.927 1.115* 
 
 
[1.280] [5.485] [2.680] [0.654] 
 
      




0.234 0.210 0.474 
 
Endogeneity test statistic 8.286 
    
Endogeneity p-value 0.004 
    
Hansen-Sargan test statistic 0.008 
    
Hansen-Sargan p-value 0.930 
    
Kleibergen-Paap LM test statistic 24.062 
    
Kleibergen-Paap p-value 0.000 
    
Kleibergen-Paap F statistic 23.271 
    
Pesaran-Taylor reset statistic 1.578 
    
Pesaran-Taylor p-value 0.209 
    
Ramsey reset F statistic 
 
0.056 2.080 1.333 
 
Probability > F   0.983 0.106 0.266 
 
Robust standard errors in brackets 
     
*** p<0.01, ** p<0.05, * p<0.1 
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A2.3 First stage of IV regressions results tables 
Table A2.21 First stage of IV regressions, preferred outcome specifications for 2003/04 
 
Table A2.22 First stage of IV regressions, preferred expenditure specifications for 2003/04 
 
Table A2.23 First stage of IV regressions, preferred outcome specifications for 2004/05 
 
Table A2.24 First stage of IV regressions, preferred expenditure specifications for 2004/05 
 
Table A2.25 First stage of IV regressions, preferred outcome specifications for 2005/06 
 
Table A2.26 First stage of IV regressions, preferred expenditure specifications for 2005/06 
 
Table A2.27 First stage of IV regressions, preferred outcome specifications for 2006/07 
 
Table A2.28 First stage of IV regressions, preferred expenditure specifications for 2006/07 
 
Table A2.29 First stage of IV regressions, preferred outcome specifications for 2007/08 
 
Table A2.30 First stage of IV regressions, preferred expenditure specifications for 2007/08 
 
Table A2.31 First stage of IV regressions, preferred outcome specifications for 2008/09 
 
Table A2.32 First stage of IV regressions, preferred expenditure specifications for 2008/09 
 
Table A2.33 First stage of IV regressions, preferred outcome specifications for 2009/10 
 
Table A2.34 First stage of IV regressions, preferred expenditure specifications for 2009/10 
 
Table A2.35 First stage of IV regressions, preferred outcome specifications for 2010/11 
 
Table A2.36 First stage of IV regressions, preferred expenditure specifications for 2010/11 
 
Table A2.37 First stage of IV regressions, preferred outcome specifications for 2011/12 
 
Table A2.38 First stage of IV regressions, preferred expenditure specifications for 2011/12 
 
Table A2.39 First stage of IV regressions, preferred outcome specifications for 2012/13 
 
Table A2.40 First stage of IV regressions, preferred expenditure specifications for 2012/13 
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Table A2.21 First stage of IV regressions, preferred outcome specifications for 2003/04 
 (1) (2) (3) (4) (5) (6) (7) 
 PBC 1 PBC 2 PBC 7 PBC 10 PBC 11 PBC 13 PBC 17 
 Infectious Cancer Neurological Circulatory Respiratory Gastro-intestinal Genito-urinary 
 2003/04 spend 2003/04 spend 2003/04 spend 2003/04 spend 2003/04 spend 2003/04 spend 2003/04 spend 
 SYLLR 2003/04/05 SYLLR 2003/04/05 SYLLR 2003/04/05 SYLLR 2003/04/05 SYLLR 2003/04/05 SYLLR 2003/04/05 SYLLR 2003/04/05 









first-stage regression first-stage regression 
        
LPROFOCCU03 0.770***       
 [0.246]       
lLAhivneedph 0.027       
 [0.063]       
lLAimd_2007exexpobook 0.625***  0.231**     
 [0.141]  [0.096]     
LWHITEEG03 -0.164    0.364***  0.190 
 [0.270]    [0.068]  [0.165] 
LPOPPUCAR03 -0.224       
 [0.419]       
LLONEPENH03  0.511***  0.604***  0.512***  
  [0.162]  [0.081]  [0.104]  
LWORKAGRI03  0.020 0.130***     
  [0.022] [0.022]     
lLAneedCARAN34  0.396**  -0.077 1.185*** -0.640** 1.402*** 
  [0.175]  [0.229] [0.120] [0.295] [0.202] 
LHHNOCAR03   0.498***     
   [0.118]     
LPC74LTUN03   -0.319***     
   [0.101]     
lLAneedCARAN342   1.680**     
   [0.772]     
LPERMSICK03    0.276***  0.449***  
    [0.070]  [0.082]  
LBORNEXEU03       0.090** 
       [0.036] 
LNQUAL17403       -0.359** 
       [0.138] 
Constant 1.321 5.263*** 2.509*** 6.727*** 4.034*** 6.516*** 3.816*** 
 [1.156] [0.274] [0.685] [0.267] [0.015] [0.302] [0.225] 
        
Observations 144 151 135 151 151 151 151 
K-P F statistic 9.795 10.26 10.04 55.86 28.45 24.26 24.69 
Robust standard errors in brackets 
*** p<0.01, ** p<0.05, * p<0.1  
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Table A2.22 First stage of IV regressions, preferred expenditure specifications for 2003/04 
 (1) (2) (3) (4) (5) (6) (7) (8) 
 PBC 2 PBC 8 PBC 9 PBC 10 PBC 11 PBC 13 PBC 20 PBC 21 
 Cancer Vision Hearing Circulatory Respiratory Gastro-intestinal Poisoning Healthy individuals 
 2003/04 spend 2003/04 spend 2003/04 spend 2003/04 spend 2003/04 spend 2003/04 spend 2003/04 spend 2003/04 spend 
 SYLLR 2003/04/05 SYLLR 2003/04/05 SYLLR 2003/04/05 SYLLR 2003/04/05 SYLLR 2003/04/05 SYLLR 2003/04/05 SYLLR 2003/04/05 SYLLR 2003/04/05 

















         
LPERMSICK03  0.254*** 0.237***      
  [0.049] [0.047]      
LNQUAL17403  0.169*** 0.224*** 0.487*** 0.558*** 0.148*** 0.547*** 0.123*** 
  [0.063] [0.054] [0.050] [0.049] [0.046] [0.049] [0.044] 
lLAgall_34netpoppheadOHP 0.875*** 0.366*** 0.162* 0.631*** 0.624*** 0.109 0.711*** 0.176** 
 [0.099] [0.119] [0.092] [0.085] [0.082] [0.090] [0.085] [0.081] 
LLONEPENH03 -0.578*** -0.400*** -0.034 -0.142*   -0.248***  
 [0.086] [0.061] [0.063] [0.082]   [0.080]  
LPOPPUCAR03   -0.414*** -0.347*** -0.559***  -0.388***  
   [0.102] [0.108] [0.080]  [0.109]  
LPC74LTUN03   -0.036      
   [0.030]      
LLONEPARH03   0.244***     0.338*** 
   [0.054]     [0.037] 
lLAimd_2007exexpobook   -0.019   0.262***   
   [0.048]   [0.027]   
LPROFOCCU03 -0.522***        
 [0.042]        
lLAneedCARAN34        0.355*** 
        [0.112] 
LWHITEEG03        0.014 
        [0.046] 
Constant -2.154*** 3.812*** 5.587*** 1.059* 1.195** 4.757*** 0.534 6.022*** 
 [0.643] [0.909] [0.627] [0.569] [0.546] [0.589] [0.556] [0.548] 
         
Observations 151 151 151 151 151 151 151 151 
K-P F statistic 45.58 35.89 28.34 19.12 48.93 96.40 35.17 19.39 
Robust standard errors in brackets 
*** p<0.01, ** p<0.05, * p<0.1 
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Table A2.23 First stage of IV regressions, preferred outcome specifications for 2004/05 
 (1) (2) (3) (4) (5) (6) 
 PBC 2 PBC 4 PBC 7 PBC 10 PBC 11 PBC 13 
 Cancer Endocrine Neurological Circulatory Respiratory Gastro-intestinal 
 2004/05 spend 2004/05 spend 2004/05 spend 2004/05 spend 2004/05 spend 2004/05 spend 
 SYLLR 2004/05/06 SYLLR 2004/05/06 SYLLR 2004/05/06 SYLLR 2004/05/06 SYLLR 2004/05/06 SYLLR 2004/05/06 
 Outcome Outcome Outcome Outcome Outcome Outcome 
VARIABLES first-stage regression first-stage regression first-stage regression first-stage regression first-stage regression first-stage regression 
       
LLONEPARH04  -0.250***     
  [0.076]     
lLAimd_2007exexpobook  0.261*** 0.216**    
  [0.045] [0.085]    
lLAdiaprev0405  0.118     
  [0.087]     
lLAneedCARAN452  1.021*     
  [0.527]     
LLONEPENH04 0.379**   0.532***  0.464*** 
 [0.151]   [0.065]  [0.080] 
LWORKAGRI04 0.023  0.104***    
 [0.016]  [0.020]    
lLAneedCARAN45 0.522***   0.426** 1.226*** 0.807*** 
 [0.131]   [0.184] [0.076] [0.088] 
LHHNOCAR04   0.457***    
   [0.100]    
LPC74LTUN04   -0.400***    
   [0.094]    
LPERMSICK04    0.106*   
    [0.062]   
LWHITEEG04     0.227***  
     [0.062]  
Constant 5.183*** 2.332*** 2.240*** 6.187*** 4.160*** 5.213*** 
 [0.260] [0.437] [0.648] [0.225] [0.013] [0.160] 
       
Observations 151 136 137 151 151 151 
K-P F statistic 9.441 10.81 14.11 67.07 13.55 33.42 
Robust standard errors in brackets 
*** p<0.01, ** p<0.05, * p<0.1 
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Table A2.24 First stage of IV regressions, preferred expenditure specifications for 2004/05 
 (1) (2) (3) (4) (5) (6) (7) 
 PBC 2 PBC 8 PBC 9 PBC 10 PBC 11 PBC 13 PBC 20 
 Cancer Vision Hearing Circulatory Respiratory Gastro-intestinal Poisoning 
 2004/05 spend 2004/05 spend 2004/05 spend 2004/05 spend 2004/05 spend 2004/05 spend 2004/05 spend 
 SYLLR 2004/05/06 SYLLR 2004/05/06 SYLLR 2004/05/06 SYLLR 2004/05/06 SYLLR 2004/05/06 SYLLR 2004/05/06 SYLLR 2004/05/06 
 Expenditure Expenditure Expenditure Expenditure Expenditure Expenditure Expenditure 
VARIABLES first-stage regression first-stage regression first-stage regression first-stage regression first-stage regression first-stage regression first-stage regression 
        
LPERMSICK04  0.308*** 0.254***     
  [0.053] [0.052]     
LNQUAL17404  0.139** 0.227*** 0.493*** 0.561*** 0.146*** 0.552*** 
  [0.064] [0.059] [0.053] [0.053] [0.046] [0.052] 
lLAgall_45netpoppheadOHP 0.567*** 0.225* 0.127 0.626*** 0.624*** 0.035 0.692*** 
 [0.138] [0.120] [0.098] [0.083] [0.081] [0.093] [0.081] 
LLONEPENH04 -0.411*** -0.403*** -0.046 -0.137   -0.251*** 
 [0.108] [0.061] [0.065] [0.089]   [0.085] 
LPOPPUCAR04   -0.409*** -0.390*** -0.594***  -0.416*** 
   [0.095] [0.118] [0.078]  [0.116] 
LPC74LTUN04   -0.062*     
   [0.037]     
LLONEPARH04   0.249***     
   [0.057]     
LPROFOCCU04 -0.570***       
 [0.046]       
LOWNOCC04 -0.227**       
 [0.087]       
lLAimd_2007exexpobook      0.283***  
      [0.027]  
Constant 0.061 4.860*** 5.679*** 0.920 1.026* 5.175*** 0.490 
 [1.035] [0.959] [0.786] [0.591] [0.582] [0.628] [0.568] 
        
Observations 151 151 151 151 151 151 151 
K-P F statistic 14.61 41.91 40.25 23.03 58.44 112.8 40.54 
Robust standard errors in brackets 
*** p<0.01, ** p<0.05, * p<0.1 
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Table A2.25 First stage of IV regressions, preferred outcome specifications for 2005/06 
 (1) (2) (3) (4) (5) (6) (7) 
 PBC 1 PBC 2 PBC 4 PBC 7 PBC 10 PBC 11 PBC 13 
 Infectious Cancer Endocrine Neurological Circulatory Respiratory Gastro-intestinal 
 2005/06 spend 2005/06 spend 2005/06 spend 2005/06 spend 2005/06 spend 2005/06 spend 2005/06 spend 
 SYLLR 2005/06/07 SYLLR 2005/06/07 SYLLR 2005/06/07 SYLLR 2005/06/07 SYLLR 2005/06/07 SYLLR 2005/06/07 SYLLR 2005/06/07 
 Outcome Outcome Outcome Outcome Outcome Outcome Outcome 
VARIABLES first-stage regression first-stage regression first-stage regression first-stage regression first-stage regression first-stage regression first-stage regression 
        
LPROFOCCU05 0.717***       
 [0.164]       
lLAhivneedph 0.243***       
 [0.039]       
lLAhivneedph2 0.170***       
 [0.024]       
lLAimd_2007exexpobook 0.524***  0.243*** 0.151    
 [0.095]  [0.043] [0.111]    
LLONEPENH05  0.320**   0.375***  0.419*** 
  [0.158]   [0.083]  [0.078] 
LWORKAGRI05  0.049**      
  [0.019]      
lLAneedCARAN56  0.754***   0.344 1.254*** 0.934*** 
  [0.117]   [0.251] [0.077] [0.096] 
LLONEPARH05   -0.241***     
   [0.077]     
lLAdiaprev0506   0.313***     
   [0.080]     
LHHNOCAR05    0.539*** -0.044   
    [0.126] [0.061]   
LPC74LTUN05    -0.556***    
    [0.114]    
LPOPPUCAR05    3.083    
    [3.779]    
LPOPPUCAR05SQ    0.495    
    [0.801]    
LPERMSICK05     0.198***   
     [0.061]   
LWHITEEG05      0.204***  
      [0.057]  
lLAneedCARAN562      0.117  
      [0.478]  
Constant 2.294*** 5.294*** 3.176*** 6.006 6.120*** 4.259*** 5.233*** 
 [0.143] [0.262] [0.426] [4.475] [0.312] [0.017] [0.158] 
        
Observations 149 151 136 136 151 151 151 
K-P F statistic 19.09 15.86 9.794 15.14 14.19 12.88 29.08 
Robust standard errors in brackets 
*** p<0.01, ** p<0.05, * p<0.1  
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Table A2.26 First stage of IV regressions, preferred expenditure specifications for 2005/06 
 (1) (2) (3) (4) (5) (6) (7) (8) 
 PBC 2 PBC 8 PBC 10 PBC 11 PBC 13 PBC 20 PBC 21 PBC 22 
 Cancer Vision Circulatory Respiratory Gastro-intestinal Poisoning Healthy individuals Social care 
 2005/06 spend 2005/06 spend 2005/06 spend 2005/06 spend 2005/06 spend 2005/06 spend 2005/06 spend 2005/06 spend 
 SYLLR 2005/06/07 SYLLR 2005/06/07 SYLLR 2005/06/07 SYLLR 2005/06/07 SYLLR 2005/06/07 SYLLR 2005/06/07 SYLLR 2005/06/07 SYLLR 2005/06/07 

















         
LLONEPENH05 -0.393*** -0.395*** -0.145   -0.245***   
 [0.100] [0.057] [0.089]   [0.088]   
lLAgall_56netpoppheadOHP 0.601*** 0.191* 0.607*** 0.604*** 0.062 0.659*** 0.092 0.116 
 [0.125] [0.106] [0.079] [0.075] [0.086] [0.076] [0.081] [0.122] 
LPROFOCCU05 -0.541***        
 [0.045]        
LOWNOCC05 -0.198**        
 [0.085]        
LPERMSICK05  0.314***      0.167*** 
  [0.055]      [0.058] 
LNQUAL17405  0.140** 0.475*** 0.543*** 0.152*** 0.535*** 0.216*** 0.106 
  [0.069] [0.055] [0.053] [0.047] [0.053] [0.055] [0.065] 
LPOPPUCAR05   -0.389*** -0.616***  -0.431*** -0.300***  
   [0.134] [0.081]  [0.129] [0.105]  
lLAimd_2007exexpobook     0.274***    
     [0.026]    
lLAneedCARAN56       0.505***  
       [0.120]  
LLONEPARH05       0.288*** 0.253*** 
       [0.050] [0.068] 
LWHITEEG05       0.097  
       [0.061]  
LBORNEXEU05       -0.005  
       [0.022]  
LWORKAGRI05       -0.004  
       [0.011]  
LHHNOCAR05        0.049 
        [0.047] 
Constant -0.169 5.105*** 0.960* 1.031* 4.992*** 0.608 5.810*** 6.691*** 
 [0.952] [0.871] [0.548] [0.530] [0.593] [0.527] [0.677] [0.945] 
         
Observations 151 151 151 151 151 151 151 116 
K-P F statistic 15.50 48.81 22.30 57.82 107.3 40.30 50.79 38.22 
Robust standard errors in brackets 
*** p<0.01, ** p<0.05, * p<0.1  
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Table A2.27 First stage of IV regressions, preferred outcome specifications for 2006/07 
 (1) (2) (3) (4) (5) (6) (7) (8) 
 PBC 1 PBC 2 PBC 4 PBC 7 PBC 10 PBC 11 PBC 13 PBC 18 & 19 
 Infectious Cancer Endocrine Neurological Circulatory Respiratory Gastro-intestinal Maternity 
 2006/07 spend 2006/07 spend 2006/07 spend 2006/07 spend 2006/07 spend 2006/07 spend 2006/07 spend 2006/07 spend 
 SYLLR 2006/07/08 SYLLR 2006/07/08 SYLLR 2006/07/08 SYLLR 2006/07/08 SYLLR 2006/07/08 SYLLR 2006/07/08 SYLLR 2006/07/08 SYLLR 2006/07/08 
 Outcome Outcome Outcome Outcome Outcome Outcome Outcome Outcome 
VARIABLES first-stage regression first-stage regression first-stage regression first-stage regression first-stage regression first-stage regression first-stage regression first-stage regression 
         
LPROFOCCU06 0.816***   -0.372*** -0.066   0.242 
 [0.208]   [0.101] [0.086]   [0.147] 
lLAhivneedph 0.209***        
 [0.042]        
lLAhivneedph2 0.139***        
 [0.025]        
lLAimd_2007exexpobook 0.586*** -0.176* 0.286*** -0.131    -0.044 
 [0.118] [0.091] [0.046] [0.132]    [0.217] 
LLONEPENH06  0.355***   0.372***  0.362***  
  [0.128]   [0.097]  [0.092]  
lLAneedCARAN67  1.355***   1.190*** 0.977*** 1.093*** 0.938* 
  [0.297]   [0.179] [0.304] [0.108] [0.542] 
lLAneedCARAN672  0.629       
  [0.671]       
LLONEPARH06   -0.308***      
   [0.100]      
lLAdiaprev0607   0.292***      
   [0.080]      
LHHNOCAR06    0.528*** -0.157***   -0.040 
    [0.137] [0.042]   [0.135] 
LPC74LTUN06    -0.394***    0.146 
    [0.126]    [0.143] 
LPOPPUCAR06    0.582***     
    [0.145]     
LWHITEEG06      0.244***   
      [0.070]   
LPERMSICK06      0.394   
      [0.421]   
LPERMSICK06SQ      0.035   
      [0.067]   
lLAmatneedindexpp        0.752*** 
        [0.189] 
LBORNEXEU06        -0.066 
        [0.045] 
Constant 2.122*** 5.634*** 2.798*** 4.276*** 5.249*** 5.078*** 5.018*** 5.073*** 
 [0.200] [0.220] [0.435] [0.913] [0.264] [0.686] [0.188] [1.091] 
         
Observations 148 150 136 117 150 150 149 149 
K-P F statistic 15.33 16.38 9.502 7.767 30.49 12.14 15.43 9.216 
Robust standard errors in brackets 
*** p<0.01, ** p<0.05, * p<0.1 
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Table A2.28 First stage of IV regressions, preferred expenditure specifications for 2006/07 
 (1) (2) (3) (4) (5) (6) 
 PBC 2 PBC 8 PBC 10 PBC 11 PBC 13 PBC 20 
 Cancer Vision Circulatory Respiratory Gastro-intestinal Poisoning 
 2006/07 spend 2006/07 spend 2006/07 spend 2006/07 spend 2006/07 spend 2006/07 spend 
 SYLLR 2006/07/08 SYLLR 2006/07/08 SYLLR 2006/07/08 SYLLR 2006/07/08 SYLLR 2006/07/08 SYLLR 2006/07/08 
 Expenditure Expenditure Expenditure Expenditure Expenditure Expenditure 
VARIABLES first-stage regression first-stage regression first-stage regression first-stage regression first-stage regression first-stage regression 
       
LPOPPUCAR06 -0.292***  -0.402*** -0.429***  -0.452*** 
 [0.102]  [0.116] [0.108]  [0.113] 
LLONEPENH06 -0.433*** -0.441*** -0.210*** -0.283***  -0.300*** 
 [0.089] [0.051] [0.076] [0.071]  [0.073] 
lLAgall_67netpoppheadOHP 0.888*** 0.327*** 0.721*** 0.729*** 0.148* 0.765*** 
 [0.093] [0.114] [0.085] [0.081] [0.089] [0.084] 
LPROFOCCU06 -0.508***      
 [0.057]      
LPERMSICK06  0.276***     
  [0.056]     
LNQUAL17406  0.166** 0.413*** 0.449*** 0.156*** 0.467*** 
  [0.064] [0.062] [0.059] [0.053] [0.061] 
lLAimd_2007exexpobook     0.263***  
     [0.028]  
Constant -2.896*** 3.930*** -0.127 -0.165 4.395*** -0.438 
 [0.595] [0.963] [0.605] [0.569] [0.615] [0.588] 
       
Observations 150 150 150 150 150 150 
K-P F statistic 46.18 74.59 33.18 56.20 85.71 59.64 
Robust standard errors in brackets 
*** p<0.01, ** p<0.05, * p<0.1 
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Table A2.29 First stage of IV regressions, preferred outcome specifications for 2007/08 
 (1) (2) (3) (4) (5) (6) (7) (8) 
 PBC 1 PBC 2 PBC 4 PBC 10 PBC 11 PBC 13 PBC 16 PBC 17 
 Infectious Cancer Endocrine Circulatory Respiratory Gastro-intestinal Trauma Genito-urinary 
 2007/08 spend 2007/08 spend 2007/08 spend 2007/08 spend 2007/08 spend 2007/08 spend 2007/08 spend 2007/08 spend 
 SYLLR 2007/08/09 SYLLR 2007/08/09 SYLLR 2007/08/09 SYLLR 2007/08/09 SYLLR 2007/08/09 SYLLR 2007/08/09 SYLLR 2007/08/09 SYLLR 2007/08/09 
 Outcome Outcome Outcome Outcome Outcome Outcome Outcome Outcome 
VARIABLES first-stage regression first-stage regression first-stage regression first-stage regression first-stage regression first-stage regression first-stage regression first-stage regression 
         
LWHITEEG07 0.322*    0.273***    
 [0.190]    [0.061]    
LPROFOCCU07 0.667***  -0.233*** -0.147    0.363*** 
 [0.192]  [0.072] [0.095]    [0.132] 
lLAhivneedph 0.339***        
 [0.050]        
lLAhivneedph2 0.174***        
 [0.023]        
lLAimd_2007exexpobook 0.539*** 0.024 -0.053      
 [0.098] [0.097] [0.057]      
LLONEPENH07  0.630***  0.478***  0.467***   
  [0.134]  [0.097]  [0.110]   
lLAneedCARAN78  0.670**  1.004*** 0.785*** 1.142*** 1.660*** 1.418*** 
  [0.295]  [0.182] [0.281] [0.117] [0.251] [0.213] 
LPERMSICK07   0.212***  1.002**    
   [0.069]  [0.396]    
LHHNOCAR07    -0.101   0.119  
    [0.062]   [0.113]  
LPERMSICK07SQ     0.119**    
     [0.058]    
LWORKAGRI07       0.108***  
       [0.027]  
LPC74LTUN07       -0.264*  
       [0.153]  
lLACKDprev0708        0.155** 
        [0.064] 
LBORNEXEU07        0.011 
        [0.026] 
Constant 2.165*** 5.705*** 4.194*** 5.470*** 6.204*** 5.257*** 3.606*** 5.201*** 
 [0.183] [0.224] [0.392] [0.315] [0.691] [0.222] [0.666] [0.321] 
         
Observations 148 152 133 152 152 151 151 152 
K-P F statistic 9.757 19.30 9.375 43.33 20.19 18.14 8.192 6.291 
Robust standard errors in brackets 
*** p<0.01, ** p<0.05, * p<0.1 
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Table A2.30 First stage of IV regressions, preferred expenditure specifications for 2007/08 
 (1) (2) (3) (4) (5) (6) (7) (8) 
 PBC 2 PBC 7 PBC 8 PBC 10 PBC 11 PBC 13 PBC 20 PBC 22 
 Cancer Neurological Vision Circulatory Respiratory Gastro-intestinal Poisoning Social care 
 2007/08 spend 2007/08 spend 2007/08 spend 2007/08 spend 2007/08 spend 2007/08 spend 2007/08 spend 2007/08 spend 
 SYLLR 2007/08/09 SYLLR 2007/08/09 SYLLR 2007/08/09 SYLLR 2007/08/09 SYLLR 2007/08/09 SYLLR 2007/08/09 SYLLR 2007/08/09 SYLLR 2007/08/09 

















         
LLONEPENH07 -0.382*** -0.491*** -0.401*** -0.198*** -0.272***  -0.284***  
 [0.079] [0.064] [0.042] [0.069] [0.064]  [0.067]  
lLAneedCARAN78  0.737***       
  [0.206]       
lLAgall_78netpoppheadOHP 0.869*** -0.017 0.319** 0.714*** 0.723*** 0.379*** 0.757*** 0.522*** 
 [0.097] [0.120] [0.125] [0.090] [0.087] [0.118] [0.090] [0.150] 
lLAepiprev0708  0.216***       
  [0.067]       
LPERMSICK07  0.164*** 0.271***     0.124** 
  [0.062] [0.057]     [0.057] 
LPOPPUCAR07 -0.213*   -0.331*** -0.367*** -0.441*** -0.390***  
 [0.111]   [0.122] [0.115] [0.109] [0.119]  
LPROFOCCU07 -0.486***        
 [0.057]        
LNQUAL17407   0.176*** 0.387*** 0.423*** 0.366*** 0.440*** 0.076 
   [0.059] [0.063] [0.060] [0.072] [0.062] [0.055] 
lLAimd_2007exexpobook      0.136***   
      [0.042]   
LHHNOCAR07        0.015 
        [0.043] 
LLONEPARH07        0.237*** 
        [0.063] 
Constant -2.531*** 6.763*** 4.022*** 0.012 -0.065 2.340*** -0.319 3.427*** 
 [0.614] [0.891] [1.061] [0.629] [0.609] [0.852] [0.629] [1.205] 
         
Observations 152 152 152 152 152 152 152 110 
K-P F statistic 49.41 35 87.35 29.95 54.03 50.77 54.96 14.92 
Robust standard errors in brackets 
*** p<0.01, ** p<0.05, * p<0.1  
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Table A2.31 First stage of IV regressions, preferred outcome specifications for 2008/09 
 (1) (2) (3) (4) (5) (6) (7) 
 PBC 1 PBC 2 PBC 4 PBC 7 PBC 10 PBC 11 PBC 13 
 Infectious Cancer Endocrine Neurological Circulatory Respiratory Gastro-intestinal 
 2008/09 spend 2008/09 spend 2008/09 spend 2008/09 spend 2008/09 spend 2008/09 spend 2008/09 spend 
 SYLLR 2008/09/10 SYLLR 2008/09/10 SYLLR 2008/09/10 SYLLR 2008/09/10 SYLLR 2008/09/10 SYLLR 2008/09/10 SYLLR 2008/09/10 
 Outcome Outcome Outcome Outcome Outcome Outcome Outcome 
VARIABLES first-stage regression first-stage regression first-stage regression first-stage regression first-stage regression first-stage regression first-stage regression 
LPOPPUCAR08 0.963***       
 [0.322]       
LNQUAL17408 -0.589***       
 [0.191]       
LWHITEEG08 0.608***     0.195***  
 [0.172]     [0.075]  
lLAhivneedph 0.511***       
 [0.064]       
lLAhivneedph2 0.193***       
 [0.021]       
lLAimd_2007exexpobook 0.472*** 0.004 -0.007     
 [0.106] [0.076] [0.074]     
LLONEPENH08  0.597***  0.225** 0.389***  0.423*** 
  [0.112]  [0.102] [0.086]  [0.079] 
lLAneedCARAN  0.801***  0.559** 1.179*** 0.938*** 1.103*** 
  [0.230]  [0.220] [0.136] [0.294] [0.075] 
LPERMSICK08   0.307***   1.144**  
   [0.095]   [0.441]  
LPROFOCCU08   -0.198**     
   [0.094]     
lLAepilepsyov18prevrate    0.393**    
    [0.162]    
LOWNOCC08    -0.200    
    [0.127]    
LHHNOCAR08     -0.098*   
     [0.052]   
LLONEPARH08      -0.107  
      [0.082]  
LPERMSICK08SQ      0.139**  
      [0.067]  
Constant 3.107*** 5.760*** 4.512*** 4.691*** 5.525*** 6.300*** 5.223*** 
 [0.888] [0.166] [0.572] [0.180] [0.238] [0.690] [0.161] 
        
Observations 148 152 149 148 152 151 150 
K-P F statistic 10.46 32.48 10.51 10.63 43.47 14.27 28.80 
Robust standard errors in brackets  
*** p<0.01, ** p<0.05, * p<0.1 
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Table A2.32 First stage of IV regressions, preferred expenditure specifications for 2008/09 
 (1) (2) (3) (4) (5) (6) (7) (8) 
 PBC 2 PBC 7 PBC 8 PBC 10 PBC 11 PBC 13 PBC 18 & 19 PBC 20 
 Cancer Neurological Vision Circulatory Respiratory Gastro-intestinal Maternity Poisoning 
 2008/09 spend 2008/09 spend 2008/09 spend 2008/09 spend 2008/09 spend 2008/09 spend 2008/09 spend 2008/09 spend 
 SYLLR 2008/09/10 SYLLR 2008/09/10 SYLLR 2008/09/10 SYLLR 2008/09/10 SYLLR 2008/09/10 SYLLR 2008/09/10 SYLLR 2008/09/10 SYLLR 2008/09/10 

















         
LPOPPUCAR08 -0.296***  -0.365*** -0.319*** -0.149 -0.359***  -0.160 
 [0.110]  [0.116] [0.119] [0.105] [0.091]  [0.110] 
LLONEPENH08 -0.319*** -0.534*** -0.308*** -0.216*** -0.251***  -0.062 -0.262*** 
 [0.077] [0.058] [0.065] [0.067] [0.074]  [0.074] [0.077] 
lLAgall_89netpoppheadOHP 0.275* 0.220* 0.784*** 0.745*** -0.005 -0.141 0.439*** 0.013 
 [0.153] [0.128] [0.082] [0.081] [0.117] [0.112] [0.134] [0.123] 
lLAneedCARAN 0.880*** 0.855***   1.222*** 1.227***  1.259*** 
 [0.197] [0.138]   [0.130] [0.214]  [0.136] 
LPROFOCCU08 -0.329***        
 [0.058]        
lLAepilepsyov18prevrate  0.256***       
  [0.053]       
LNQUAL17408   0.420*** 0.369***     
   [0.057] [0.057]     
lLAneedCARAN2     0.128    
     [0.292]    
lLAimd_2007exexpobook      0.045 0.213***  
      [0.048] [0.048]  
LWHITEEG08       0.241***  
       [0.059]  
lLAmatneedindexpp       0.297***  
       [0.088]  
Constant 1.887* 3.412*** -0.588 -0.305 5.193*** 6.085*** 2.109** 5.057*** 
 [1.133] [0.960] [0.589] [0.588] [0.835] [0.800] [0.907] [0.879] 
         
Observations 152 150 152 152 152 152 152 152 
K-P F statistic 56.43 82.27 51.87 29.65 34.27 22.22 11.22 33.86 
Robust standard errors in brackets 
*** p<0.01, ** p<0.05, * p<0.1  
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Table A2.33 First stage of IV regressions, preferred outcome specifications for 2009/10 
 (1) (2) (3) (4) (5) (6) (7) (8) 
 PBC 1 PBC 2 PBC 4 PBC 7 PBC 10 PBC 11 PBC 13 PBC 17 
 Infectious Cancer Endocrine Neurological Circulatory Respiratory Gastro-intestinal Genito-urinary 
 2009/10 spend 2009/10 spend 2009/10 spend 2009/10 spend 2009/10 spend 2009/10 spend 2009/10 spend 2009/10 spend 
 SYLLR 2009/10/11 SYLLR 2009/10/11 SYLLR 2009/10/11 SYLLR 2009/10/11 SYLLR 2009/10/11 SYLLR 2009/10/11 SYLLR 2009/10/11 SYLLR 2009/10/11 
 Outcome Outcome Outcome Outcome Outcome Outcome Outcome Outcome 
VARIABLES first-stage regression first-stage regression first-stage regression first-stage regression first-stage regression first-stage regression first-stage regression first-stage regression 
         
LPOPPUCAR09 1.037***        
 [0.301]        
LNQUAL17409 -0.713***        
 [0.201]        
LWHITEEG09 0.578***     -0.080  -0.124 
 [0.147]     [0.053]  [0.089] 
LWORKAGRI09 0.062*       -0.036*** 
 [0.034]       [0.012] 
lLAhivneedph 0.535***        
 [0.062]        
lLAhivneedphSQ 0.141***        
 [0.025]        
lLAIMD2010 0.564*** -0.042 -0.020      
 [0.099] [0.057] [0.081]      
LLONEPENH09  0.313***   0.373***  0.186***  
  [0.088]   [0.118]  [0.064]  
lLACARANneed910  0.792***  0.389** 0.851*** 0.306 0.988*** 1.011*** 
  [0.159]  [0.195] [0.146] [0.239] [0.072] [0.188] 
LPERMSICK09   0.427***   1.779***   
   [0.103]   [0.410]   
LPROFOCCU09   0.034     0.320*** 
   [0.102]     [0.110] 
LOWNOCC09    -0.349***    -0.063 
    [0.109]    [0.105] 
lLAepiprev0910    0.545***     
    [0.137]     
LBORNEXEU09    -0.012     
    [0.028]     
LHHNOCAR09     0.009    
     [0.059]    
LLONEPARH09      -0.282***   
      [0.069]   
LPERMSICK09SQ      0.204***   
      [0.062]   
lLACARANneed910SQ       0.711*  
       [0.426]  
lLACKDprev18        0.071 
        [0.064] 
Constant 3.367*** 5.445*** 5.346*** 6.779*** 5.705*** 7.233*** 4.823*** 4.796*** 
 [0.757] [0.133] [0.599] [0.674] [0.315] [0.677] [0.133] [0.246] 
         
Observations 147 150 148 140 150 148 148 150 
K-P F statistic 8.698 17.79 17.22 10.20 10.90 9.051 8.446 19.95 
Robust standard errors in brackets 
*** p<0.01, ** p<0.05, * p<0.1  
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Table A2.34 First stage of IV regressions, preferred expenditure specifications for 2009/10 
 (1) (2) (3) (4) (5) (6) (7) (8) (9) 
 PBC 2 PBC 4 PBC 7 PBC 8 PBC 10 PBC 11 PBC 13 PBC 18 & 19 PBC 20 
 Cancer Endocrine Neurological Vision Circulatory Respiratory Gastro-intestinal Maternity Poisoning 
 2009/10 spend 2009/10 spend 2009/10 spend 2009/10 spend 2009/10 spend 2009/10 spend 2009/10 spend 2009/10 spend 2009/10 
spend 
 SYLLR 2009/10/11 SYLLR 2009/10/11 SYLLR 2009/10/11 SYLLR 2009/10/11 SYLLR 2009/10/11 SYLLR 2009/10/11 SYLLR 2009/10/11 SYLLR 2009/10/11 SYLLR 
2009/10/11 



















          
LLONEPENH09 -0.159* -0.138* -0.498*** -0.190** -0.051 -0.123*  -0.078 -0.140* 
 [0.082] [0.079] [0.059] [0.074] [0.072] [0.068]  [0.072] [0.072] 
LPOPPUCAR09 -0.402*** -0.315**  -0.297** -0.303*** -0.317*** -0.263**  -0.314*** 
 [0.123] [0.123]  [0.132] [0.109] [0.102] [0.101]  [0.105] 
lLAgall_0910pheadOHP 0.009 -0.293** 0.219* 0.711*** -0.192* -0.280** -0.338*** 0.130 -0.233** 
 [0.153] [0.121] [0.125] [0.072] [0.116] [0.117] [0.113] [0.087] [0.112] 
lLACARANneed910 1.114*** 1.468*** 0.678***  1.279*** 1.392*** 1.026***  1.396*** 
 [0.215] [0.140] [0.149]  [0.135] [0.131] [0.197]  [0.130] 
lLACARANneed910SQ  0.566*    0.537*    
  [0.302]    [0.275]    
lLAdiaprev0910  -0.027        
  [0.062]        
LPROFOCCU09 -0.263***         
 [0.062]         
lLAepiprev0910   0.326***       
   [0.065]       
LNQUAL17409    0.403***      
    [0.055]      
lLAIMD2010       0.138*** 0.341***  
       [0.044] [0.034]  
LWHITEEG09        0.357***  
        [0.042]  
lLAmatneedindexpp        0.194***  
        [0.070]  
Constant 3.944*** 7.081*** 4.927*** 0.213 6.422*** 7.052*** 7.446*** 3.919*** 6.730*** 
 [1.103] [0.811] [0.841] [0.531] [0.789] [0.789] [0.760] [0.632] [0.767] 
          
Observations 150 148 140 150 150 148 148 150 150 
K-P F statistic 27.74 23.10 55.10 17.74 11.76 22.22 29.99 69.22 21.30 
Robust standard errors in brackets 
*** p<0.01, ** p<0.05, * p<0.1 
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Table A2.35 First stage of IV regressions, preferred outcome specifications for 2010/11 
 (1) (2) (3) (4) (5) (6) (7) (8) 
 PBC 1 PBC 2 PBC 7 PBC 10 PBC 11 PBC 13 PBC 17 PBC 18 & 19 
 Infectious Cancer Neurological Circulatory Respiratory Gastro-intestinal Genito-urinary Maternity 
 2010/11 spend 2010/11 spend 2010/11 spend 2010/11 spend 2010/11 spend 2010/11 spend 2010/11 spend 2010/11 spend 
 SYLLR 2010/11/12 SYLLR 2010/11/12 SYLLR 2010/11/12 SYLLR 2010/11/12 SYLLR 2010/11/12 SYLLR 2010/11/12 SYLLR 2010/11/12 SYLLR 2010/11/12 
 Outcome Outcome Outcome Outcome Outcome Outcome Outcome Outcome 
VARIABLES first-stage regression first-stage regression first-stage regression first-stage regression first-stage regression first-stage regression first-stage regression first-stage regression 
         
LNQUAL17410 -0.506***      0.209**  
 [0.151]      [0.080]  
lLACARANneed1011 1.453*** 0.861*** 0.822*** 0.709***  1.110***  -0.175 
 [0.373] [0.282] [0.107] [0.125]  [0.152]  [0.210] 
lLAhivneedph 0.368***        
 [0.039]        
lLAIMD2010 0.124 -0.061       
 [0.131] [0.111]       
LLONEPENH10  0.465***  0.146     
  [0.128]  [0.095]     
LWHITEEG10   0.231***    -0.093  
   [0.057]    [0.087]  
LHHNOCAR10    -0.125**    0.188*** 
    [0.056]    [0.063] 
LLONEPARH10     -0.239***    
     [0.072]    
LPERMSICK10     2.703***    
     [0.488]    
LPERMSICK10SQ     0.343***    
     [0.076]    
LPC74LTUN10      -0.205***   
      [0.069]   
lLACARANneed1011SQ      1.789***   
      [0.662]   
LWORKAGRI10       -0.055***  
       [0.016]  
LPOPPUCAR10       0.227  
       [0.168]  
lLAmatneedindexpp        0.796*** 
        [0.163] 
LBORNEXEU10        -0.011 
        [0.040] 
Constant 2.229*** 5.799*** 4.380*** 5.015*** 8.864*** 3.540*** 4.936*** 4.640*** 
 [0.500] [0.192] [0.019] [0.260] [0.761] [0.298] [0.297] [0.089] 
         
Observations 147 150 150 150 150 150 152 149 
K-P F statistic 9.561 25.02 16.65 12.59 10.90 8.704 11.41 23.73 
Robust standard errors in brackets 
*** p<0.01, ** p<0.05, * p<0.1 
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Table A2.36 First stage of IV regressions, preferred expenditure specifications for 2010/11 
 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) 
 PBC 2 PBC 4 PBC 6 PBC 7 PBC 8 PBC 10 PBC 11 PBC 13 PBC 14 PBC 18 & 
19 
PBC 20 
 Cancer Endocrine Learning Disability Neurological Vision Circulatory Respiratory Gastro-intestinal Skin Maternity Poisoning 



































            
LLONEPENH10 -0.126 -0.265*** -0.290*** -0.255*** -0.165**  -0.157**  -0.349*** -0.049 -0.165** 
 [0.083] [0.059] [0.058] [0.064] [0.070]  [0.068]  [0.059] [0.072] [0.070] 
lLAIMD2010  0.240*** 0.227*** 0.265***  0.132***  0.251***  0.345***  
  [0.038] [0.044] [0.041]  [0.037]  [0.029]  [0.033]  
LPROFOCCU10 -0.261*** -0.354*** -0.212***   -0.241**   -0.388***   
 [0.061] [0.071] [0.049]   [0.102]   [0.048]   
lLAgall_1011pheadOHP 0.035 0.301*** -0.020 0.197*** 0.733*** 0.418*** 0.688*** 0.185** 0.673*** 0.124 0.733*** 
 [0.155] [0.091] [0.125] [0.073] [0.069] [0.100] [0.065] [0.078] [0.093] [0.083] [0.069] 
LNQUAL17410  -0.643**   0.405*** -0.013 0.390*** 0.140***   0.405*** 
  [0.270]   [0.054] [0.088] [0.052] [0.029]   [0.054] 
LNQUAL17410SQ  -0.169**          
  [0.083]          
LWHITEEG10  0.319*** 0.287***      0.344*** 0.350***  
  [0.037] [0.038]      [0.062] [0.039]  
LPOPPUCAR10 -0.429***   -0.165* -0.345***  -0.315**    -0.345*** 
 [0.121]   [0.087] [0.130]  [0.124]    [0.130] 
lLACARANneed1011 1.126***  0.408**         
 [0.212]  [0.183]         
LWORKAGRI10   -0.025***         
   [0.008]         
LPC74LTUN10   -0.079 -0.049     0.058   
   [0.053] [0.048]     [0.047]   
lLAepiprev1011    0.502***        
    [0.055]        
LBORNEXEU10         0.044**   
         [0.018]   
lLAmatneedindexpp          0.212***  
          [0.072]  
Constant 3.806*** 1.632** 4.285*** 5.148*** 0.046 2.042** 0.396 4.097*** 0.279 4.091*** 0.046 
 [1.148] [0.804] [1.008] [0.569] [0.508] [0.791] [0.489] [0.531] [0.922] [0.593] [0.508] 
            
Observations 150 150 137 150 150 150 150 150 147 150 150 
K-P F statistic 30.07 56.66 20.44 22.77 18.70 20.27 17.31 73.90 23.61 75.02 18.70 
Robust standard errors in brackets 
*** p<0.01, ** p<0.05, * p<0.1 
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Table A2.37 First stage of IV regressions, preferred outcome specifications for 2011/12 
 (1) (2) (3) (4) (5) 
 PBC 2 PBC 7 PBC 10 PBC 11 PBC 13 
 Cancer Neurological Circulatory Respiratory Gastro-intestinal 
 2011/12 spend 2011/12 spend 2011/12 spend 2011/12 spend 2011/12 spend 
 SYLLR 2011/12/13 SYLLR 2011/12/13 SYLLR 2011/12/13 SYLLR 2011/12/13 SYLLR 2011/12/13 
 Outcome Outcome Outcome Outcome Outcome 
VARIABLES first-stage regression first-stage regression first-stage regression first-stage regression first-stage regression 
      
lLACARANneed1112 0.716*** 0.647*** 0.600***  1.082*** 
 [0.128] [0.219] [0.114]  [0.081] 
LWORKAGRI11  -0.020    
  [0.015]    
lLAIMD2010  -0.065    
  [0.063]    
lLAepiprev1112  0.466***    
  [0.104]    
LLONEPENH11 0.328***  0.390***   
 [0.085]  [0.088]   
LHHNOCAR11   0.025  -0.092*** 
   [0.044]  [0.030] 
LLONEPARH11    -0.257***  
    [0.060]  
LPERMSICK11    2.057***  
    [0.389]  
LPERMSICK11SQ    0.241***  
    [0.060]  
lLACARANneed1112SQ     0.719 
     [0.481] 
Constant 5.329*** 6.729*** 5.731*** 7.848*** 4.321*** 
 [0.187] [0.461] [0.236] [0.639] [0.049] 
      
Observations 148 148 148 148 148 
K-P F statistic 14.77 8.746 17.47 18.12 9.678 
Robust standard errors in brackets 
*** p<0.01, ** p<0.05, * p<0.1  
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Table A2.38 First stage of IV regressions, preferred expenditure specifications for 2011/12 
 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) 
 PBC 2 PBC 4 PBC 7 PBC 8 PBC 10 PBC 11 PBC 12 PBC 13 PBC 14 PBC 20 
 Cancer Endocrine Neurological Vision Circulatory Respiratory Dental Gastro-intestinal Skin Poisoning 













































           
LLONEPENH11 -0.086 -0.246*** -0.246*** -0.148*  -0.127* -0.244***  -0.385*** -0.148* 
 [0.094] [0.061] [0.061] [0.082]  [0.075] [0.054]  [0.062] [0.082] 
lLAIMD2010  0.252*** 0.252***  0.131***  0.276*** 0.264***   
  [0.041] [0.041]  [0.042]  [0.040] [0.027]   
LPROFOCCU11 -0.351*** -0.362*** -0.362***  -0.206*  -0.253***  -0.362***  
 [0.058] [0.063] [0.063]  [0.107]  [0.045]  [0.043]  
lLAgall_1112pheadOHP 0.085 0.180** 0.180** 0.719*** 0.400*** 0.655*** 0.115 0.095 0.592*** 0.719*** 
 [0.185] [0.087] [0.087] [0.072] [0.122] [0.066] [0.083] [0.083] [0.076] [0.072] 
LNQUAL17411  -0.114 -0.114 0.420*** 0.044 0.430***  0.187***  0.420*** 
  [0.075] [0.075] [0.055] [0.092] [0.054]  [0.032]  [0.055] 
LWHITEEG11  0.354*** 0.354***    0.318***  0.288***  
  [0.038] [0.038]    [0.032]  [0.043]  
LPOPPUCAR11 -0.389***   -0.364***  -0.360***    -0.364*** 
 [0.144]   [0.138]  [0.133]    [0.138] 
lLACARANneed1112 1.025***          
 [0.242]          
lLACARANneed1112SQ      0.910*** 0.820*** 1.106***   
      [0.344] [0.299] [0.288]   
LPC74LTUN11         0.094**  
         [0.044]  
Constant 3.477*** 2.909*** 2.909*** 0.147 2.282** 0.623 3.610*** 4.760*** 0.844 0.147 
 [1.328] [0.645] [0.645] [0.534] [0.964] [0.480] [0.598] [0.575] [0.786] [0.534] 
           
Observations 148 148 148 148 148 148 148 148 145 148 
K-P F statistic 18.61 66.39 117.5 19.19 19.92 19.84 51.66 94.01 35.96 19.19 
Robust standard errors in brackets 
*** p<0.01, ** p<0.05, * p<0.1  
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Table A2.39 First stage of IV regressions, preferred outcome specifications for 2012/13 
 (1) (2) (3) (4) (5) 
 PBC 2 PBC 4 PBC 10 PBC 11 PBC 13 
 Cancer Endocrine Circulatory Respiratory Gastro-intestinal 
 2012/13 spend 2012/13 spend 2012/13 spend 2012/13 spend 2012/13 spend 
 SYLLR 2012/13/14 SYLLR 2012/13/14 SYLLR 2012/13/14 SYLLR 2012/13/14 SYLLR 2012/13/14 
 Outcome Outcome Outcome Outcome Outcome 
VARIABLES first-stage regression first-stage regression first-stage regression first-stage regression first-stage regression 
      
LWHITEEG11  -0.389***    
  [0.060]    
lLACARANneed1213 0.743*** 0.870*** 0.847***  0.817*** 
 [0.142] [0.190] [0.119]  [0.082] 
LNQUAL17411  0.445***    
  [0.104]    
lLAIMD2010  -0.051    
  [0.056]    
LPROFOCCU11  0.360***    
  [0.102]    
LLONEPENH11 0.342***  0.203**  0.214*** 
 [0.102]  [0.100]  [0.066] 
LHHNOCAR11   -0.116**   
   [0.045]   
LPOPPUCAR11    0.449***  
    [0.094]  
LLONEPARH11    0.012  
    [0.076]  
LPERMSICK11    1.797***  
    [0.339]  
LPERMSICK11SQ    0.229***  
    [0.052]  
lLACARANneed1213SQ     0.310 
     [0.434] 
Constant 5.382*** 5.190*** 5.122*** 8.924*** 4.939*** 
 [0.225] [0.252] [0.260] [0.635] [0.138] 
      
Observations 149 149 149 149 149 
K-P F statistic 11.26 24.51 19.52 16.64 10.36 
Robust standard errors in brackets 
*** p<0.01, ** p<0.05, * p<0.1  
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Table A2.40 First stage of IV regressions, preferred expenditure specifications for 2012/13 
 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) 
 PBC 2 PBC 4 PBC 7 PBC 8 PBC 10 PBC 11 PBC 12 PBC 13 PBC 14 PBC 20 
 Cancer Endocrine Neurological Vision Circulatory Respiratory Dental Gastro-
intestinal 
Skin Poisoning 










































           
LPOPPUCAR11 -0.404***  -0.292*** -0.467***  -0.451***    -0.467*** 
 [0.128]  [0.071] [0.124]  [0.117]    [0.124] 
LLONEPENH11 -0.074 -0.355***  -0.093  -0.075   -0.286*** -0.093 
 [0.090] [0.063]  [0.082]  [0.074]   [0.064] [0.082] 
lLAgall_1213pheadOHP -0.119 0.650*** 0.032 0.693*** 0.055 0.636*** -0.005 0.044 0.499*** 0.693*** 
 [0.230] [0.055] [0.082] [0.073] [0.094] [0.065] [0.093] [0.078] [0.071] [0.073] 
lLACARANneed1213 1.259***          
 [0.289]          
LPROFOCCU11 -0.366*** -0.530***   -0.277***  -0.208***  -0.362***  
 [0.063] [0.074]   [0.067]  [0.039]  [0.042]  
LNQUAL17411  -0.072  0.492*** -0.091 0.495***  0.245***  0.492*** 
  [0.079]  [0.052] [0.070] [0.050]  [0.031]  [0.052] 
LWHITEEG11  0.241***   0.313***  0.252***  0.276***  
  [0.066]   [0.042]  [0.041]  [0.048]  
lLAIMD2010   0.300***  0.318***  0.287*** 0.274***   
   [0.025]  [0.041]  [0.049] [0.025]   
lLAepiprev1213   0.531***        
   [0.048]        
lLACARANneed1213SQ      0.802** 0.807*** 1.035***   
      [0.317] [0.293] [0.257]   
LBORNEXEU11       -0.000    
       [0.015]    
LLONEPARH11       0.140***    
       [0.053]    
LPC74LTUN11         0.163***  
         [0.042]  
Constant 4.972*** -0.252 6.825*** 0.300 4.068*** 0.738 5.393*** 5.186*** 2.008*** 0.300 
 [1.674] [0.451] [0.634] [0.546] [0.687] [0.477] [0.574] [0.544] [0.738] [0.546] 
           
Observations 149 149 149 149 149 149 149 149 147 149 
K-P F statistic 18.75 43.93 130.4 23.27 65.25 23.54 50.77 122.4 20.12 23.27 
Robust standard errors in brackets 
*** p<0.01, ** p<0.05, * p<0.1 
